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Abstract 
 
This thesis was based on a collection of my published works. Chapter 1 introduced 
the idea that infections, both acute and chronic, were risk factors for stroke. Various 
infections and micro-organisms associated with stroke were discussed. Specifically, 
the relationship between micro-organisms such as Cytomegalovirus, Helicobacter 
pylori, dental pathogens, and stroke were discussed. The theories of the pathogenesis 
of atherosclerosis were presented. Chapter 1 also reviewed the association between 
Chlamydia pneumoniae, an atypical respiratory pathogen, and atherosclerosis in detail. 
 
Chapter 2 introduced the ‘Chlamydia pneumoniae in elderly patients with stroke’ or 
‘C-PEPS’ study from which published works in subsequent chapters of this thesis 
were based. The C-PEPS was a case-control study that investigated the 
seroprevalence of C pneumoniae in 100 elderly acute stroke and transient ischaemic 
attack (TIA) patients versus 87 control medical patients. The C-PEPS study showed a 
high seroprevalence (immunoglobulin IgG) of C pneumoniae infection in both cases 
and controls. There was no significant association between C pneumoniae 
seropositivity and stroke / TIA.  
 
Chapter 3 presented a study that investigated the reproducibility of a commercial 
enzyme linked immunosorbent assay (ELISA) kit (SeroCP, Savyon) used in the C-
PEPS study. The study concluded that SeroCP ELISA had a good reproducibility for 
the detection of C pneumoniae IgA and moderately good reproducibility for C 
pneumoniae IgG and IgM.   
 
In chapter 4, the ‘Mycoplasma pneumoniae in elderly patients with stroke’ or ‘M-
PEPS’ case-control study was based on the same cohort of patients as in the C-PEPS 
study. The M-PEPS study showed a high seroprevalence of M pneumoniae, another 
atypical respiratory pathogen, in the cohort. However, the study had ruled out M 
pneumoniae as a major risk factor for stroke / TIA. 
 
In chapter 5, the ‘Legionella pneumophila in elderly patients with stroke’ or ‘L-PEPS’ 
was another case-control study based on the same cohort of patients as in the C-PEPS 
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study. The L-PEPS study established that there was no statistical difference between 
the seroprevalence of L pneumophila, another atypical respiratory pathogen, in both 
the stroke / TIA patients and control medical patients. However, when the results of 
C-PEPS, M-PEPS and L-PEPS studies were analysed together, it appeared that the 
aggregate number or infectious burden of chronic atypical respiratory infections was 
associated with the risk of stroke / TIA. 
 
Chapter 6 presented a pilot study that investigated the seroprevalence of Coxiella 
burnetii, another atypical respiratory pathogen, in the same cohort of patients as in the 
C-PEPS study. Due to very low seropositivity and zero counts, a conclusion could not 
be made on any association between C burnetii seropositivity and stroke / TIA. 
 
Chapter 7 presented the electrocardiographic findings such as rhythms and ischaemic 
changes of the same cohort of patients as in the C-PEPS study. Atrial fibrillation was 
the commonest rhythm abnormality in both elderly stroke / TIA cases and medical 
controls. After adjusment for background history of ischaemic heart disease, there 
was a statistical trend to suggest an association between ischaemic elctrocardiographic 
changes and stroke / TIA. 
 
Chapter 8 presented a case-control study that investigated the relationsips between 
socioeconomic deprivation (SED) status, atypical respiratory infections and survival 
outcome in the same cohort of patients as in the C-PEPS study. The SED status of 
stroke / TIA cases and controls were similar. Although an association between acute 
atypical respiratory infection and SED was only found in the control medical patients, 
acute atypical respiratory infectious burden was found to associate with income 
deprivation in the whole cohort of elderly stroke / TIA and medical patients. SED on 
its own had only a modest effect on the association between chronic atypical 
respiratory infectious burden and stroke / TIA. Elderly patients’ duration of survival 
after an acute stroke / TIA appeared not to be affected by their background SED status. 
 
Chapter 9 was the concluding chapter. The main findings of the published works 
submitted for the thesis were summarised and discussed. Some directions for future 
research were also discussed.  
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Chapter 1 
 
Infections as risk factor for stroke: focusing on the 
association between Chlamydia pneumoniae and 
atherosclerosis 
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1.1. Introduction 
 
Stroke is defined clinically as ‘a syndrome of rapidly developing clinical signs of 
focal or global disturbance of cerebral function, with symptoms lasting 24 hours or 
longer or leading to death, with no apparent cause other than of vascular origin’. 
[World Health Organisation, 1978] Events lasting less than 24 hours are termed as 
transient ischaemic attacks (TIA).  
 
Stroke is the third most common cause of death after coronary heart disease (CHD) 
and all cancers in the developed world. [Murray and Lopez, 1997] World Health 
Organisation data has revealed that world-wide 4.5 million people die each year due 
to stroke. [Al-Shahi, 2000] It is the commonest serious neurological problem 
[Hachinski, 1998] and a major cause of disability [Murray and Lopez, 1996] in the 
world. 
 
In the United Kingdom, the incidence of first and recurrent stroke is around 2.4 per 
1,000 people per year. [Wade, 1994] This rises to 3 per 1,000 per year among the 55-
64-year-olds, and rapidly to 20 per 1,000 per year in people aged 85 years and over. 
The prevalence of stroke in the United Kingdom is 5-8 per 1,000 in people aged over 
25. [Al-Shahi, 2000] 
 
Stroke has been accounted for about 5% of the National Health Service (NHS) budget 
[Rudd et al, 1999] or £500 million (12%) of the NHS and Social Services budget [Al-
Shahi, 2000]. It has been estimated that in England and Wales, there will be an 
increase of around 30% in the number of first-ever strokes between the years 1983-
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2023. [Malmgren et al, 1989] With an ageing population, the burden of stroke in 
terms of mortality, morbidity and cost will continue to be enormous.  
 
Stroke prevention will therefore continue to be the most effective strategy for 
reducing the adverse health and financial consequences of stroke. [Wolf, 1998] The 
identification and treatment of established stroke risk factors such as hypertension, 
cigarette smoking, diabetes mellitus, atrial fibrillation and hypercholesterolaemia, as 
well as the search and research for novel risk factors, are vital in the context of 
primary and secondary prevention strategies. [Warlow, 1998] 
 
1.2. Pathological causes of stroke 
 
Stroke is a heterogeneous condition that may be due to arterial occlusion or 
haemorrhage. About 85% of strokes are occlusive. [Bamford, 1990] The occlusion of 
large vessels may be due to thrombosis or embolism, [Kalra, 1998] and accounts for 
approximately 70% of ischaemic stroke (50% from atherothromboembolism and 20% 
from cardiac embolism) [Warlow, 1996]. The occlusion of intracranial small vessels 
may give rise to lacunar stroke, which is associated with hypertension or embolism 
[Kalra, 1998] and causes about 25% [Warlow, 1996] of ischaemic strokes.  
 
Haemorrhagic stroke accounts for about 15% of all strokes. The haemorrhage may be 
parenchymal due to Charcot-Bouchard microaneurysms (11 to 12%), or secondary to 
extracerebral rupture of intracranial vessels (berry aneurysms) in the subarachnoid 
space (3-4%). [Bamford, 1990] [Ebrahim, 1998] [Kalra, 1998] 
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A high index of suspicion of rare (about 5%) underlying causes of stroke is required, 
as they often require different management. [Anonymous, 1989], [Ebrahim, 1998] 
Examples of rare occlusive causes of stroke include arteritis, hyperviscosity 
syndromes, infections, atrial myxoma, arterial dissection, inherited collagen disorders. 
Haemorrhagic causes include bleeding diatheses, ateriovenous malformations, 
warfarin treatment, head injury, cerebral tumours and amphetamine abuse. Other 
miscellaneous rare causes of ischaemic stroke include congenital arterial anomalies 
and unruptured aneurysms, migraine, marantic endocarditis, malignant 
angioendotheliosis, the oral contraceptive pill and hormone replacement therapy, 
pregnancy, Moyamoya syndrome, mitochondrial cytopathy, cholesterol embolisation 
syndrome. [Warlow et al, 1996] 
 
1.3. Acute infection and stroke 
 
Ischaemic stroke of undertermined aetiology represents approximately 40% of cases 
in stroke data banks, and the importance of potential precipitants or risk factors has 
not been well defined. [Sacco, 1989] Recent infection may be an underestimated risk 
factor for stroke. [Grau, 1995] For example, the increased rate of cardiovascular and 
stroke mortality in the winter months may partly be due to an increased prevalence of 
respiratory tract infections. [Woodhouse et al, 1994] It has been estimated that stroke 
occurs in almost 10% of bacteraemic cases without endocarditis [Svanbom, 1980] 
[Syrjanen, 1989], and about 10% of all strokes are associated with bacteraemic 
infections [Valtonen, 1993]. For the following discussion, acute infection is arbitrarily 
divided into systemic, central or local infection, although they often coexist clinically. 
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1.3.1. Acute systemic infection and stroke 
 
Acute infection is recognised as an important risk factor for ischaemic stroke. 
[Syrjanen et al, 1988] [Ameriso et al, 1991] [Grau et al, 1995] [Macko et al, 1996] 
[Bova et al, 1996] [Bornstein et al, 1997] [Grau et al, 1998] [Nencini et al, 2003] 
[Palm and Grau, 2007] In a case-control study involving patients aged under 50 years, 
a febrile infection during the preceding month was shown to be a significant and 
independent risk factor for ischaemic stroke [Relative Risk (RR)= 14.5; 95% 
Confidence Interval (CI)= 1.9 to 112]. [Syrjanen et al, 1988] In a larger case-control 
study involving patients aged 18 to 80 years, recent infection during the preceding 
week was found to be a significant risk factor for cerebral ischaemia, even when other 
risk factors for stroke were controlled for [Odds Ratio (OR)= 4.6; 95% CI= 1.9 to 
11.3]. [Grau et al, 1995] Both of these studies revealed that infections among their 
patients were mainly of bacterial origin, and commonly affected the respiratory tract. 
Interestingly, a significant association of respiratory tract infection with the onset of 
myocardial infarction had also been reported. [Spodick et al, 1984]  
 
A further case-control study suggested that both febrile and non-febrile infectious or 
inflammatory syndromes within the preceding one week were a common and 
important predisposing risk factor for brain infarction. [Macko et al, 1996] Using a 
control group consisting of consecutive patients who had suffered ischaemic stroke at 
least 6 months previously, a prospective, case-control study reported that acute 
infections of different types (mainly bacterial infection of the respiratory and urinary 
tracts) during the preceding week, among all age groups, constitute a significant risk 
factor for ischaemic stroke, even when other risk factors for stroke were adjusted for 
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(OR= 2.93; 95% CI= 1.64 to 5.26; P= 0.0002). [Bova et al, 1996] It was commented 
that recall bias or differences in motivation could not have explained the striking 
results. In another case-control study, the role of recent infection within the preceding 
week was found to be an independent risk factor for acute cerebrovascular ischaemia 
(adjusted OR= 3.1; 95% CI= 1.6 to 6.1), especially in the younger age groups. [Grau 
et al, 1998] 
 
Recently, a very large UK study using within-person comparisons and case-series 
method confirmed that recent infection increased the risk of stroke and myocardial 
infarction. [Smeeth et al, 2004] Based on the United Kingdom General Practice 
Research Database, a total of 20,486 persons with a first myocardial infarction and 
19,063 persons with a first stroke who received influenza vaccine were included in the 
analysis. The study showed that the risks of both vascular events were substantially 
increased after a diagnosis of systemic respiratory tract infection was made within the 
first three days (incidence ratio for stroke= 3.19; 95% CI= 2.81 to 3.62; incidence 
ratio for myocardial infarction= 4.95; 95% CI= 4.43 to 5.53) The risk of stroke was 
also increased within the first three days after diagnosis of urinary tract infection 
(incidence ratio= 2.72; 95% CI= 2.32 to 3.2). The risks then gradually fell during the 
following weeks after infection. In contrast, the study found no increase in the risk of 
stroke or myocardial infarction during the days or months after influenza, tetanus, or 
pneumococcal vaccination. [Smeeth et al, 2004] Indeed, influenza vaccination was 
associated with a reduction in the risk of stroke in two case-control studies [Lavallee 
et al, 2002] [Grau et al, 2005] and in one large observational study [Nichol et al, 
2003]. [Palm and Grau, 2007] 
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The strong associations between recent respiratory infection and stroke or myocardial 
infarction were confirmed in a large case-control study recently [Clayton et al, 2008] 
Using a general practice database, the study identified 9,208 stroke cases and 11,155 
myocardial infarction cases. The study found a strong evidence of an increased risk of 
both vascular events in the 7 days following respiratory infection: for stroke OR= 
1.92 (95% CI= 1.24 to 2.97); for myocardial infarction OR= 2.10 (95% CI= 1.38 to 
3.21). The investigators concluded that the benefits of reducing respiratory infection 
either through immunization or treating or preventing infection might be substantial. 
[Clayton et al, 2008] 
 
1.3.2. Acute central or local infection and stroke 
 
Various bacterial, viral, fungal infections and worm infestations, affecting the 
meninges, carotid arteries, and endocardium have been described as causes of 
ischaemic stroke and TIA. [Warlow, 1996] Meningitis causes inflammation and 
secondary thrombosis of arteries and veins traversing the meninges to enter the brain. 
Therefore ischaemic events may be caused by acute bacterial meningitis due to 
organisms such as Meningococcus, Pneumococcus, Haemophilus, Borrelia and 
Leptospira. [Igarashi et al, 1984] Similarly acute tuberculous, syphilitic, or fungal 
(Cryptococcus, Candida, Aspergillus, mucormycosis) meningitis may cause sudden 
focal or multifocal ischaemic strokes. [Dalal and Dalal, 1989]  
 
Some viruses such as herpes zoster, can cause periarterial inflammation and 
thrombosis. For example, middle cerebral artery occlusion with cerebral infarction has 
 35
been described a few weeks after the onset of ophthalmic zoster [Bourdette et al, 1983] 
[Sigal, 1987] and chickenpox (Varicella zoster) [Leopold, 1993]. 
 
Acquired immune deficiency syndrome (AIDS) caused by Human immunodeficiency 
virus (HIV) can be complicated by stroke. Although 40% of AIDS, AIDS-related 
complex, and HIV carriers have a neurological complication, only 1.3% has a stroke 
syndrome. [Pinto, 1996] Ischaemic infarcts are more common than intracerebral 
haemorrhages. [Pinto, 1996] Thrombocytopenia, primary central nervous system 
lymphoma, and metastatic Kaposi’s sarcoma in AIDS may lead to intracranial 
haemorrhages. [Pinto, 1996] On the other hand, cerebral infarction can be caused by 
fungal meningitis, Herpes zoster and HIV vasculopathy, non-bacterial thrombotic or 
marantic endocarditis, and radiotherapy. [Park et al, 1990] [Kieburtz et al, 1993] 
[Pinto, 1996] 
 
Worm infestation such as neurotrichinosis [Fourestie et al, 1993] and cysticercosis 
[Del Brutto, 1992], mycoplasma [Mulder and Spierings, 1987], cat-scratch disease 
[Selby and Walker, 1979] and tick-born diseases e.g. Neuroborreliosis (Borrelia 
burgdoferi) [Reik, 1993], Rocky Mountains spotted fever (Rickettsia rickettsiae) 
[Grau et al, 2006], are all occasionally complicated by stroke. 
 
Upper respiratory tract infection such as pharyngitis, tonsillitis and lymphadenitis, 
particularly in children, may be complicated by inflammation of the internal carotid 
artery in the neck, with secondary thrombosis. [Bickerstaff, 1964] 
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Infective causes of ischaemic stroke that are more prevalent in the developing than in 
the developed world include syphilis (Treponema pallidum), tuberculosis 
(Mycobacterium tuberculosis), cerebral embolism due to rheumatic heart disease or 
infective endocarditis, and malaria (Plasmodium falciparum). Parasitic infestations 
such as gnathostomiasis, schistosomiasis and larva migrans are recognised causes of 
intracerebral haemorrhage that are also more prevalent in the developing countries. 
[Poungvarin, 1998] Chagas disease (Trypanosoma cruzi) with embolism resulting 
from cardiomyopathy may lead to a stroke. [Grau et al, 2006] 
 
1.3.3. Infective endocarditis and stroke 
 
Infective endocarditis is more common in the elderly, with more than 50% of patients 
having their first episode of endocarditis after the age of 60 years. [Von Reyn et al, 
1981] Stroke, including cerebral infarctions due to cerebral artery thrombosis and 
emboli, and intracranial haemorrhages, is clinically the most common thrombo-
embolic complication in patients with infective endocarditis. [Valtonen et al, 1993] 
About 20% of patients with endocarditis will develop a stroke during their illness. 
[Hart et al, 1990] Cerebral infarctions are about three or four times more common 
than intracranial haemorrhages, which are often due to ruptured mycotic aneurysms or 
pyogenic arteritis. [Hart et al, 1990] [Jones et al, 1969]  
 
Apart from Viridans streptococci, [Grau et al, 2006] Staphylococcus aureus [Hart et 
al, 1990] and Haemophilus parainfluenzae [Chunn et al, 1977] [Lynn et al, 1977] 
endocarditis are predisposed to the development of thrombo-embolic complications. 
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However, intracranial haemorrhages may be more common in intravenous drug 
abusers due to Staphylococcus aureus endocarditis and associated pyogenic arteritis. 
 
1.4. Mechanisms of infection-associated stroke 
 
A procoagulant state is a link between infection and ischaemic stroke. [Grau et al, 
1995] Infection may stimulate coagulation through inflammatory mechanisms such as 
the expression of thromboplastin by monocytes and macrophages. [Rivers et al, 1975] 
With an increased serum levels of tumour necrosis factor-α (TNF-α) and other 
cytokines, [Van der Poll et al, 1990] [Schleef et al, 1988] the coagulant function of the 
endothelium may be altered to express tissue factor, increased levels of plasminogen 
activator inhibitor (PAI-1) and reduced levels of tissue plasminogen activator, [Palm 
and Grau, 2007], inhibition of the protein C / protein S anticoagulant system, [Esmon 
et al, 1991] [Hesselvik et al, 1991] and leading to increased levels of clotting factors 
such as fibrinogen and Factor VII [Woodhouse et al, 1994]. Indeed, stroke patients 
with a recent infection were found to have the lowest concentrations of activated 
protein C, elevated levels of C4b-binding protein which binds protein S (an important 
cofactor of protein C), and a lower ratio of active tissue plasminogen activator to PAI. 
[Macko et al, 1996(b)] 
 
Patients with infection-associated ischaemic stroke have significantly increased fibrin 
D-dimer generation, increased cardiolipin immunoreactivity, and 
hyperfibrinogenemia, when compared with stroke patients without infections. 
[Ameriso et al, 1991] Antithrombin III and protein C and S deficiency, increased 
platelet activation, aggregation and adhesion, impairment of endogenous fibrinolysis 
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as indicated by reduced tissue plasminogen activator (TPA) activity, and a lower ratio 
of active TPA to plasminiogen activator inhibitor-1, may contribute to the increased 
risk for brain infarction after recent infection / inflammation. [Bone 1992] [Macko et 
al, 1996] [Palm and Grau, 2007] Antiphospholipid antibodies formed in septic 
patients may interact with protein C and S, leading to thrombo-embolic complications 
such as stroke. [McNeil et al, 1991] [Parke AL et al, 1992] [Macko et al, 1996] 
 
Infection is known to activate leucocytes, which in turn interact with platelets. 
[Marcus et al, 1988] [Vasthare et al, 1990] [Galante et al, 1992] [Carlos and Harlan, 
1994] [Grau et al, 1995] [Elneihoum et al, 1996] Leucocytes e.g. monocytes may be 
induced to produce tissue factor, secrete cytokines such as TNF-α, interleukin-1β, 
interleukin-6, and interferon-γ, and others that have a procoagulant effect, resulting in 
thrombotic events. [Passbender et al, 1994] [Barone et al, 1997] [Garcia et al, 1995] 
[Elkind and Cole, 2006] Higher levels of C-reactive protein that can induce increased 
tissue factor expression by monocytes, were also found in infection-associated stroke. 
[Grau et al, 1998] Therefore, inflammation may lead to endothelial dysfunction, 
linking infection and risk of an acute cardiovascular event. [Hingorani et al, 2000] 
[Vallance et al, 1997] [Palm and Grau, 2007] 
 
In addition to activation of the coagulation system, septic emboli, cerebral vasculitis, 
meningitis, and spasms of arteries, can all lead to thrombosis of cerebral arteries and 
ischaemic stroke in patients with infective endocarditis. [Valtonen et al, 1993] [Grau 
et al, 1995] Although stroke in septic patients is infrequent, mental changes or so-
called septic encephalopathy is the most common central nervous system 
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complication in patients with bacteraemia. [Syrjanen, 1989] Acute infection, although 
underestimated, is undoubtedly an important and significant risk factor of stroke.  
 
1.5. Pathogenesis of atherosclerosis 
 
1.5.1. Definition of atherosclerosis 
 
Atherosclerosis is a disease of the blood vessels consisting of both degenerative and 
regenerative processes that initially affect the intima and at a later stage the media at 
the bifurcations of the major arteries. [Tegos et al, 2001] The term atherosclerosis is 
derived from the Greek words ‘athero’ and ‘sclerosis’. ‘Athero’ means gruel and 
corresponds to the necrotic core at the base of the atherosclerotic plaque, whereas 
‘sclerosis’ means hardening or induration, and corresponds to the fibrotic cap at the 
luminal edge of the plaque. [Tegos et al, 2001] The three main components of 
atherosclerotic lesions are: 1. cholesterol esters; 2. smooth muscle cells, macrophages 
and other cell types; and 3. connective tissue composed of collagen, elastin and 
glycosaminoglycans. [Woolf et al, 1990] [Davies and Woolf, 1993] [Tegos et al, 2001] 
 
1.5.2. Theories of atherogenesis 
 
The five theories of atherogenesis are: 1. the lipid theory; 2. the haemodynamic theory; 
3. the fibrin incrustation theory; 4. the nonspecific mesenchymal hypothesis; and 5. 
the response to injury hypothesis. [Tegos et al, 2001] 
 
The lipid theory has established that earlier atherosclerotic lesions i.e. fatty streaks, 
are characterized by the accumulation of cholesterol esters within the macrophage 
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foam cells. [Stary et al, 1994] [McGill HC Jr, 1968] [Tegos et al, 2001] Subsequent 
atherosclerotic plaque is characterised by the accumulation of cholesterol esters in the 
extracellular space. [Stary et al, 1994] [Stary et al, 1995] [Tegos et al, 2001] The 
accumulation of LDL-cholesterol in the intima could be due to: 1. increased plasma 
LDL concentrations; [Smith, 1990] 2. alteration of the arterial intima permeability to 
LDL, [Zhang et al, 1993] mediated via vesicular transport [Smith, 1990]; 3. increased 
LDL retention in the intima [Bondjiers et al, 1990]; and 4. impeded LDL transport 
from the intima to the media. [Smith, 1990] 
 
The haemodynamic theory of atherogenesis first proposed in 1950 suggested that 
hydrostatic and shear forces are responsible for the development and focal nature of 
atherosclerotic lesions. [Tegos et al, 2001] Hypertension may therefore predispose to 
the development of atherosclerotic lesions which have a predilection for the branching 
sites of the arterial system whereby turbulence, oscillating or low shear stress is 
usually detected. [Tegos et al, 2001] As a result of altered haemodynamics, the 
clearance of blood components may be delayed, thereby allowing prolonged contact 
of potentially toxic substances with the intima. [Tegos et al, 2001] This could 
potentiate endothelial injury, modify endothelial permeability and facilitate LDL 
transport to the intima. [Davies et al, 1984] [Ku et al, 1985] [Glagov et al, 1988] 
[Tegos et al, 2001] 
 
The fibrin incrustation theory was first proposed by Rokitansky, a nineteenth century 
pathologist. [Rokitansky, 1952] [Tegos et al, 2001] It was postulated that fibrinogen is 
converted into fibrin with the formation of a thrombus on the arterial luminal surface. 
Duguid [Duguid, 1946] and Hand [Hand and Chandler, 1962] independently 
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demonstrated thrombus formation on plaque surface and its subsequent incorporation 
and transformation into fibrous tissue over time, thus increasing the plaque’s size. 
[Tegos et al, 2001] They also proposed the phagocytosis of cholesterol-rich platelets 
by macrophages leading to the production of lipid-rich foam cells. [Tegos et al, 2001] 
However, it was commented that the layered appearance of the atheroma is more 
easily explainable on the basis of smooth muscle hyperplasia and connective tissue 
deposition rather than on the organisation of the thrombus. [Tegos et al, 2001] 
Nevertheless, this theory proposed the idea that thrombus formation in a complicated 
atherosclerotic plaque can lead to its instability. [Badimon et al, 1992] [Tegos et al, 
2001] 
 
The non-specific mesenchymal hypothesis proposed that a wide range of stimuli to 
the arterial wall, such as shear stress or vasoactive agents, may induce a migration of 
smooth muscle cells (mesenchymal cells) from the media to the intima, and which 
may subsequently proliferate and produce connective tissue. [Hauss, 1962] [Tegos et 
al, 2001] The main components of this connective tissue are: 1. proteoglycans, which 
may trap the infiltrating LDL; and 2. collagen, which is the main space-filling agent 
of the atherosclerotic plaque. [Berenson et al, 1984] [Tegos et al, 2001] Indeed, the 
proliferation of smooth muscle cells and connective tissue production represent the 
regenerative process of atherosclerosis, which resembles the healing process in many 
aspects. [Tegos et al, 2001] 
 
The ‘response to injury’ hypothesis was proposed in the 1970s. [Ross and Glamset, 
1973] The hypothesis was progressively modified with increasing knowledge on the 
cellular and molecular biology of the arterial wall, the interaction between the cells of 
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the arterial wall and blood circulation, the role of vascular risk factors and endothelial 
cell damage. [Ross, 1993] According to the hypothesis, a number of factors may 
cause injury to the endothelial cells at specific sites in the artery. [Mora et al, 1987] 
[Tegos et al, 2001] These factors include hypertension, LDL-cholesterol, toxins in 
cigarette smoking, glycosylated end-products (diabetes mellitus), immune complexes 
and infection. [Fuster et al, 1992] [Tegos et al, 2001] Endothelial cell damage caused 
by these factors may lead to cellular activation and expression of binding sites for 
circulating monocytes via adhesion molecules e.g. vascular cell adhesion molecule-1 
(V-CAM-1) and monocyte chemotactic agents e.g. monocyte chemotactic protein-1 
(MCP-1). [Valente et al, 1992] [Tegos et al, 2001] With an increased vascular 
permeability, the monocytes and T lymphocytes attached to the endothelium migrate 
into the intima; and the monocytes then transform into tissue macrophages. [Gerrity 
RG, 1981] [Taylor and Lewis, 1986] [Munro and Cotran, 1988] [Hansson et al, 
1989(b)] [Tegos et al, 2001] The plasma LDL-cholesterol may also traverse the 
endothelium, accumulate in the interstitial space of the intima, and form complexes 
with extracellular tissue collagen, elastin and proteoglycans. [Berenson et al, 1984] 
[Tegos et al, 2001] Oxidised LDL-cholesterol within the subendothelial space may 
also be internalised by the tissue macrophages (via the scavenger receptor) which 
become lipid-laden and transform into foam cells. [Jurgens et al, 1987] [Steinberg et 
al, 1989] [Tegos et al, 2001] Together with the lymphocytes, these foam cells that 
make up the fatty streak are the pathological hallmarks of early atherosclerotic lesions. 
[Faggiotto et al, 1984] [Rosenfeld et al, 1987] [Masuda and Ross, 1990] [Stary et al, 
1994]. In addition, the platelets adhered to the site of endothelial injury may release 
platelet-derived growth factor which in turn may induce the migration of smooth 
muscle cells from the media to the intima. [Tegos et al, 2001] These smooth muscle 
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cells may proliferate and produce connective tissue such as collagen, elastin and 
proteoglycans. [Clowes et al, 1989] [Tegos et al, 2001] These smooth muscle cells 
and extracellular matrix ultimately lead to the genesis of fibrous tissue and 
calcification, forming an advanced atherosclerotic plaque. [Stary et al, 1995] However, 
the activated T lymphocytes found in the fibrous cap of the atherosclerotic lesions 
may be stimulated by oxidised LDL-cholesterol to produce γ-interferon which may 
inhibit smooth muscle proliferation, collagen and elastin synthesis, and decrease 
cholesterol accumulation. [Munro and Cotran, 1988] [Hansson et al, 1989(a)] 
[Hansson et al, 1989(b)] [O’Brien, 1994] [Stary et al, 1995] [Tegos et al, 2001] The 
interactions of macrophages, smooth muscle cells and T lymphocytes are therefore 
important in the synthesis of the extracellular matrix and plaque remodeling as the 
atherosclerotic lesion progresses. [Tegos et al, 2001] 
 
1.6. Chronic infection and atherosclerosis or stroke 
 
The idea that chronic infection could play an important role in atherosclerosis is not 
entirely new. In fact the concept of an ‘infectious’ hypothesis of atherosclerosis was 
proposed by several prominent historical figures such as Virchow in 1859 and Osler 
in 1908, followed by Frothingham in 1911, and Ophuls in 1921. [Ngeh and Gupta, 
2002] Indeed, over 20 specific microorganisms (bacteria and viruses) / antigens have 
been named to associate infection and atherosclerosis (see Table 1). [Nieto, 1998] 
[Ngeh and Gupta, 2004] [Xu et al, 1993] [Mayr et al, 1999] [2005, Fiehn et al] 
Among these, Cytomegalovirus (CMV), C pneumoniae, Helicobacter pylori, and 
dental (periodontal) pathogens are the micro-organisms most commonly studied. 
[Fong, 2002] [Leinonen and Saikku, 2002] [Ngeh and Gupta, 2004] 
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Table 1. Microorganisms implicated to associate infections with atherosclerotic 
vascular diseases [Ngeh and Gupta, 2004] 
 
Microorganism                                         Year and author of publication 
      Bacillus typhosus                                           1889, Gilbert and Lion  
Streptococci                                           1931, Benson et al 
Coxsackie B virus                                           1968, Sohal et al  
Adenovirus                                           1973, Fabricant et al 
Mycoplasma gallisepticum                             1973, Clyde and Thomas  
Marek’s disease virus                               1978, Fabricant et al  
Cytomegalovirus                                             1987, Petrie et al  
Herpes simplex virus                                      1987, Hajjar et al  
Chlamydia pneumoniae                               1988, Saikku et al  
Measles virus                                        1990, Csonka et al 
Epstein-Barr virus                                          1993, Straka et al  
Human immunodeficiency virus                   1993, Paton et al  
Mycobacteria (hsp65)                                     [1993, Xu et al]                                      
Helicobacter pylori                               1994, Mendall et al  
Mycoplasma fermentans                               1996, Ong et al  
Enteroviruses                                                  1998, Roivainen et al 
Coxiella burnetti                                       1999, Lovey et al  
Escherichia coli                                              [1999, Mayr et al]                                              
Porphyromonas gingivalis                   1999, Chiu et al  
Streptococcus sanguis                               1999, Chiu et al  
Actinobacillus actinomycetemcomitans          2000, Haraszthy et al  
Bacteroides forsythus                                  2000, Haraszthy et al  
Hepatitis A virus                                           2000, Zhu et al  
Influenza virus                                           2000, Naghavi et al  
Mycoplasma pneumoniae                               2000, Higuchi et al 
Prevotella intermedia                               2000, Haraszthy et al 
Varicella-zoster virus                                      2000, Moriuchi and Rodriguez 
Hepatitis C virus                                           [2002(a), Ishizaka et al] 
      Hepatitis B virus                                             [2002(b), Ishizaka et al]  
      Campylobacter rectus                                     [2005, Fiehn et al] 
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1.6.1. Cytomegalovirus 
 
Cyotmegalovirus is ubiquitously present and it was estimated that 60-90% of adults 
have been infected with this virus. [Bruggeman, 1993] [Palm and Grau, 2007] CMV 
infections can present as an acute febrile illness although they are often asymptomatic. 
[Palam and Grau, 2007] CMV has been associated with post-transplant vasculopathy 
in heart transplant patients. [Ventura et al, 1995] [Elkind and Cole, 2006] Serological 
evidence of CMV infection has also been found more commonly in patients with CHD 
than normal controls. [Melnick et al, 1990] Elevated levels of CMV antibody titres 
were also found to associate with an increased risk of carotid-intimal thickening 13-18 
years later, [Nieto et al, 1996] [Palm and Grau, 2007] and atherosclerotic carotid 
stenosis [Espinola-Klein et al, 2000] [Elkind and Cole, 2006] 
 
Prospective studies have also shown that subjects in the upper quintile of CMV titres 
have twice the risk of developing CHD than those in the lowest. [Sorlie et al, 2000] 
[Elkind and Cole, 2006] Among those with CHD, elevated CMV titres, as well as 
titres for hepatitis A virus and herpes simplex virus-2, were found to be associated 
with an increased risk of future myocardial infarction. [Muhlestein et al, 2000] 
[Elkind and Cole, 2006] Other studies have found that restenosis after coronary 
angiography occurs more frequently in patients positive for CMV. [Speir et al, 1994] 
[Elkind and Cole, 2006] Indeed, CMV has been detected by polymerase chain reaction 
(PCR) techniques in atherosclerotic lesions of those with CHD more frequently than 
in those without atherosclerosis. [Hendrix et al, 1990] [Elkind and Cole, 2006] 
However, two prospective studies have not confirmed the association between 
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seropositivity for CMV and future risk of stroke and cardiovascular events. [Ridker et 
al, 1998] [Fagerberg et al, 1999] [Palm and Grau, 2007] 
 
CMV infection might promote atherogenesis through a number of potential 
mechanisms. [Elkind and Cole, 2006] [Palm and Grau, 2007] These include 
disrupting cell cycle control in vascular endothelial and smooth  muscle cells [Speir et 
al, 1994] [Murphy et al, 2000], increasing procoagulant proteins [van Dam-Mieras et 
al, 1992],   reactive oxygen species [Shibutani et al, 1997] [Speir et al, 1996] [Speir et 
al, 1998] and leucocyte adhesion molecules [Sindre et al, 2000]. Other mechanisms 
include an increased expression of proinflammatory cytokines such as interleukin-2 
and interleukin-2 receptor [Geist et al, 1991], tumour necrosis factor-alpha [Geist et al, 
1994] and nuclear factor-kappa B (a pro-inflammatory transcription factor) [Kowalik 
et al, 1993]; expression of platelet-derived growth factor and transforming growth 
factor [Lemstrom et al, 1994]; and smooth muscle cell proliferation and migration 
[Yonemitsu et al, 1997]. Although most of these mechanisms have been demonstrated 
in animal models, CMV infection has not been fully established as a risk factor for 
atherosclerosis and stroke. [Palm and Grau, 2007] 
 
1.6.2. Helicobacter pylori 
 
Helicobacter pylori are Gram-negative spiral bacteria. Infection begins in childhood 
and is influenced by socioeconomic factors. [Graham et al, 1991] [Mendall et al, 1992] 
[Palm and Grau, 2007] H pylori may cause gastritis, peptic ulcers, non-ulcer 
dyspepsia and gastric cancers, but often remain asymptomatic. [Veldhuyzen van 
Zanten et al, 1994] 
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Retrospective seroepidemiological investigations have found an association between 
H pylori infection and atherosclerosis, [Danesh et al, 1997] although prospective 
studies that adjusted for other risk factors have not confirmed an association [Koenig 
et al, 1999]. [Elkind and Cole, 2006]  Some studies have shown a correlation between 
H pylori seropositivity and risk of atherothrombotic or lacunar stroke, [Markus and 
Mendall, 1998] [Heuschmann et al, 2001] [Grau et al, 2001] [Ponzetto et al, 2002] but 
others did not [Whincup et al, 1996]. [Palm and Grau, 2007] In a recent case-control 
study, chronic H pylori infection was found to be associated with acute ischaemic 
stroke (OR= 2.57; 95% CI= 1.09 to 6.08] due to large and small artery diseases, but 
not cardiogenic embolism. [Sawayama et al, 2005] 
 
Some studies have found that certain virulent H pylori strains bearing cytotoxin-
associated gene-A (CagA), [Pasceri et al, 1998] can increase cytokine expression and 
are associated with increased inflammation. [Elkind and Cole, 2006] [Grau et al, 2006] 
[Palm and Grau, 2007] Seroepidemiological case-control studies of H pylori CagA 
strains were found to be significantly associated with stroke risk after adjustment for 
parental social class and other potential confounders. [Pietroiusti et al, 2002] [Preusch 
et al, 2004] [Palm and Grau, 2007] A meta-analysis including seven studies have 
reported an odds ratio of 1.49 (95% CI: 1.24-1.81) for the association between H 
pylori seropositivity and stroke, and an odds ratio of 2.23 (95% CI: 1.49-3.36) for the 
association between anti-CagA seropositivity and stroke. [Cremonini et al, 2004] 
[Palm and Grau, 2007] Furthermore, infection with CagA positive H pylori strains in 
atherosclerotic stroke patients has been found to associate with greater intima-media 
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thickness and poorer short-term outcome compared with CagA negative patients. 
[Diomedi et al, 2004] 
 
Indeed, H pylori have also been identified directly in carotid plaques. [Ameriso et al, 
2001] Postulated mechanisms linking H pylori infection and stroke include molecular 
mimicry leading to a cross-reaction between antibodies against CagA and vascular 
wall antigens. [Palm and Grau, 2007] Others have postulated that chronic H pylori 
infection would increase the pH level of gastric juice and decrease ascorbic acid level. 
This would result in a reduction of folate absorption which could hamper methionine 
synthase reaction. [Corrado and Novo, 2005] This may lead to an increased 
homocysteine level in the blood that may contribute to endothelial cell damage and 
atherosclerosis. [Corrado and Novo, 2005] However, a causal relationship between H 
pylori infection and atherosclerosis or stroke has not been proven conclusively. [Palm 
and Grau, 2007] 
 
1.6.3. Periodontal pathogens 
 
Periodontal disease is a chronic progressive infection of the gingival, supporting 
connective tissue, and alveolar bone that hold the teeth in place. [Elkind and Cole, 
2006] There are over 300 types of bacteria that live in the oral cavity, but only a 
minority of these, predominantly gram-negative micro-organisms, is associated with 
gingivitis and periodontitis. [Elkind and Cole, 2006] Some more important examples 
of these micro-organisms are Porphyromonas gingivalis, Bacteroides intermedius, 
Actinobacillus actinomycetemcomitans, Bacteroides forsythus, Selonomonas 
sputigena, Eikenella corrodens, Fusobacterium nucleatum, Peptostreptococcus 
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anaerobius, Haemophilus wolinella, Prevotella intermedia, Campylobacter rectus, 
Tannerella forsythensis, oral streptococci and spirochetal species. [Williams, 1990] 
[Elkind and Cole, 2006] [Grau et al, 2006] A prospective seroepidemiological study 
has observed an association between two major periodontal pathogens and future 
stroke. [Pussinen et al, 2004] [Palm and Grau, 2007] Several periodontal pathogens 
including Porphyromonas gingivalis, Prevotella intermedia, Campylobacter rectus, 
Actinobacillus actinomycetemcomitans, Tannerella forsythensis, and oral streptococci   
have also been identified in carotid atherosclerotic plaques [Chiu, 1999] [Fiehn et al, 
2005] [Grau et al, 2006], although this has not been confirmed in another study 
[Aimetti et al, 2007]. However, experimental animal model has demonstrated that 
chronic inoculation of P gingivalis could worsen lipid profiles, enhance atheroma 
formation and produce calcification of aortic atherosclerotic plaques. [Li et al, 2002] 
[Palm and Grau, 2007] 
 
An association between tooth loss, periodontitis and carotid artery plaque prevalence 
has been observed. [Desvarieux et al, 2004] [Palm and Grau, 2007] Cross-sectional 
studies have demonstrated a correlation between dental radiograph abnormalities and 
carotid plaque. [Engebretson et al, 2005] [Elkind and Cole, 2006] Periodontal bone 
loss scores have also been found to be associated with stroke (adjusted odds ratio= 
2.8), more significantly than total coronary heart disease (OR= 1.5) and fatal coronary 
heart disease (OR= 1.9). [Beck et al, 1996] [Elkind and Cole, 2006] Other studies that 
have adjusted for confounding factors, have found an association between periodontal 
disease and stroke (relative risk= 2.1), [Wu et al, 2000] but not for coronary heart 
disease [Hujoel et al, 2000]. [Elkind and Cole, 2006] A more recent case-control 
study has also found an association between severe periodontitis (mean attachment 
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loss > 6 mm) and stroke / TIA, independent of traditional risk factors (odds ratio= 4.3, 
95% CI= 1.85-10.2). [Grau et al, 2004] [Palm and Grau, 2007]   
 
The periodontal pathogens may enter into the blood stream during minor dental 
manipulations including chewing, brushing and flossing. [Silver et al, 1977] 
Bacteremia and secondary infection of heart valves with embolism to the brain may 
cause a stroke. [Elkind and Cole, 2006] These micro-organisms can produce 
lipopolysaccharide that activates macrophages and contributes to the production of 
proinflammatory cytokines such as prostaglandins E2, interleukin-1β, and TNF-α. 
[Williams, 1990] These cytokines may also contribute to a pro-coagulant state 
through activation of endothelial cells and platelets, and an increased production of 
fibrinogen and von Willebrand factor. [Elkind and Cole, 2006] Indeed, in prospective 
interventional studies, a reduction in serum inflammatory markers (C-reactive protein 
and interleukin-6) and blood pressure, and an improvement in lipid profiles after 
intensive periodontal therapy have been demonstrated. [D’Aiuto et al, 2004(a)] 
[D’Aiuto et al, 2004(b)] [D’Aiuto et al, 2005] [D’Aiuto et al, 2006] [Palm and Grau 
2007] However, definitive evidence of a causal relationship between periodontal 
disease and stroke has not been established. [Palm and Grau, 2007] 
 
1.7. Chlamydia pneumoniae 
 
1.7.1. Introduction 
 
By far, the evidence linking Chlamydia pneumoniae infection and atherosclerosis or 
stroke is most abundant and appears to be the strongest. [Ngeh et al, 2002] [Ngeh and 
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Gupta, 2004] C pneumoniae was first isolated from the conjunctiva of a child in 
Taiwan in 1965 and designated as TW-183. [Dugan et al, 2002] [Ngeh and Gupta, 
2004] In 1983, it was isolated from the respiratory tract of a university student 
suffering from pharyngitis in Seattle, and designated as AR-39. [Dugan et al, 2002] 
[Ngeh and Gupta, 2004] C pneumoniae, thought to be a new strain of Chlamydia 
psitacci causing acute respiratory tract infection, was described by Grayston and his 
colleagues in 1986, and given the acronym TWAR (TaiWan Acute Respiratory). 
[Ngeh and Gupta, 2004] However, it was Saikku and his colleagues who first 
suggested that Chlamydia TWAR was associated with CHD or atherosclerosis in 
1988. [Leinonen and Saikku, 2002] TWAR was subsequently renamed as Chlamydia 
pneumoniae, and recognised as a separate species in the genus Chlamydia in 1989. 
[Ngeh and Gupta, 2004] 
 
1.7.2. Microbiology and epidemiology of Chlamydia pneumoniae 
 
Apart from Chlamydia trachomatis and Chlamydia psitacci, C pneumoniae is the only 
other species that causes human diseases within the genus of Chlamydia. [Ngeh and 
Gupta, 2004] C pneumoniae is a gram-negative, obligate intracellular bacterium that 
depends on its host cell for growth and survival. [Kalayoglu et al, 2002] The outer 
membrane of C pneumoniae is composed of lipopolysaccharides (LPS) and heat-
shock proteins (HSP) that are genus specific. [Ngeh and Gupta, 2004] However, 
several major outer membrane proteins (MOMP) identified are detectable by 
monoclonal antibodies and are species specific. [Ngeh and Gupta, 2004] 
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Chlamydia pneumoniae exists in three forms in its unique life cycle: 1. infectious, 
non-replicating elementary body (EB), 2. non-infectious but actively replicating 
reticulate body (RB), and 3. non-infectious, non-replicating persistent body (PB) (see 
Figure 1). [Kalayoglu et al, 2002] [Dugan et al, 2002] [Ngeh and Gupta, 2004] For 
example, the EB spore attacks the host’s cell by endocytosis and differentiates into 
RBs by binary fission in enlarging vacuoles called inclusion bodies. [Kalayoglu et al, 
2002] [Dugan et al, 2002] [Ngeh and Gupta, 2004] After inclusion maturation, the 
RBs redifferentiate into EBs, which are released by cytolysis, and start another cycle 
of infection. [Kalayoglu et al, 2002] [Dugan et al, 2002] [Ngeh and Gupta, 2004] 
However, the EB may transform into PB under conditions of immune stress such as in 
the presence of gamma interferon. [Kalayoglu et al, 2002] [Ngeh and Gupta, 2004] 
The PB may remain metabolically inactive and undetected by the host’s immune 
system, and remain unresponsive to antibiotics. [Kalayoglu et al, 2002] [Ngeh and 
Gupta, 2004] When the stress is removed, the PB may redifferentiate into infectious 
EB and released by cell lysis to begin a new life cycle. (see Figure 1) [Kalayoglu et al, 
2002] [Ngeh and Gupta, 2004] 
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Figure 1. Life cycle of Chlamydia pneumoniae 
 
Elementary body (EB) penetrates the host cell by endocytosis 
 
EB differentiates into Reticulate body (RB) 
       
     Replication of RB by binary fission in inclusion body 
                 No immune stress                        Immune stress e.g. γ-interferon 
   Inclusion body maturation     Transformation of RB into Persistent body (PB) 
                                                                     Removal of immune stress 
                    Redifferentiation of RB or PB into EBs 
                             EBs released by cytolysis      
                       EB begins a new cycle of infection 
 
 
Clinically, C pneumoniae is primarily a respiratory pathogen, although it also 
contributes to extra-pulmonary manifestations. [Kalayoglu et al, 2002] [Leinonen and 
Saikku, 2002] [Ngeh and Gupta, 2004] The infection is common worldwide and 
accounts for 5-20% of all cases of community-acquired pneumonia. [Ngeh and Gupta, 
2004] However, C pneumoniae infection can also be asymptomatic. [Dugan et al, 
2002] The incubation period of the infection is around 3-4 weeks. [Ngeh and Gupta, 
2004] Cyclical epidemics due to C pneumoniae have been observed to occur every 4-
7 years in western European countries. [Ngeh and Gupta, 2004] Most people are 
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infected several times in their lifetime. [Dugan et al, 2002] [Ngeh and Gupta, 2004] 
The seroprevalence of C pneumoniae is about 50% in middle-aged adults and rises to 
70%-80% in older populations. [Ngeh and Gupta, 2004] [Higgins, 2003] [Kalayoglu 
et al, 2002]  [Ngeh, 2000]  
 
The evidence linking C pneumoniae infection and atherosclerosis is derived from five 
areas of research: seroepidemiological, pathological, animal, immunological and 
antibiotic treatment studies. [Dugan et al, 2002] [Fong, 2002] [Kalayoglu et al, 2002] 
[Leinonen and Saikku, 2002] [Higgins, 2003] [Ngeh and Gupta, 2004] 
 
1.7.3. Evidence linking Chlamydia pneumoniae and atherosclerosis:  
1.7.3.1. Seroepidemiological observations 
 
Seroepidemiological studies are credited as the earliest area of research linking C 
pneumoniae and atherosclerotic vascular diseases. Since Saikku and his colleagues 
first showed a positive association between CHD and C pneumoniae antibodies in a 
case-control study in 1988, numerous (n> 100) sero-epidemiological studies of 
various designs i.e. retrospective, cross-sectional, case-control, or prospective studies, 
have suggested a positive association. [Ngeh and Gupta, 2004] More recently, 
seroepidemiological studies have also showed a positive association between C 
pneumoniae serological markers and other atherosclerotic vascular diseases such as 
stroke, abdominal aortic aneurysm, and peripheral arterial diseases. [Dugan et al, 
2002] [Ngeh et al, 2002] [Ngeh and Gupta, 2004] 
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Most of these positive seroepidemiological studies reported odds ratios (ORs) of 2 or 
higher. [Kalayoglu et al, 2002] [Higgins, 2003] [Ngeh and Gupta, 2004] However, a 
number of negative studies have also emerged. [Dugan et al, 2002] [Fong, 2002] 
[Kalayoglu et al, 2002] [Higgins, 2003] [Ngeh et al, 2002] [Ngeh and Gupta, 2004] 
More recently, large-scale prospective seroepidemiological studies and meta-analyses 
involving over 5000 cases have suggested a modest or weak association between C 
pneumoniae serological markers and CHD, with ORs between 1.15 to 1.25. 
[Kalayoglu et al, 2002] [Fong, 2002] [Ngeh and Gupta, 2004] Although some studies 
do not fully adjust for the influence of risk factors associated with C pneumoniae 
infection, others have been criticised for over-adjustment. [Fong, 2002] 
 
The current gold standard in C pneumoniae serology is microimmunofluorescence 
(MIF), a test originally developed to diagnose clinical C pneumoniae infection, rather 
than for epidemiological study of the role of C pneumoniae in atherosclerosis. 
[Leinonen and Saikku, 2002] The MIF is a subjective test and is dependent on an 
experienced microscopist. [Ngeh and Gupta, 2004] Different seroepidemiological 
studies have used different cut-off titres making comparison of data difficult. 
[Kalayoglu et al, 2002] [Higgins, 2003] [Ngeh and Gupta, 2004] Further efforts are 
required to standardise C pneumoniae serological assays and promote uniformity in 
laboratory practice. [Kalayoglu et al, 2002] [Ngeh and Gupta, 2004] 
 
Newer serological methods such as the enzyme-linked immunosorbent assays (ELISA) 
have been developed and readily available as commercial kits. [Ngeh and Gupta, 2004] 
[Ngeh et al, 2004(a)] These ELISAs give qualitative results that can be read by 
photometric machine rapidly and objectively. [Ngeh et al, 2004(a)] [Ieven and 
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Hoymans, 2005] Because ELISAs can afford a relatively high throughput and 
objectivity, they are increasingly used in seroepidemiological studies. [Ngeh and 
Gupta, 2004] [Ngeh et al, 2004(a)]  Preliminary data suggest that ELISA has a good 
sensitivity, specificity, and reproducibility when compared to MIF. [Ngeh and Gupta, 
2004] [Ngeh et al, 2004(a)] However, like the MIF, ELISA is still far from perfect as 
a diagnostic tool, and will require further standardisation and improvement. [Ngeh 
and Gupta, 2004] [Ngeh et al, 2004(a)] 
 
Serological markers such as immunoglobulin titres tend to fluctuate over time, and 
there is variability both within individuals and across populations. [Kalayoglu et al, 
2002] [Leinonen and Saikku, 2002] [Ngeh and Gupta, 2004] Moreover, C 
pneumoniae infection is more common in autumn or winter seasons, and during 
cyclical epidemics. [Dugan et al, 2002] [Ngeh and Gupta, 2004] The time of sampling 
will therefore affect the results of serological studies. In older age groups, the 
seroprevalence of C pneumoniae is over 70%, making comparison of the actual, 
though small, difference in seropositivity between the cases and the controls difficult.  
[Leinonen and Saikku, 2002] [Ngeh, 2000] There were also reports suggesting a poor 
correlation between endovascular or intracellular C pneumoniae infection or detection 
(e.g. by culture / polymerase chain reaction) and serological positivity. [Leinonen and 
Saikku, 2002] [Ngeh et al, 2002] [Apfalter, 2006] 
 
Nevertheless, obtaining patients’ serum and other blood components remain a 
relatively convenient and non-invasive method to study for C pneumoniae infection. 
Currently, serological methods alone may not reliably detect chronic or persistent C 
pneumoniae infection in a subgroup of patients that might benefit from antibiotic 
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interventional therapy. [Ngeh and Gupta, 2004] It remains unclear which classes and 
titres of antibodies in fact represent acute first or reinfection, past, persistent but 
inactive, or chronically active C pneumoniae infection. [Apfalter, 2006] C 
pneumoniae serology has also been criticized as problematic in terms of specificity, 
reproducibility, and uncertainty regarding the clinical meaning of specific titres. 
[Apfalter, 2006] Indeed, investigators are studying other blood markers such as C 
pneumoniae immune complexes and circulating leucocytes e.g. macrophages with 
detectable C pneumoniae DNA and mRNA as markers of underlying infection. 
[Kalayoglu et al, 2002] [Ngeh and Gupta, 2004] Seroepidemiological studies have 
progressed to examine for other blood markers of infections implicated in 
atherosclerosis, to correlate inflammatory markers such as C-reactive protein (CRP) 
in conjunction with C pneumoniae serology, and have shown association between 
‘infectious’ and ‘inflammatory’ burdens and atherosclerosis. [Leinonen and Saikku, 
2002] [Ngeh and Gupta, 2004] 
 
1.7.3.2. Evidence linking Chlamydia pneumoniae and atherosclerosis: 
Pathological specimen findings 
 
Shor and colleagues provided the first evidence that C pneumoniae can be detected 
within atherosclerotic or CHD specimen and visualised with electronmicroscopy (EM) 
in 1992 (see Figure 2). [Shor and Phillips, 2000] [Ngeh and Gupta, 2004] Since then, 
many (probably over 60) published reports have demonstrated the presence of C 
pneumoniae not only in coronary arteries, but also in cerebral, carotid, internal 
mammary, pulmonary, aorta, renal, iliac, femoral and popliteal arteries, and occluded 
bypass grafts, obtained from postmortem and surgical atheromatous tissues. 
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[Leinonen and Saikku, 2002] [Rassu et al, 2001] [Ngeh and Gupta, 2004] Different 
techniques such as immunocytochemistry (ICC), polymerase chain reaction (PCR), in 
situ hybridisation (ISH), and EM were used in these studies. [Ngeh and Gupta, 2004]  
The rate of detection was about 50% (range varies from 0-100%) in atheromatous 
tissues, [Grayston, 2000] [Taylor-Robinson, 1998] but less than 1% in ‘healthy’ 
arteries free from obvious atheroma. [Ngeh and Gupta, 2004] Specifically, PCR 
evidence of C pneumoniae can be found in the middle cerebral artery [Virok et al, 
2001] and other cerebral blood vessels [Vink et al, 2001]. C pneumoniae can also be 
detected in about 10% of non-cardiovascular and granulomatous tissues, showing a 
non-specific, ubiquitous distribution in human body. [Jackson et al, 1997] [Ngeh and 
Gupta, 2004] However, the distribution of C pneumoniae is known to correlate well 
with the distribution of atherosclerosis within the same individual. [Vink et al, 2001] 
[Ngeh and Gupta, 2004] 
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Figure 2. Transmission electron micrograph of smooth muscle cells in an early 
atherosclerotic lesion of the aorta positive for Chlamydia pneumoniae by polymerase 
chain reaction 
 
 
 
 
 
On the left, a smooth muscle cell containing vacuoles (V) and Chlamydia pneumoniae 
elementary bodies (arrowhead) are demonstrated. The other fragmenting cell and 
actin (A) filaments are also shown. On the right, macrophage pseudopodia (P) are 
shown in contact with a fragment of smooth muscle cell (SMC) containing Chlamydia 
pneumoniae (arrowheads).  
 
(Figure reproduced from: Shor A, Phillips J. Histological and ultrastructural findings 
suggesting an initiating role for Chlamydia pneumoniae in the pathogenesis of 
atherosclerosis: a study of fifty cases. Cardiovas J S Afr 2000;11:16-23, with 
permission. [Ngeh and Gupta, 2004]) 
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The presence of C pneumoniae in atherosclerotic lesions is not unique. It is known 
that other micro-organisms such as H pylori, CMV, Herpes simplex virus, periodontal 
pathogens, Mycoplasma pneumoniae [Higuchi et al, 2000], have also been detected in 
human atherosclerotic tissues. [Fong, 2002] [Leinonen and Saikku, 2002] However, C 
pneumoniae is to date, the only micro-organism that can be cultured alive, albeit with 
difficulty, from atheromatous plaques [Leinonen and Saikku, 2002] (Table 4) 
[Kalayoglu et al, 2002] [Johnston et al, 2001] [Ngeh and Gupta, 2004].  
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Table 2. Pathological studies that have detected or cultured viable C pneumoniae from 
human atherosclerotic tissues  
 
Year          Author                 Specimen            Detection Method     Positive (%)       Viable (%) 
 
1996          Ramirez                 Coronary             Culture/EM/ICC/       7/10 patients        1/10 patients  
                                                                             ISH/PCR                    (70%)                  (10%), by 
                                                                                                                                              culture 
                        
1997          Jackson et al          Carotid                Culture/EM/ICC/       12/16                    1/25  
                                                                             ISH/PCR                   specimens             specimens 
                                                                                                               (75%), other          (4%), by                                              
                                                                                                               than by culture      culture 
 
1998          Maass et al            Coronary,             Culture/PCR              21/70                   11/70  
                                                CABG                                                     patients               patients 
                                                                                                                (30%)                  (16%), by  
                                                                                                                                            culture                                          
 
1999          Bartels et al            Saphenous vein   Culture/PCR             8/32                        5/32 
                                                 CABG                                                   specimens               specimens 
                                                                                                               (25%)                     (16%), by 
                                                                                                                                              culture 
 
1999          Esposito et al          Carotid                 PCR/RT-PCR          18/30                      10/30 
                                                                                                                patients                   patients 
                                                                                                                (60%)                     (33%),  
                                                                                                                                               presence of 
                                                                                                                                               chlamydial 
                                                                                                                                               mRNA  by 
                                                                                                                                               RT-PCR 
  
2000          Karlsson et al          AAA                    Culture/IHC            21/26                      10/25 
                                                                                                               patients                   patients 
                                                                                                               (81%)                     (40%), by 
                                                                                                                                              culture 
 
2000          Apfalter et al      Carotid, coronary,    Culture/DIF/            -                              3/38          
                                             AAA, iliac,               PCR                                                        specimens 
                                             femoral, AV                                                                             (7.9%) 
 
2001          Johnston et al          Carotid                 PCR/RT-PCR           19/48                     18/48 
                                                                                                                specimens             specimens 
                                                                                                                (40%)                    (38%),  
                                                                                                                                              presence of 
                                                                                                                                              chlamydial 
                                                                                                                                              mRNA by 
                                                                                                                                              RT-PCR 
AAA= Abdominal aortic aneurysm, AV= Aortic valve, CABG= Coronary artery 
bypass graft, DIF= Direct, genus specific immunofluorescence staining, EM= 
Electron microscopy, ICC= Immunocytochemistry, IHC= Immunohistochemistry, 
ISH= In situ hybridisation, PCR= Polymerase chain reaction, RT-PCR= Reverse 
transcriptase-PCR 
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The methods used in histopathlogical studies i.e. EM, ICC, PCR, ISH, do not 
correlate with one another consistently, making comparison of studies in this area and 
others difficult. [Kalayoglu et al, 2002] [Leinonen and Saikku, 2002] [Ngeh and 
Gupta, 2004] PCR technique alone tends to give the lowest rate of C pneumoniae 
detection, whereas the highest rate of detection is by ICC or a combination of 
methods. [Kalayoglu et al, 2002] Further efforts are therefore required to improve and 
standardise these methods. [Ngeh and Gupta, 2004] 
 
In spite of methodological limitations, pathological examinations have shown that C 
pneumoniae has a tropism for arterial tissues and atherosclerotic lesions. [Jackson et 
al, 1997] [Ngeh and Gupta, 2004] Although the mere presence of C pneumoniae or its 
antigens in atheroma do not prove a causal role, pathological studies nevertheless 
support the rejection of the notion that C pneumoniae is simply an innocent 
‘bystander’. [Jackson et al, 1997] [Ngeh and Gupta, 2004] Increasingly, 
histopathological methods are used in conjunction with animal, immunological and 
antibiotic studies to examine for causal, mechanistic and treatment susceptibility 
effects of C pneumoniae in atherosclerosis. [Ngeh and Gupta, 2004] 
 
1.7.3.3. Evidence linking Chlamydia pneumoniae and atherosclerosis: Animal 
experimental models 
 
Historical precedents of animal models used to demonstrate infection-induced 
atherosclerosis include Benson’s Streptococcus-rabbit and Fabricant’s Herpesvirus-
chicken experimental models in 1931 and 1978 respectively. [Leinonen and Saikku, 
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2002] [Ngeh and Gupta, 2004] In 1997, Fong, Laitinen and co-workers were amongst 
the first to report that repeated C pneumoniae infection through the respiratory tract 
could induce not only pneumonia, but also inflammatory and atherosclerotic changes 
in the aortas of rabbits. [Fong et al, 1997] [Laitinen et al, 1997] [Ngeh and Gupta, 
2004]  Mycoplasma pneumoniae, another atypical respiratory pathogen used as a 
control in the study, was not found to induce any atherosclerotic lesions. [Leinonen 
and Saikku, 2002] Further animal experimentation demonstrated that treatment using 
azithromycin, a macrolide antibiotic active against C pneumoniae, could - though not 
invariably - counteract or reduce the atherogenic effect of C pneumoniae in the aortas 
of infected animals. [Dugan et al, 2002] [Leinonen and Saikku, 2002] [Ngeh and 
Gupta, 2004] 
 
Animal models are invaluable laboratory tools used to study the synergistic effects of 
some of the well-established cardiovascular risk factors e.g. atherogenic diet and 
genetic predisposition, in the context of C pneumoniae induced atherosclerosis. [Ngeh 
and Gupta, 2004] Dietary supplementations with cholesterol in C pneumoniae 
infected rabbits have been shown to increase the animals’ vascular intimal wall 
thickening. [Kalayoglu et al, 2002] [Fong, 2002] [Leinonen and Saikku, 2002] [Ngeh 
and Gupta, 2004] Genetically modified mouse such as ApoE-deficient mouse are 
known to develop atherosclerosis in the absence of a fatty diet. [Kalayoglu et al, 2002] 
[Fong, 2002] [Leinonen and Saikku, 2002] [Ngeh and Gupta, 2004] Repeated C 
pneumoniae infection has been shown to accelerate atherosclerotic lesion progression 
in this model, although a short 2-week course of azithromycin treatment did not 
reduce the size of the lesion. [Ngeh and Gupta, 2004] [Rothstein et al, 2001] 
Specifically, C pneumoniae infection was shown to increase T-lymphocyte influx in 
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the atherosclerotic plaques and to accelerate the formation of more advanced 
atherosclerotic lesions in ApoE3-Leiden mice. [Ezzahiri et al, 2002] [Ngeh and Gupta, 
2004] 
 
Further evidence suggests that the atherogenic effects of C pneumoniae infection were 
dependent on cholesterol and species specific to C pneumoniae as opposed to C 
trachomatis, in LDL-receptor-knockout transgenic mouse model. [Hu et al, 1999] 
[Ngeh and Gupta, 2004] On the other hand, the C57BL/6J mouse that does not 
develop atherosclerosis when fed a normal diet was shown to produce intimal 
thickening and carditis on repeated intranasal innoculation with C pneumoniae. 
[Campbell et al 1998] [Campbell et al, 1999] In addition, when fed a high fat diet, the 
infected C57BL/6J mice developed significantly larger atherosclerotic lesion areas 
compared with control mice. [Blessing et al, 2001] [Ngeh and Gupta, 2004] 
 
More recently, larger mammals such as dogs and pigs were used in animal studies. 
[Sako et al, 2002] [Liuba et al, 2002] [Pislaru et al, 2003] [Ngeh and Gupta, 2004] 
Using EM, ICC and PCR methods, a Japanese group of researchers have reported the 
presence of viable C pneumoniae in canine atheromatous tissues. [Sako et al, 2002] 
Report from Sweden has demonstrated that acute C pneumoniae infection of pigs 
through the respiratory tract could cause profound endothelial dysfunction in coronary 
arteries, thus supporting the role of C pneumoniae in artherogenesis. [Liuba et al, 
2002] More recently, a report using a pig model has shown that intracoronary and 
intrapulmonary C pneumoniae inoculation could induce coronary intimal proliferation 
in the absence of a lipid-rich diet. [Pislaru et al, 2003] However, direct administration 
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of macrophages infected with C pneumoniae into the pigs’ coronary arterial wall was 
not associated with the development of coronary lesions. [Pislaru et al, 2003] 
 
Animal models are useful to demonstrate a causal and temporal effect of C 
pneumoniae infection and subsequent development of atherosclerosis. [Ngeh and 
Gupta, 2004] They have shown that C pneumoniae infection could initiate and 
accelerate athrosclerotic process. [Kalayoglu et al, 2002] [Leinonen and Saikku, 2002]  
Moreover, the induced atherogenic process appears to correlate with increasing C 
pneumoniae infective dose and time from exposure, and accelerate with other 
atherogenic risk factors. [Leinonen and Saikku, 2002] [Ngeh and Gupta, 2004] The 
models could also help to define the role of antibiotic treatment in atherosclerosis. 
[Kalayoglu et al, 2002] [Ngeh and Gupta, 2004] However, exactly to what extent 
could laboratory induced atherogenesis in animal models reflects human 
atherosclerosis (which may take years to develop) remains an important issue to be 
resolved. [Ngeh and Gupta, 2004] 
 
1.7.3.4. Evidence linking Chlamydia pneumoniae and atherosclerosis: Molecular 
and immunological mechanisms 
 
Studies in this area have focused on the mechanistic roles of C pneumoniae in the 
inflammatory processes of atherosclerosis. [Ngeh and Gupta, 2004] A variety of 
studies have examined the interactions between C pneumoniae infections or antigens 
and components of athero-thrombotic tissues: (1) cells such as leucocytes, platelets, 
monocytes, endothelium, smooth muscle cells (SMC) and fibroblasts; (2) extra-
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cellular matrix and substrates such as collagens, elastin, gelatin and fibronectin. [Ngeh 
and Gupta, 2004] [Loftus et al, 2002] 
 
A range of molecules expressed by these cells have been identified: [Ngeh and Gupta, 
2004]  
1. Cytokines and chemokines: interleukins (e.g. IL-1, IL-2, IL-6, IL-8), tumour 
necrosis factors (e.g. TNF-α ), gamma interferon, monocyte integrins, monocyte 
chemotactic protein-1 (MCP-1), colony stimulating factor, growth factors (e.g. 
platelet-derived growth factor or PDGF,  basic fibroblast growth factor or bFGF), 
tissue factor. 
2. Adhesion molecules:  vascular cell adhesion molecule-1 (VCAM-1), intercellular 
adhesion molecule-1 (ICAM-1), E-selectin, P-selectin.  
 
These inflammatory cells and mediators are known to participate in complicated 
immunological cross-talks between C pneumoniae antigens and atherogenic / 
atherothrombotic processes. [Ngeh and Gupta, 2004]  
 
Chlamydia pneumoniae can infect and reproduce in human macrophages / monocytes, 
endothelial and smooth muscle cells. [Gaydos et al, 1996] These are the key cells 
involved in atherogenesis that have been shown to support the growth and 
proliferation of C pneumoniae in laboratory studies. [Ngeh and Gupta, 2004] From 
pathological, animal and clinical observations, it is postulated that C pneumoniae can 
infect macrophages in human respiratory tract and be carried by circulatory 
monocytes to invade arterial sites that are either developing or prone to develop 
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atherosclerosis. [Ngeh and Gupta, 2004] At the endothelial surfaces of these sites, C 
pneumoniae antigens could cause endothelial dysfunction and monocyte activation, 
and initiate or exacerbate a series of endovascular immunological reactions. [Gupta, 
1999] [Kalayoglu et al, 2002] [Ngeh and Gupta, 2004] Postulated mechanisms by 
which C pneumoniae could mediate proatherogenic effects include induction of these 
peripheral monocytes to secrete proinflammatory cytokines, [Kaukoranta-Tolvanen et 
al, 1996] association with cytotoxic (CD8) T cells, [Nadareishvili et al, 2001] and 
production of immune complexes [Linnanmaki et al, 1993] [Wimmer et al, 1996] 
 
Exprimental data has shown that C pneumoniae A-03 (a coronary strain) could 
stimulate the production of MCP-1, IL-8, and ICAM-1 by human endothelial cells in 
vitro. [Molestina et al, 1998] Circulating leucocytes e.g. monocytes and T-
lymphocytes, attracted by various mediators to the activated endothelial surface, could 
themselves be activated and express further inflammatory molecules (e.g. ILs and 
TNFs), which contribute to further cellular recruitment and chronic endothelial cell 
damage. [Ngeh and Gupta, 2004] Indeed, the ‘response-to-injury’ hypothesis refers to 
the fact that endothelial cell damage is the crucial initial stage in atherogenesis. [Ngeh 
and Gupta, 2004] Moreover, a number of traditional cardiovascular risk factors and 
infections are known to cause endothelial injury, dysfunction and activation. [Ngeh 
and Gupta, 2004] 
 
Monocytes and macrophages are the key transporters of LDL-cholesterol from 
systemic circulation into subendothelial space. [Kalayoglu et al, 2002] [Ngeh and 
Gupta, 2004] Indeed, C pneumoniae LPS has been identified as the antigen that could 
enhance LDL-cholesterol uptake and down-regulate cholesterol efflux in monocytes 
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and macrophages. [Kalayoglu et al, 2002] [Leinonen and Saikku, 2002] [Ngeh and 
Gupta, 2004] Once the monocytes and leucocytes (T-lymphocytes and neutrophils) 
are anchored by adhesion molecules onto the dysfunctional endothelial surface, 
transendothelial penetration into the subendothelial space occurs. [Koenig, 1999] 
[Molestina et al, 1999] [Ngeh and Gupta, 2004] Many of these monocytes loaded with 
oxidised LDL-cholesterol then transform into tissue macrophages known as foam 
cells. [Kalayoglu et al, 2002] [Fong, 2002] [Leinonen and Saikku, 2002] [Ngeh and 
Gupta, 2004] Indeed, Kalayoglu and Byrne in 1998 demonstrated that C pneumoniae 
LPS could induce not only LDL-cholesterol oxidation but also macrophage 
transformation into foam cells, a key atherogenic process. [Kalayoglu and Byrne, 
1998] [Kalayoglu et al, 2002] Furthermore, C pneumoniae heat shock protein-60 
(cHSP60) was found to induce cellular oxidation of LDL-cholesterol. [Kalayoglu et al, 
1999] [Ngeh and Gupta, 2004] The foam cells are known to participate in 
inflammatory and immunological reactions that lead to a fibroproliferative response 
from the arterial SMCs and the formation of artherosclerotic plaque. [Kalayoglu et al, 
2002] [Ngeh and Gupta, 2004] Moreover, C pneumoniae infected human SMCs have 
been shown to stimulate the production of IL-6 and bFGF that contribute to 
atherosclerotic fibrous plaque formation. [Kalayoglu et al, 2002] [Ngeh and Gupta, 
2004] 
 
Chlamydial cHSP60 and human hHSP60 were frequently found together in human 
atherosclerotic plaques. [Kol et al, 1998] [Ngeh and Gupta, 2004] Because they share 
sequence homology, cHSP60 could cross-react with hHSP60, causing antibody-
mediated cytotoxicity. [Ngeh and Gupta, 2004] In contrast, C pneumoniae-reactive T 
lymphocytes in human atherosclerotic plaques represent specific cell-mediated 
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immunity. [Kalayoglu et al, 2002] [Leinonen and Saikku, 2002] [Ngeh and Gupta, 
2004] These lymphocytes can produce gamma interferon and convert C pneumoniae 
into PB or persistent infection. [Kalayoglu et al, 2002] C pneumoniae can also inhibit 
apoptosis in infected host cells through inhibition of mitochondrial cytochrome-c 
release and caspase-3 activation, mediating a chronic infection. [Airenne et al, 2002] 
[Ngeh and Gupta, 2004]     
 
HSP60 could activate macrophages to release TNF-α and matrix metalloproteinases 
that can degrade connective tissue and cause plaque rupture leading to acute 
atherothrombotic events. [Kalayoglu et al, 2002] [Fong, 2002] [Ngeh and Gupta, 2004]     
These adverse events are enhanced by an increased vascular tone resulting from 
decreased nitric oxide and prostacyclin production by dysfunctional endothelium, in a 
procoagulant environment due to tissue factor expression by activated monocytes. 
[Ngeh and Gupta, 2004] Apart from its local endovascular effects, C pneumoniae can 
also systemically interact with circulating blood cells; stimulate hepatic synthesis of 
inflammatory markers e.g. CRP, fibrinogen and neopterin; disturb lipoptotein 
metabolism; enhance clotting cascade; and promote atherothrombotic events (see 
Figure 3 below). [Ngeh and Gupta, 2004] [Gupta, 1999]      
 
More recent studies have reported specific signalling pathways involved in C 
pneumoniae pathogenic mechanisms. [Ngeh and Gupta, 2004] For example, C 
pneumoniae and cHSP60 were shown to stimulate human vascular SMCs 
proliferation through the activation of toll-like receptor 4 that acts as antigenic sensor 
for C pneumoniae, with signalling through the p44/p42 mitogen-activated protein 
kinase (MAPK) pathway. [Sasu et al, 2001] The activation of nuclear transcription 
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factors such as NF-κB and Activator Protein-1 (proliferative intracellular signals) by 
C pneumoniae was found to induce vascular SMCs proliferation, an effect that can be 
abolished by the antibiotic azithromycin. [Miller et al, 2000] NF-κB activation in C 
pneumoniae infected cells was shown to induce the production of pro-inflammatory 
and pro-coagulant substances. [Dechend et al, 1999] [Molestina et al, 2000] [Miller et 
al, 2000] In addition, NF-κB was found to regulate many of the inflammatory 
vascular effects in hypercholesterolaemia. [Wilson et al, 2000] [Lindsberg and Grau, 
2003] 
  
In conjunction with traditional atherosclerotic risk factors, Figure 3 [Ngeh and Gupta, 
2004] [Kalayoglu et al, 2002] [Gupta, 1999] in the following page showed that C 
pneumoniae infected monocyte may be activated and contribute towards endothelial 
dysfunction and subsequent foam cell transformation and inflammatory response in 
the subendothelial space. Monocyte activation and endothelial dysfunction also lead 
to secretion of cytokines and acute-phase proteins, expression of adhesion molecules, 
and up-regulation of tissue factor and monocyte integrins. These processes may either 
act independently or interact leading to atherogenesis and athrothrombosis.  
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In keeping with traditional theories of atherogenesis, various mechanistic, molecular 
and immunological studies have demonstrated a pathogenic role of C pneumoniae 
infection in different stages of atherosclerosis. Further understanding and progress in 
this area of research – the ‘infectious hypothesis of atherosclerosis’ – may provide 
important ‘laboratory-based’ causal evidence of C pneumoniae or other micro-
organisms in atherosclerosis; and stimulate ‘clinical’ prevention, interventional and 
therapeutic strategies. [Ngeh and Gupta, 2004] 
 
1.7.3.5. Evidence linking Chlamydia pneumoniae and atherosclerosis: Antibiotic 
treatment studies 
 
Most of the investigations in this area involved clinical antibiotic interventional trials 
in the secondary prevention of coronary heart disease (CHD). Others have examined 
the impact of antibiotic treatment on CHD in retrospective epidemiological studies. 
The results of these studies in the context of CHD are largely negative or at best, 
inconclusive. Apart from CHD, antibiotic treatment studies in the clinical context of 
abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD), and carotid 
artery stenosis are emerging (see Table 5). [Ngeh and Gupta, 2004] [Higgins, 2003] 
[Dugan et al, 2002] [Grayston, 2003] [Cercek et al, 2003] [Hansen et al, 2001] 
[Melissano et al, 1999] [Parchure et al, 2002] [Hillis et al, 2004] [Grayston et al, 2005] 
[Cannon et al, 2005] [Vainas et al, 2005] [Jespersen et al, 2006] 
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Table 5. Antibiotic treatment studies and atherosclerotic vascular diseases 
 
 
Trial/Year        Population/Number        Antibiotic/Course        Trial duration        Results     
        
       Antibiotic Treatment and Coronary Heart Disease 
 
 
St George’s        Post MI, 220 males           Azithromycin,                1.5 years                 Positive 
Hospital,                                                      3 or 6 days 
London, UK. 
RCT, 1997 
 
ROXIS,              ACS, 202 (76% men)        Roxithromycin,              6 months                 Positive at  
Argentina.                                                     30 days                                                          1 month, 
RCT, 1997                                                                                                                           negative at 
                                                                                                                                             3 and 6 
                                                                                                                                             months 
 
University of     Post PTCA, 88                    Azithromycin,                6 months                 Positive 
Washington,                                                  28 days 
USA                                                                
RCT, 1998 
 
ACADEMIC,     Stable CAD, 302                Azithromycin,                2 years                    Negative 
USA.                  (89% men)                          3 months                                                    
RCT, 1999    
 
ISAR-3,              Post coronary stenting,       Roxithromycin,              1 year                     Negative,  
Germany.            1010 (78% men)                 28 days                                                         restenosis  
RCT, 2001                                                                                                                            reduced in  
                                                                                                                                             patients  
                                                                                                                                             with titres 
                                                                                                                                             1/512 
 
Siriraj Hospital,   ACS, 84 (63% men)          Roxithromycin,               90 days                 Negative 
Bangkok,                                                        30 days 
Thailand. 
RCT, 2001 
 
STAMINA,        ACS, 325 (69% men)          Azithromycin or            1 year                     Positive 
UK.                                                                 Amoxicillin, and 
RCT, 2002                                                       Metronidazole, 
                                                                        7 days 
                                                                         
WIZARD,           Stable CAD, 7724               Azithromycin,                1-4 years                7% event 
International        (83% men)                          3 months                        (mean 2.5 years)    reduction 
multicentre                                                                                                                            (hazard   
trial.                                                                                                                                       ratio 0.93, 
RCT, 2002                                                                                                                             P= 0.23) 
 
CLARIFY,          ACS, 148 (70% men)          Clarithromycin,             138-924 days         Positive 
Finland.                                                            3 months                       (mean 555 days 
RCT, 2002                                                                                              or 1.5 years) 
 
St George’s         Stable CAD,                         Azithromycin,               5 weeks            Improvement 
Hospital,             40 males                               3 days, then weekly                                in FMD of 
London, UK.                                                    for 4 weeks                                           brachial artery, 
RCT, 2002                                                                                                                      P< 0.005  
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AZACS,              ACS, 1439 (74% men)        Azithromycin,                6 months               Negative  
USA.                                                                5 days 
RCT, 2003 
 
       ANTIBIO,          ACS, 872 (79% men)          Roxithromycin,               1 year                    Negative 
Germany.                                                        6 weeks 
RCT, 2003 
 
Hillis et al,          ACS, 141                             Azithromycin,                3 months               soluble  
Edinburgh, UK                                                5 days                                                       intercellular 
RCT, 2004                                                                                                              adhesion molecule 
                                                                                                                                             reduced 
 
ACES,                  Stable CAD, 4012             Azithromycin,                 4 years                  Negative 
USA.                                                               weekly for 1 year                                       
RCT, 2005 
 
PROVE IT,          ACS, 4162                        Gatifloxacin,                     2 years                  Negative 
International                                                    2 weeks, then                                                  
Multicentre                                                      10-day course 
trial.                                                                 monthly for 
RCT, 2005                                                       2 years 
 
Berg et al,             Pre-CABG surgery,          Clarithromycin,                2 years                  Negative 
Netherlands.          473                                    mean= 16 days 
RCT, 2005 
 
CLARICOR,         Stable CAD                      Clarithromycin,                3 years                  Negative    
Denmark.               4373                                 2 weeks 
Multicentre trial. 
RCT, 2006 
    
       Antibiotic Treatment and Carotid Atherosclerosis (CA), Abdominal Aortic Aneurysm (AAA), 
and Peripheral Arterial Disease (PAD) 
 
 
       Italy                       C pneumoniae                    Roxithromycin,               17-35 days             Positive, 
       RT, 1999                burden in CA,                     17-35 days                      (mean 26 days)     P= 0.034   
                                      32 (16 males)                     (mean 26 days) 
       
       Finland                   AAA growth,                     Doxycycline,                   1.5 years                Positive, 
       RCT, 2001             32 (29 males)                      3 months                                                        P= 0.03 
        
       Denmark                AAA growth,                      Roxithromycin,               1.5 years               Positive, 
       RCT, 2001             92 males                              28 days                                                          P= 0.02 
 
       Switzerland            PAD progression,               Roxithromycin,                2.7 years              Positive, 
       RCT, 2002             40 males                               28 days                                                         P< 0.05 
 
       Germany                CA progression,                  Roxithromycin,                2 years                 Positive,  
       RCT, 2002             272 (56% men)                    30 days                                                         P< 0.01 
 
       SPACE Trial,         PAD, 509                            Azithromycin,                  2 years                Negative 
       Netherlands                                                         3 days 
       RCT, 2005   
 
ACS= Acute coronary syndrome, CAD= Coronary artery disease, FMD= Flow mediated dilation, MI= 
Myocardial infarction, PTCA= Percutaneous transluminal coronary angioplasty, RCT= Randomised 
controlled trial 
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In 1997, the positive results of two pilot antibiotic treatment studies were reported 
independently by Gupta and colleagues in the United Kingdom (UK) [Gupta et al, 
1997] and Gurfinkel and colleagues in Argentina [Gurfinkel et al, 1997].  In the UK 
study, 60 male survivors of acute myocardial infarction (MI) with persistently raised 
C pneumoniae IgG antibody titres > 1:64 were randomised to receive placebo or a 
macrolide antibiotic azithromycin (500mg per day for 3 or 6 days). Apart from a 
reduction in cardiovascular events at 18 months in the treatment group, there was also 
a reduction in several inflammatory / monocyte activation markers and C pneumoniae 
IgG antibody titres, in comparison with the placebo group and non-randomised group 
with high antibody titres. 
 
The Argentinian ROXIS (Roxithromycin in Ischaemic Syndromes) study randomised 
hospitalised patients with unstable angina or non Q-wave MI (n= 202) to receive a 
placebo or another macrolide antibiotic roxithromycin (150mg twice daily) for 30 
days. [Gurfinkel et al, 1997] At 1 month, a reduction in the combined triple end-point 
(severe recurrent angina, acute MI, ischaemic death) in the treatment group was 
reported. However, at 3 and 6 months, the beneficial effect of antibiotic treatment 
became non-significant, although inflammatory markers such as the CRP level 
decreased more significantly in the treatment group. This implied that a longer 
duration of antibiotic treatment trial might have been necessary to confer more lasting 
protective effects. [Ngeh and Gupta, 2004] 
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Another pilot antibiotic treatment study was reported in 1998 [Dugan et al, 2002]. 
Eighty-eight patients who had had percutaneous transluminal coronary angioplasty 
were randomised to receive azithromycin 500mg daily or placebo for 2 days, followed 
by azithromycin 250mg daily or placebo for 28 days. The investigators found that 
patients in the treatment group had less re-stenosis (9%) than those in the placebo 
group (16%), and also less recurrent angina (40% versus 60%, respectively). However, 
the positive results were not sustained in a larger follow-up study. 
 
In 1999, the findings of Azithromycin in Coronary Artery Disease Elimination of 
Myocardial Infection with Chlamydia (ACADEMIC) study were reported from the 
United States. [Anderson et al, 1999] The ACADEMIC study randomised 302 
subjects with elevated C pneumoniae antibody titres and CHD to receive a placebo or 
a 3-month course of azithromycin (500mg/day for 3 days, then 500mg/week). The 
investigators found no difference in clinical outcome at 6 months and at 2 years in 
both placebo and treatment groups. [Anderson et al, 1999] [Muhlestein et al, 2000] 
However, a reduction in inflammatory markers such as CRP, IL-1, IL-6, and TNF-α 
was found at 6 months. [Anderson et al, 1999] 
 
The ISAR-3 (Intracoronary Stenting and Antibiotic Regime trial-3) study published in 
2001 investigated whether roxithromycin could prevent C pneumoniae-associated re-
stenosis after coronary stent placement. [Neumann et al, 2001] Consecutive patients 
were randomised in a double-blind fashion to receive a placebo (n= 504) or 300mg 
daily of roxithromycin (n= 506) for 28 days. The investigators reported no real 
difference in outcome as the rate of angiographic stenosis was 31% in the treatment 
group versus 29% in placebo group at follow-up. The combined 1-year mortality and 
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MI rates were also similar in both groups i.e. 7% in treatment group versus 6% in 
placebo group. However, in those patients with high C pneumoniae antibody titres i.e. 
1:152, the investigators found that roxithromycin treatment significantly reduced the 
rate of re-stenosis after coronary stenting. This suggested that selective usage of 
roxithromycin in some patients with C pneumoniae infection might reduce post 
coronary stenting re-stenosis. [Ngeh and Gupta, 2004] 
 
In a small Thai study, 84 patients with acute coronary syndrome were randomized to 
receive roxithromycin (150mg BD) or placebo for 30 days. [Leowattana et al, 2001] 
[Higgins, 2003] [Grayston, 2003] After a follow-up period of 90 days, the 
investigators found no significant difference in adverse cardiovascular events between 
the roxithromycin and placebo groups (17 versus 16). 
 
Several antibiotic treatment studies were reported in 2002. The South Thames Trial of 
Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA) is another 
small UK study. [Higgins, 2003] [Grayston, 2003] In this study, 325 patients with 
acute coronary syndromes (unstable angina or first MI) were randomised to receive a 
1-week course of either placebo; amoxicillin (500mg BD), metonidazole (400mg BD), 
and omeprazole (20mg BD); or azithromycin (500mg OD), metronidazole (400mg 
BD), and omeprazole (20mg BD). The investigators found that antibiotic treatment 
significantly reduced adverse cardiac events at 12 months. This favourable treatment 
effect appeared to be independent of seropositivity to C pneumoniae and H pylori, and 
there was no difference found between the azithromycin and amoxycillin groups. The 
CRP and fibrinogen levels were found to decrease in the antibiotic treatment groups. 
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The WIZARD (Weekly Intervention with Zithromax for Atherosclerosis and Its 
Related Disorders) study is a large randomised, placebo controlled study that has 
enrolled more than 7,000 patients who had an MI at least 6 weeks before enrolment 
and had C pneumoniae IgG titres > 1:16. [O’Connor et al, 2003] Of these, 3,868 
patients were randomised to receive azithromycin 600mg/day for 3 days, then 600mg 
weekly for 11 weeks, and 3,856 patients received placebo. At the 2-year follow-up, 
the investigators found a 7% reduction in the composite primary end point of all-
cause mortality, recurrent MI, hospitalisation, and revascularisation (hazard ratio= 
0.93, P= NS).  
 
The Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) 
study reported favourable results with antibiotic treatment. [Sinisalo et al, 2002] In 
this small study, 148 patients with unstable angina or acute non-Q-wave coronary 
events were randomised to receive either clarithromycin 500mg or a placebo once 
daily for 85 days. During the initial 3-month treatment period, there were 11 patients 
in the treatment group compared to 19 patients in the placebo group that met the 
combined primary end point of death, MI, or unstable angina (P= 0.1). Over an 
average period of 555 days, there were also fewer patients experiencing 
cardiovascular events in the treatment group (16 versus 27 in the placebo group; P= 
0.03). 
 
In the AZACS (Azithromycin in Acute Coronary Syndromes) study, 1439 patients 
with unstable angina or acute MI were randomly assigned to receive azithromycin 
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(500mg for 1 day, then 250mg for 4 more days) or placebo. [Cercek et al, 2003] 
Patients were followed-up for 6 months. There were no differences found between the 
two groups in terms of adverse outcome such as the incidence of death, recurrent MI 
and revascularisation.  
 
The ANTIBIO was a German study reported in 2003. [Zahn et al, 2003] A total of 
872 patients with an acute MI were randomized to receive either roxithromycin 
300mg or placebo daily for 6 weeks. After a 12-month follow-up period, the 
investigators found that roxithromycin treatment did not reduce death and adverse 
cardiac events when compared with the placebo group. 
 
The ACES (Azithromycin and Coronary Events Study) was an American study 
published in 2005. [Grayston et al, 2005] In this study, 4,012 patients with stable 
coronary artery disease were randomised to receive either 600mg of azithromycin or 
placebo weekly for one year. The mean duration of follow-up was 3.9 years. The 
results showed that there was no significant risk reduction in the azithromycin group 
as compared with the placebo group with regard to cardiac events, death from any 
cause, or stroke. 
 
The PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) study 
was a double-blind, randomised, placebo-controlled trial published in 2005. [Cannon 
et al, 2005] In this study, 4162 patients who had been hospitalised for an acute 
coronory syndrome within the preceding 10 days were randomized to receive 400 mg 
of gatifloxacin daily during an initial 2-week course of treatment that began 2 week 
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after randomisation, followed by a 10-day course every month for a mean duration of 
2 years, or placebo. The results showed that long term treatment with gatifloxacin, a 
bactericidal antibiotic effective against C pneumoniae, did not reduce the rate of 
cardiovascular events, death from all causes, or stroke. 
 
In 2005, another study reported that treatment with clarithromycin (mean duration= 
16 days) prior to coronary artery bypass graft surgery did not prevent subsequent 
cardiac events or mortality during a 2-year follow-up period. [Berg et al, 2005(a)] The 
investigators also reported that C pneumoniae DNA was not present in vascular tissue, 
including atherosclerotic plaques of patients with advanced coronary artery disease. 
[Berg et al, 2005(b)] They concluded that antibiotic treatment was unlikely to have 
any effect in patients with advanced atherosclerosis. 
 
The CLARICOR trial published in 2006 was a randomised placebo controlled 
multicentre trial that assessed a 2-week treatment effect of clarithromycin (500 mg per 
day) in patients with stable coronary heart disease. [Jespersen et al, 2006] 2,172 
participants were randomised to clarithromycin and 2,201 to placebo. The study found 
no significant beneficial effects of clarithromycin on adverse cardiovascular events. In 
addition, the study found that cardiovascular mortality was significantly higher in 
patients treated with clarithromycin (hazard ratio= 1.45; 95% CI= 1.09 to 1.92; P= 
0.01). The long term safety issue of clarithromycin treatment in patients with stable 
ischaemic heart disease was raised. [Jespersen et al, 2006] 
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Contradictory results have been reported in several large-scale retrospective, 
antibiotic treatment case-control studies. In the first study involving 3,315 cases and 
13,139 controls, Meier and colleagues provided indirect evidence for a positive 
association between past usage of antibiotics such as tetracycline or quinolones (but 
not macrolides) and the reduction in risk of first-time MI. [Meier et al, 1999] 
However, the results of another similar study (1,796 cases vs 4,882 controls) 
suggested that past usage of tetracycline, doxycycline or erythromycin (a macrolide) 
was not associated with the risk of first MI. [Jackson et al, 2000]  Further study on the 
usage of a variety of antibiotics and their relationship to first MI in a population 
involving 354,258 patients was also reported with negative results. [Luchsinger et al, 
2002] Another study involving a database of 26,195 patients concluded that exposure 
to anti-chlamydial antibiotics (tetracyclines, macrolides and quinolones) during the 3 
months after an acute MI was associated with a small survival benefit, whereas 
exposure during the 6 months before an acute MI did not affect survival. [Pilote et al, 
2002] In another case-control study nested within a cohort of 29,937 elderly subjects 
on antihypertensive treatment, a trend was observed for a decreased risk of acute MI 
in patients receiving a prescription for antichlamydial antibiotics in the preceding 3 
months (Odds ratio= 0.68; 95% CI= 0.46 to 1.00); but antibiotics without 
antichlamydial activity showed no benefit in reducing the risk of MI. [Brassard et al, 
2003(a)] Using the same study design and cohort of patients, the investigators 
reported no clear, consistent associations between overall antibiotic use and stroke; 
although penicillin was the only individual antibiotic class that showed a protective 
association between penicillin use and stroke. [Brassard et al, 2003(b)] Indeed, an 
earlier study  has concluded that exposures to short courses of antibiotics were not 
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associated with lower risk of ischaemic stroke in patients aged 65 years and older 
[Luchsinger et al, 2001] 
 
Several meta-analyses on randomized controlled trials (enrolling almost 20,000 
patients) that evaluated the effect of antibiotics on the secondary prevention of 
coronary artery diseases have been reported. [Etminan et al, 2004] [Wells et al, 2004] 
[Andraws et al, 2005] [Baker and Couch, 2007]. These meta-analyses concluded that 
evidence available to date did not demonstrate an overall benefit of antibiotic or 
macrolide therapy in the reduction of cardiovascular events or mortality in patients 
with coronary artery disease.  
 
A positive treatment effect of roxithromycin on small abdominal aortic aneurysm 
(AAA) expansion rate especially in patients with C pneumoniae IgA seropositivity 
was reported in 2001. [Vammen et al, 2001] The investigators in this study 
randomised 92 male subjects to receive either roxithromycin 300mg per day or 
placebo for 28 days, and patients were followed up for a mean period of 1.5 years. 
They found that the expansion rate of AAA was reduced by 44% i.e. 1.56mm per year 
in the treatment group versus 2.80 mm per year in the placebo group (p= 0.02). 
During the second year, the difference was only 5%. The results remained significant 
even after multiple linear and logistic regression statistical analyses. A similar 
positive result of a significant reduction in the AAA expansion rate was reported in 
another randomised, double-blind, placebo-controlled pilot study (32 patients 
followed up for 18 months) using the antibiotic doxycycline. [Mosorin et al, 2001] 
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In the clinical context of peripheral arterial disease (PAD), a pilot study that 
randomised 40 C pneumoniae seropositive men suffering from peripheral arterial 
occlusive disease to receive either roxithromycin 300mg daily or placebo for 28 days 
reported its results in 2002. [Wiesli et al, 2002] During a follow-up period of 2.7 years, 
the investigators found that there were significantly fewer numbers of invasive 
revascularisation per patient in the treatment group (5 interventions performed on 4 
patients) in comparison with the placebo group (29 interventions on 9 patients), even 
after multiple regression analyses. They also reported that limitation of walking 
distance to 200 metres or less occurred in fewer patients in the treatment group than in 
the placebo group (4 vs 13). Interestingly, they also observed a significant regression 
of the size of soft carotid plaques in the roxithromycin treated patients. [Wiesli et al, 
2002] However, a subsequent randomised, placebo-controlled study involving 509 
patients with PAD reported that a 3-day course of azithromycin (500mg daily) did not 
show any benefit for survival or ankle pressure during 2 years of follow-up. [Vainas 
et al, 2005] 
 
In 1999, an Italian randomised study reported that treatment with a course of 
roxithromycin (150mg twice daily for a mean of 26 days) before carotid 
endarterectomy appeared effective in reducing the bacterial burden of C pneumoniae 
within carotid atherosclerotic specimens using PCR detection method. [Melissano et 
al, 1999] In 2002, a group of investigators in Germany reported that roxithromycin 
treatment reduced progression of early carotid atherosclerosis in C pneumoniae 
seropositive patients with ischaemic stroke. [Sander et al, 2002] They randomized 272 
patients with ischaemic stroke aged over 55 years to receive either roxithromycin 150 
mg twice daily or placebo for 30 days. In the 62 C pneumoniae seropositive patients 
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that received roxithromycin, there was a significantly decreased common carotid 
artery intima-to-media thickness (IMT) progression after 2 years, when compared 
with C pneumoniae seropositive patients (n= 63) that received placebo. They 
observed no significant difference in IMT progression in C pneumoniae seronegative 
patients that received either roxithromycin (n= 74) or placebo (n= 73). In addition, no 
significant difference in the occurrence of future cardiovascular events (stroke, MI or 
vascular death) was observed in either the treatment or placebo groups. The CRP 
levels decreased after roxithromycin treatment more significantly in the C 
pneumoniae- seropositive than in the seronegative patients, when compared with their 
respective pre-treatment values. When the CRP levels in these 2 treatment groups 
were compared with their respective placebo groups, a significant difference was only 
observed in the C pneumoniae positive group. These results implied that 
roxithromycin might have a greater anti-chlamydial than its anti-inflammatory effects. 
[Grayston et al, 2003] [Ngeh and Gupta, 2004] However, these investigators 
subsequently reported that the IMT progression increased again during the third and 
fourth year to similar values as before treatment, and suggested that antibiotic therapy 
had limited positive impact on early atherosclerosis progression in C pneumoniae 
positive patients. [Sander et al, 2004] A need for long-term or intermittent treatment 
may be indicated, since C pneumoniae may persist in monocytes in a latent state. 
[Elkind and Cole, 2006]    
 
Rather than focussing on adverse clinical events as outcome measures, a recent UK 
study assessed the treatment effect of azithromycin on endothelial function in patients 
with CHD that were seropositive to C pneumoniae. [Parchure et al, 2002] The 
investigators randomised 40 male patients with CHD and C pneumoniae IgG antibody 
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to receive either azithromycin (500mg per day for 3 days, then 500mg once weekly 
for 4 weeks) or placebo. They found that patients in the treatment group, irrespective 
of their initial C pneumoniae antibody titres, had a significant improvement in flow-
mediated dilation (FMD) of the brachial artery when compared to those in the placebo 
group. Azithromycin treatment also resulted in a significant decrease in E-selectin and 
von Willebrand factor (both markers of endothelial dysfunction) but not CRP levels. 
They concluded that azithromycin treatment had a favourable effect on endothelial 
function in patients with CHD and evidence of C pneumoniae infection. Indeed, 
another randomised treatment study reported that after an acute coronary syndrome, a 
5-day course of azithromycin reduced levels of soluble intercellular adhesion 
molecule-1, a marker of endothelial cell activation. [Hillis et al, 2004] 
 
Several important issues need to be addressed in future antibiotic treatment studies. 
The macrolides and tetracyclines used in the treatment studies are known to possess 
anti-inflammatory and immuno-modulatory effects, in addition to their anti-
chlamydial activities. [Higgins, 2003] [Leinonen and Saikku, 2002] [Ngeh and Gupta, 
2004] The relative contribution of these independent pharmacological properties in 
treatment studies and their concurrent anti-microbial effects on other micro-organisms 
need to be delineated. [Ngeh and Gupta, 2004] Furthermore, the optimal dose and 
dosing regime, duration and even cycles of antibiotic treatment in future studies will 
need to be tested; since reinfection with C pneumoniae is common. [Andraws et al, 
2005] Previous study has found that C pneumoniae infection in circulating human 
monocytes was not ameliorated by antibiotics. [Gieffers et al, 2001] While under 
immune stress, C pneumoniae may transform into PB and becomes resistant to 
treatment yet capable of inciting inflammation. (Figure 1) [Kalayoglu et al, 2002] 
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[Andraws et al, 2005]  Apart from its bacteriostatic or bacteriocidal property, whether 
an antimicrobial can reliably eradicate different forms of C pneumoniae (including PB) 
or can penetrate atheromas effectively, will also need to be explored and determined. 
[Ngeh and Gupta, 2004] [Andraws et al, 2005]  
  
It is also important to develop reliable methods that can detect true markers reflecting 
chronic / persitent C pneumoniae infection or high infectious burden in individuals 
targeted in future antibiotic treatment studies. [Ngeh and Gupta, 2004] As C 
pneumoniae is known to associate with different stages of atherosclerosis, it will be 
important to target homogenous populations with similar atherosclerotic burden and 
in different age groups to verify treatment effects. [Ngeh and Gupta, 2004]  Hence, 
antibiotic treatment studies in the setting of primary prevention in high risk population 
with silent / subclinical atherosclerosis should be considered. [Ngeh and Gupta, 2004] 
Future antibiotic treatment studies should increasingly utilise and incorporate other 
surrogate (e.g. radiological, pathological, blood) markers of plaque activities (which 
may be clinically silent) to assess treatment effects, rather than using clinical vascular 
events as the sole outcome measure. [Ngeh and Gupta, 2004] 
 
1.7.4. Chlamydia pneumoniae, atherosclerotic risk factors and Koch’s postulates 
 
Because atherosclerosis is a complicated multifactorial disease with many clinical 
variables, it is important to assess the role of C pneumoniae in the context of other 
well established atherosclerotic risk factors. [Ngeh and Gupta, 2004] Interestingly, C 
pneumoniae infection is known to be associated with classical vascular risk factors 
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such as smoking and those of the metabolic syndrome: hypertension, dyslipidaemia, 
diabetes, obesity. [Kalayoglu et al, 2002] [Fong, 2002] [Leinonen and Saikku, 2002] 
[Ngeh and Gupta, 2004] In addition, C pneumoniae infection is also more commonly 
associated with other non-modifiable vascular risk factors such as male sex, age, and 
certain genetic predisposition (HLA DRII genotype 13a or 17) [Dahlen et al, 1995]. 
[Leinonen and Saikku, 2002] [Ngeh and Gupta, 2004] Furthermore, C pneumoniae 
infection is also associated with novel vascular risk factors such as 
hyperhomocysteinaemia [Stanger et al, 2002] and elevated CRP [Kalayoglu et al, 
2002] [Leinonen and Saikku, 2002] [Ngeh and Gupta, 2004]. As all major vascular 
risk factors are known to correlate with one another in a synergistic way, it is 
conceivable that chronic C pneumoniae infection may represent a forceful 
inflammatory stimulus that will interact with all these major vascular risk factors in 
the pathogenesis and clinical manifestations of atherosclerosis. [Ngeh and Gupta, 
2004] Indeed, studies that examined specific mechanistic interactions (e.g. iron and 
lipid metabolisms, immunological expressions) between C pneumoniae and specific 
vascular risk factors (e.g. gender, dyslipidaemia, genetic polymorphisms) are 
emerging. [Leinonen and Saikku, 2002] 
 
C pneumoniae is unlikely to be the sole cause of atherosclerosis, a complicated 
disease with its many clinical manifestations. [Ngeh and Gupta, 2004] This is in 
contrast to the H Pylori-peptic ulcer disease causal link, where the latter is a more 
straightforward disease with fewer risk factors and clinical variables. Traditionalists 
may demand a strict fulfilment of Koch’s postulates in order to establish that C 
pneumoniae infection is a cause of atherosclerosis. [Ngeh and Gupta, 2004]  Although 
this is not always possible in the case of C pneumoniae-atherosclerosis association, it 
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must be remembered that the accepted H pylori-peptic ulcer causal link does not 
always satisfy Koch’s postulates either. [Ngeh and Gupta, 2004] (see Table 6) [Ngeh 
and Gupta, 2000]  
 
Table 6. Koch’s postulates for infectious diseases: Chlamydia pneumoniae in 
atherosclerosis versus Helicobacter pylori in peptic ulcer disease. 
  
Koch's Criteria Chlamydia pneumoniae in 
atherosclerosis 
Helicobacter pylori in peptic 
ulcer disease 
Microorganism always 
present in the diseased 
tissue 
Not always Not always 
Viable microorganism 
could be cultured from 
the diseased tissue  
Yes (not always) Yes (not always) 
Inoculation of 
microorganism into 
susceptible animal 
would produce disease 
Yes Yes 
Microorganism could 
be detected in the 
pathological tissue 
from diseased animal 
Yes Yes 
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1.8. Concluding comments 
 
This chapter reviewed the evidence and established that both acute and chronic 
infections are risk factors for stroke. Specific examples of acute, local and systemic 
infections caused by various micro-organisms resulting in stroke were discussed. In 
keeping with the theories of atherogenesis, the infectious hypothesis of atherosclerosis 
suggested that chronic infections could play an important role in the pathogenesis of 
atherosclerosis, and hence, clinical ischaemic event such as a stroke. The roles of 
chronic infections caused by specific mocro-organisms such as Cytomegalovirus, 
Helicobacter pylori, dental pathogens and Chlamydia pneumoniae in the context of 
atherosclerosis or stroke were discussed in details. However, the main focus of the 
discussion was on C pneumoniae as it was the most widely studied ‘model’ micro-
organism in the context of infectious hypothesis of atherosclerosis. Currently, the 
concordance of evidence and definitive causal evidence for the involvement of C 
pneumoniae in atherosclerosis are considered lacking. [Ieven and Hoymans, 2005] 
However, the evidence that infection can be a stimulus for atherogenesis and 
atherothrombosis continues to mount. [Anderson JL, 2005] The next chapter shall 
introduce a case-control study on the seroprevalence of C pneumoniae in elderly 
stroke / transient ischaemic attack and control medical patients, from which further 
research studies submitted for this thesis, were based. 
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Chapter 2 
 
An introduction to the ‘Chlamydia pneumoniae in elderly 
patients with stroke’ (C-PEPS) study 
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2.1. Introduction 
 
As reviewed in chapter 1, the link between Chlamydia pneumoniae and 
atherosclerosis or cerebrovascular disease has been investigated from a number of 
seroepidemiological, pathological, antibiotic intervention, and carotid doppler 
imaging studies [Ngeh et al, 2003]. Specifically, the seroepidemiological studies of C 
pneumoniae infection in patients with overt stroke or transient ischaemic attack (TIA) 
have also been investigated [Wimmer et al, 1996] [Cook et al, 1998] [Fagerberg et al, 
1999] [Glader et al, 1999] [Elkind et al, 2000] [Kawashima and Kawada, 2000] 
[Heuschmann et al, 2001] [Madre et al, 2002] [Tanne et al, 2003] [Bucurescu et al, 
2003] [Sirmatel et al, 2003] [Kawamoto et al, 2003] [Anzini et al, 2004] [Johnsen et 
al, 2005] [Elkind et al, 2006] [Njamnshi et al, 2006] [Piechowski-Jozwiak et al, 2007] 
[Alamowitch et al, 2008] . The association remains inconclusive with conflicting 
findings. [Ngeh et al, 2003] [Palm and Grau, 2007] 
 
Most of the studies on the role of C pneumoniae in atherosclerotic vascular disease 
have focussed on younger age groups of patients, and almost entirely excluded the 
elderly people [Ngeh, 2000]. It is known that most stroke events occur in older people 
aged 65 to 89 years [Wolf, 1998], and compared with myocardial infarction, stroke 
patients are at least 10 years older [Warlow, 1998]. The aim of the 'Chlamydia 
pneumoniae in elderly patients with stroke' or C-PEPS study was to investigate 
whether serological markers of C pneumoniae infection were associated with acute 
stroke or TIA in hospital patients aged 65 years or older. 
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2.2. Subjects and Methods 
 
The C-PEPS study was a case-control study conducted at Whipps Cross University 
Hospital, a 750-bed acute district general hospital, situated in north-east London, 
United Kingdom. The period of investigation was from 20 December 1999 to 31 
March 2000. [Ngeh et al, 2003] 
 
In this study, stroke was defined clinically as 'a syndrome of rapidly developing 
clinical signs of focal or global disturbance of cerebral function, with symptoms 
lasting 24 hours or longer or leading to death, with no apparent cause other than of 
vascular origin'. [World Health Organisation, 1978] Events lasting less than 24 hours 
were considered as transient ischaemic attacks. Patients were eligible for inclusion if 
they were white (to ensure genetic / ethnic homogeneity), aged 65 years or older, and 
admitted acutely to the hospital under the care of general physicians or geriatricians. 
[Ngeh et al, 2003]  
 
Exclusion criteria included known immunodeficiency, hypergammaglobulinaemia, 
connective tissue disease, and other autoimmune disease, as they may interfere with 
immunoglobulin production and analysis. The exclusion criteria for the controls were 
history of stroke or TIA, acute or active cardiopulmonary or infective conditions on 
admission. [Ngeh et al, 2003] 
 
One hundred consecutive subjects aged over 65 years admitted to the Departments of 
Geriatric and General Medicine, with a primary diagnosis of acute stroke or TIA, 
were recruited prospectively. Concurrently, 87 control subjects aged over 65 years, 
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with no past history of stroke or TIA, and admitted with acute non-cardiopulmonary, 
non-infective disorders to the same medical departments were recruited consecutively. 
As there was no evidence of active or acute cardiovascular, pulmonary, or infective 
disease in the controls, there was no reason to suspect that the controls were more 
predisposed to acquire C pneumoniae infection. [Ngeh et al, 2003] 
 
A standardised interview was performed with patients, carers or family doctors in 
order to obtain a demographic history, and a profile of risk factors for vascular disease 
such as history of hypertension, smoking habit (current, former: >3 months, never, 
unknown), diabetes mellitus, hypercholesterolaemia, ischaemic heart disease (IHD), 
stroke or TIA. Where clinically indicated, computed tomography (CT) brain scan, 
electrocardiography (ECG), and routine blood tests, were performed under the 
requests made by clinicians who were not directly involved in the recruitment of 
patients. [Ngeh et al, 2003] 
 
2.3. Serological analysis 
 
Up to 2 millilitres of each patient’s serum obtained on admission was stored at -20°C 
for subsequent analysis. A commercial kit (SeroCP, Savyon Diagnostics Limited, 
Israel) was used for the analysis of C pneumoniae antibodies. The SeroCPTM is an 
Enzyme Linked Immunosorbent Assay (ELISA) used for the detection of C 
pneumoniae specific IgG, IgA and IgM antibodies in serum. The antigens used are 
derived from purified C pneumoniae elementary bodies (TWTM 183). Serum samples 
intended for C pneumoniae IgM testing were pre-treated with manufacturer's serum 
diluent which contains anti-human IgG, to remove Rheumatoid factor and reduce IgG 
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interference. Sera were analysed independently by two investigators blinded to 
patients’ case or control status. [Ngeh et al, 2003] 
 
2.4. Statistical methods 
 
From two previous case-control studies involving mainly younger patients [Wimmer 
et al, 1996] [Cook et al, 1998], the odds ratio for C pneumoniae infection and 
cerebrovascular disease was 2 and 4 respectively, and the rate of exposure 
(seroprevalence) on average was 50% and 30% respectively. A two-sided 5% test 
(Za/2= 1.96), required to detect a relative risk (or odds ratio as an approximate) of 3 
(R= 3), with 90% power (Zb= 1.28) was used for sample size calculation. [Woodward, 
1992] [Ngeh et al, 2003] Because C pneumoniae seroprevalence increases with age 
[Kanamoto et al, 1991] [Wang et al, 1993] [Paltiel et al, 1995], an exposure rate of 
60% (p= 0.6) in London's elderly population was assumed, for the purpose of the 
calculation. [Ngeh et al, 2003] As equal numbers of cases and controls were intended 
for the sample, case:control ratio of r:1 (r= 1) subjects were to be recruited in the 
study. [Woodward, 1992] [Ngeh et al, 2003] Substituting the above data into a 
validated statistical formula [Woodward, 1992], a study size of 89 cases and 89 
controls was calculated. [Ngeh et al, 2003] 
 
Raw data collected were initially computed using the Microsoft Excel programme. 
Using the SAS statistical package, a logistic regression model controlling for age, sex, 
history of hypertension, smoking habit, diabetes mellitus, hypercholesterolaemia, IHD 
and ischaemic ECG, was constructed to analyse the association of C pneumoniae 
antibody prevalence and stroke or TIA. Odds ratios expressing the associations of 
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stroke or TIA with C pneumoniae IgA, IgG, IgM, and the corresponding 95% 
confidence intervals (CIs), and P-values, were derived. [Ngeh et al, 2003] 
 
2.5. Ethics committe approval 
 
The study was approved by the Local Research Ethics Committee, Redbridge and 
Waltham Forest Health Authority, London. Informed consent was obtained from 
every participant or his / her next of kin. [Ngeh et al, 2003] 
 
2.6. Results 
 
The age and sex distribution were similar in the stroke / TIA and control groups. The 
median age was 80 years in both groups (range= 65to 98 in cases, 65 to 95 in controls, 
P= 0.16). Fifty-nine cases (59%) and 60 controls (69%) were females, P= 0.17. [Ngeh 
et al, 2003] 
 
Among the 100 acute stroke (90) or TIA (10) patients, 64 subjects were admitted with 
first ever presentation of acute stroke / TIA. Thirty-five subjects had one or more 
episodes of stroke / TIA in the past. No data for previous stroke / TIA was available 
for 1 case. None of the subjects was recruited more than once in the study. [Ngeh et al, 
2003] 
 
The acute medical conditions of the control patients on admission were grouped as: 1. 
gastrointestinal (40 subjects), 2. musculoskeletal pain / immobility / falls (20 subjects), 
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3.  haematological (12 subjects), 4. neurological / psychiatric (11 subjects), 5. renal / 
metabolic disturbances (4 subjects). [Ngeh et al, 2003] 
 
Computed tomography (CT) head scan results were available for 80 of the 100 stroke 
/ TIA patients. Of the 80 stroke / TIA patients who had had CT head scan, 50 were 
found to have an infarct, 6 had a haemorrhage, 2 a haemorrhagic infarct, 2 a 
haemorrhage with old infarct, and in 20 no lesion was demonstrated. [Ngeh et al, 
2003] 
 
Table 1 shows the distribution of vascular risk factors in stroke / TIA cases and 
controls. [Ngeh et al, 2003] 
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Table 1.  Distribution of risk factors in stroke or TIA cases and controls 
Confounder / vascular risk factor Number (%) Number (%) Number (%) 
 of cases of controls of all subjects 
History of         No 
hypertension    Yes 
               n 
50 (51) 
49 (49) 
99 
   
52 (60) 
35 (40) 
87 
 
102 (55) 
  84 (45) 
186 
  
Smoking status Never 
   Former 
   Current 
   n   
37 (38) 
43 (44) 
18 (18) 
98 
  
29 (33) 
47 (54) 
11 (13) 
87 
  
 66 (36) 
 90 (48) 
 29 (16) 
185 
History of diabetes No 
mellitus             Yes 
   n 
 91 (91) 
   9 (9) 
100 
77 (89) 
10 (11) 
87 
168 (90) 
  19 (10) 
187 
History of raised No 
cholesterol  Yes 
   n 
   Missing 
 7 (54) 
 6 (46) 
13 
87 
 8 (67) 
 4 (33) 
12 
75 
 15 (60) 
 10 (40) 
 25 
162 
History of ischaemic No 
heart disease             Yes 
                                     n 
83 (83) 
17 (17) 
100 
63 (72) 
24 (28) 
87 
146 (78) 
  41 (22) 
187 
ECG ischaemia No  
                                    Yes 
                                    n 
 42 (44) 
 54 (56) 
 96  
38 (54) 
32 (46) 
70  
80 (48) 
86 (52) 
166  
 98
 
As shown in Table 2, the seroprevalence of C pneumoniae antibodies IgA, IgG, and 
IgM in the stroke / TIA group was similar to the control group. [Ngeh et al, 2003] 
 
Table 2.  Seroprevalence of Chlamydia pneumoniae antibody in cases and 
controls 
    
Chlamydia pneumoniae Number (%) Number (%) P-value  
antibody of cases of controls  
    
Ig A Negative 
 Borderline 
 Positive 
 
 Total 
33 (33) 
 4 (4) 
63 (63) 
 
100  
29 (33) 
 4 (5) 
54 (62) 
 
 87  
P= 1.0 
Ig G Negative 
 Borderline 
 Positive 
 
 Total 
27 (27) 
  2 (2) 
71 (71) 
 
100  
26 (30) 
  4 (5) 
57 (65) 
 
 87  
P= 0.53 
Ig M Negative 
 Borderline 
 Positive 
 
 Total 
80 (80) 
 6 (6) 
14 (14) 
 
100  
68 (78) 
  4 (5) 
15 (17) 
 
 87  
P= 0.78 
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The ORs of having a stroke or TIA compared to not having a stroke / TIA in relation 
to C pneumoniae seropositivity were presented in table 3 and were not statistically 
significant. [Ngeh et al, 2003] 
 
Table 3.  Odds ratios for stroke or TIA in relation to serological markers of C 
pneumoniae infection 
    
 Odds ratio 95% confidence 
Interval 
P-value from 
logistic regression 
    
    Unadjusted1 
Ig A 1.04 0.57-1.88 1.00 
Ig G 1.29 0.69-2.39 0.53 
Ig M 0.78 0.35-1.73 0.78 
    
   Adjusted for age and sex 
Ig A 1.02 0.55-1.87 0.96 
Ig G 1.25 0.67-2.35 0.48 
Ig M 0.79 0.35-1.76 0.56 
    
 Adjusted for history of high blood pressure, smoking, 
diabetes and IHD 
Ig A 0.94 0.51-1.74 0.86 
Ig G 1.24 0.65-2.35 0.51 
Ig M 0.78 0.33-1.83 0.57 
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 Adjusted for history of high blood pressure, smoking, 
diabetes, IHD and high cholesterol2 
Ig A 0.58 0.05-6.35 0.66 
Ig G 0.52 0.05-5.18 0.58 
Ig M 0.87 0.06-13.25 0.92 
    
 Adjusted for history of high blood pressure, smoking, 
diabetes, IHD, age and sex 
Ig A 0.90 0.47-1.69 0.74 
Ig G 1.17 0.61-2.27 0.63 
Ig M 0.81 0.34-1.92 0.63 
    
 Adjusted for history of high blood pressure, smoking, 
diabetes, IHD, age, sex and ischaemic ECG 
Ig A 1.04 0.52-2.05 0.92 
Ig G 1.24 0.61-2.53 0.55 
Ig M 0.79 0.32-1.96 0.60 
                                    
1 The P values for this analysis came from a Fisher’s exact test. 
2 This analysis was only based on 25 subjects since most subjects had missing data for 
cholesterol history (see table 1). 
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The seroprevalence of C pneumoniae in the 64 cases who presented with first ever 
stroke / TIA was 64% for IgA, 73% for IgG, and 17% for IgM. In comparison, the 35 
subjects who presented with a recurrent stroke / TIA had a seroprevalence of 60% for 
C pneumoniae IgA, 66% for IgG, and 6% for IgM. The seroprevalence of C 
pneumoniae in the stroke / TIA patients whose CT head scan showed infarction (50 
subjects) or no evidence of stroke (20 subjects) was 63% for IgA, 67% for IgG, and 
16% for IgM. In the 6 cases whose CT head scan showed only a haemorrhage, the C 
pneumoniae seroprevalence was 83%, 100%, 17% for IgA, IgG, IgM, respectively. 
[Ngeh et al, 2003] 
 
In order to eliminate any potential influence of IHD on the seroprevalence of C 
pneumoniae, a subgroup of 43 (28 females) acute stroke / TIA patients (median age= 
80) and 44 (31 females) control medical patients (median age= 80), who had no 
known history of IHD or ischaemic ECG or both, were identified in the study 
retrospectively. Forty-two percent of stroke / TIA patients and 34% of control medical 
patients had history of hypertension. 36% of stroke / TIA patients and 34% of control 
medical patients never smoked. 14% of both stroke / TIA patients and control medical 
patients had diabetes. The seroprevalence of C pneumoniae IgA, IgG, and IgM were 
67%, 77%, and 19% respectively in stroke / TIA patients, and 61%, 59%, and 14% 
respectively in control medical patients. The ORs were 1.40 for IgA (95% CI 0.53 to 
3.65; P= 0.49), 2.41 for IgG (95% CI 0.90 to 6.46; P= 0.08), 1.55 for IgM (95% CI 
0.45 to 5.40; P= 0.49), after adjusting for history of hypertension, smoking, diabetes 
mellitus, age and sex. [Ngeh et al, 2003] 
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2.7. Discussion 
 
This case-control study conducted in a busy, large district general hospital in London 
was the first to recruit elderly hospital patients prospectively to examine for the 
seroprevalence of C pneumoniae, and its relationship with acute stroke / TIA. [Ngeh 
et al, 2003] 
 
In contrast to numerous studies that had reported the seroepidemiology of C 
pneumoniae in the context of ischaemic heart disease [Ngeh et al, 2003], relatively 
few studies had investigated the association specifically between C pneumoniae and 
overt cerebrovascular disease. Apart from several prosepective [Glader, 1999] [Tanne 
et al, 2003] and case-control [Heuschmann et al, 2001] [Sirmatel et al, 2003] 
[Alamowitch et al, 2008] studies, most case-control [Wimmer et al, 1996] [Cook et al, 
1998] [Elkind et al, 2000] [Kawashima and Kawada, 2000] [Madre et al, 2002] 
[Bucurescu et al, 2003] [Kawamoto et al, 2003] [Anzini et al, 2004] [Johnsen et al, 
2005] [Elkind et al, 2006] [Njamnshi et al, 2006] [Piechowski-Jozwiak et al, 2007] 
and one prospective [Fagerberg et al, 1999] studies demonstrated a positive 
association between serological markers of C pneumoniae infection and stroke / TIA. 
The median age of the stroke / TIA and control medical patients in the C-PEPS study 
was 80 years for both groups, and they were among the oldest age groups ever studied 
in this clinical context. [Ngeh et al, 2003] 
 
The C-PEPS study utilised an ELISA method for the detection of C pneumoniae 
antibody. Unlike the gold-standard microimmunofluorescence (MIF) assay for C 
pneumoniae serology, the ELISA serological method has only been used in a few 
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seroepidemiological studies of C pneumoniae in the setting of stroke. [Kawashima 
and Kawada, 2000] [Kawamoto et al, 2003] [Tanne et al, 2003] [Johnsen et al, 2005] 
[Piechowski-Jozwiak et al, 2007]. The ELISA test is less subjective or operator 
dependent than the MIF assay [Ngeh and Gupta, 2000]. The overall agreement 
between MIF and SeroCP tests, according to the manufacturer, was 98% for IgA, 95% 
for IgG, and 89% for IgM. The results of ELISA were reported as positive, boderline 
or negative on the basis of a single dilution of a serum sample, and not as an endpoint 
titre. Nevertheless, like the MIF assay, its reproducibility, sensitivity, and specificity 
would need further clarification. [Ngeh et al, 2003] 
 
The presence of C pneumoniae IgA, IgG, or IgM in the serum generally reflects 
recurrent / persistent, chronic / past, or acute infection, respectively [Ngeh and Gupta, 
2001]. However, C pneumoniae IgA may not be a reliable marker, and increased level 
should not be taken as evidence for ongoing chronic infection [Tompkins et al, 2000]. 
Serological markers of chronic C pneumoniae infection in the C-PEPS study were 
found to be much more prevalent than in the other UK study [Cook et al, 1998], and 
reached a seroprevalence of 71% of cases and 65% of controls for IgG antibody. This 
is in keeping with reports from other countries that C pneumoniae seropositivity 
increases with age [Kanamoto et al, 1991] [Wang et al, 1993] [Paltiel et al, 1995], 
with a 50 to 70% prevalence of seropositivity in middle-aged adults [Leinonen, 1993]. 
In contrast, a few studies report declining C pneumoniae IgG titres with age. 
[Einarsson et al, 1994] [Coles et al, 1999] Most adults are infected two to three times 
during their lifetime [Leinonen, 1993], and increasing seropositivity with age is 
suggestive of chronic infection or reinfection throughout life. [Ngeh et al, 2003] 
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The seroprevalence of C pneumoniae in stroke / TIA patients did not differ 
significantly from controls (Table 2). Among the stroke / TIA patients, there was no 
significant difference when comparing the seroprevalence of C pneumoniae between 
patients presenting with first ever and recurrent stroke / TIA. The inclusion of the 
very few haemorrhagic stroke patients in the study might weaken any association 
between C pneumoniae infection and stroke, since atherosclerosis could be an 
important common link. However, as previously reported [Cook et al, 1998], the 
seroprevalence of C pneumoniae in patients suffering from ischaemic and 
haemorrhagic strokes were similar. [Ngeh et al, 2003]   
 
The unadjusted ORs for having an acute stroke / TIA, and IgA, IgG and IgM 
seropositivity were 1.04, 1.29 and 0.78, respectively (Table 3). Using a logistic 
regression statistical model, the ORs were adjusted for age and sex, and essentially 
remained unchanged. After adjustment for history of hypertension, smoking, diabetes, 
IHD, age and sex, the ORs for having an acute stroke or TIA were 0.90, 1.17 and 0.81 
for IgA, IgG and IgM seropositivity, respectively, and the corresponding P-values 
were not significant. The ORs remained 1.04, 1.24, 0.79 (P= NS), essentially 
unchanged even after adjusting for the presence of ischaemic ECG. These results 
suggested that serological markers of C pneumoniae infection were not significantly 
associated with acute stroke / TIA. The ORs after adjustment for 
hypercholesterolaemia revealed an inverse relationship between C pneumoniae 
infection and stroke or TIA, which was unexpected. This could be an artefact due to 
the analysis which was based on only 25 subjects, since data for cholesterol history 
was not available in most subjects (see Table 1). [Ngeh et al, 2003] 
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Ischaemic heart disease has been associated with C pneumoniae in 
seroepidemiological studies [Ngeh and Gupta, 2001]. To exclude any possible 
influence of IHD on the seroprevalence of C pneumoniae, 43 acute stroke / TIA cases 
(median age= 80) and 44 controls (median age= 80) without any history of IHD or 
ischaemic ECG were identified. There was a trend towards increased ORs for acute 
stroke or TIA, especially for IgG (OR= 2.41, CI 0.90-6.46, P= 0.08), even after 
statistical adjustment. This suggested that C pneumoniae specific IgG may be weakly 
associated with acute cerebrovascular disease in a subgroup of elderly patients 
without any known history of IHD / ischaemic ECG. [Ngeh et al, 2003] This implied 
that chronic or previous C pneumoniae infection may serve as a link between 
inflammation and atherogenesis or atherothrombosis in cerebrovascular disease [Ngeh 
et al, 2003]. However, a firm conclusion was limited by the reduced sample size. 
 
The C-PEPS study was conducted during the winter months of December to March, 
which were usually associated with a high incidence of respiratory tract infection in 
the elderly population [Woodhouse et al, 1994]. Subclinical infections or even recent 
epidemics might temporarily induce a high antibody response in the control subjects, 
and thereby obscure any genuine serological association between C pneumoniae 
infection and stroke / TIA [Ngeh, 2000].  
 
To minimise background differences in cases and controls, suitable hospital elderly 
patients (often with a number of comorbidities and cardiovascular risk factors) were 
recruited as controls. Although the controls gave no clinical history of stroke or TIA, 
silent cerebrovascular disease in this group could not be excluded as atherosclerosis is 
commonly associated with ageing [Stout, 1998]. Therefore a link between subclinical 
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atherosclerosis and C pneumoniae infection as reflected by its high seroprevalence in 
the elderly population is a possibility [Ngeh, 2000]. However, this could also explain 
the negative results of this study. [Ngeh et al, 2003] CT brain scan would be useful to 
exclude asymptomatic stroke in the elderly control subjects in future studies. 
Moreover, high C pneumoniae seroprevalence could simply reflect life-long recurrent 
or chronic infection- an infective burden without any aetiological link with 
atherosclerosis [Ngeh, 2000].  
 
The C-PEPS study confirmed a high seroprevalence of C pneumoniae antibody levels 
in older patients. [Ngeh et al, 2003]  A significant association between serological 
markers of C pneumoniae infection and acute cerebrovascular events in an elderly 
hospital population was not found. [Ngeh et al, 2003]  However, there was a weak 
trend towards increased ORs for acute stroke / TIA in a subgroup of elderly patients 
without any history of IHD or ischaemic ECG. [Ngeh et al, 2003] 
 
2.8. Aims of further published works and thesis 
 
The patients recruited for the C-PEPS study have allowed further original research 
opportunities and resulted in published works submitted for this thesis. The aims of 
the published works submitted for this thesis are summarised as follows: 
 
1. To investigate the reproducibility of SeroCP, an enzyme-linked 
immunosorbent assay (ELISA) commercial kit used to detect Chlamydia 
pneumoniae-specific antibodies in the C-PEPS study 
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2. To establish the seroprevalences of other atypical respiratory pathogens such 
as Mycoplasma pneumoniae, Legionella pneumophila, Coxiella burnetii in 
elderly stroke / TIA and medical patients 
 
3. To conduct a case-control study on the relationship between seropositivity of 
individual atypical respiratory pathogen and elderly stroke / TIA versus 
medical patients 
 
4. To conduct a case-control study on the relationship between an aggregate 
number of chronic infectious buden of aypical respiratory pathogens and 
elderly stroke / TIA versus medical patients  
 
5. To conduct a case-control study on the prevalence of electrocardiographic 
rhythms and ischaemic changes in elderly stroke / TIA and medical patients 
 
6. To conduct a case-control study on the relationship between socioeconomic 
deprivation, atypical respiratory infections and survival outcome in elderly 
stroke / TIA and medical patients 
 
The next chapter will report a study on the reproducibility of SeroCP enzyme-linked 
immunosorbent assay (ELISA) used in the detection of C pneumoniae-specific 
antibodies in the C-PEPS study.  
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Chapter 3 
 
The reproducibility of SeroCP enzyme-linked 
immunosorbent assay (ELISA) for detection of Chlamydia 
pneumoniae-specific antibodies 
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3.1. Introduction 
 
As discussed in previous chapters, the association between Chlamydia pneumoniae 
and atherosclerotic vascular diseases has been investigated extensively. These 
investigations include sero-epidemiological observations, pathological specimen 
examinations, animal models, immunological / molecular studies, and antibiotic 
intervention studies [Ngeh et al, 2002]. Among these diversified areas of research, 
sero-epidemiology was the first and most commonly used method in this context. 
[Ngeh et al, 2004(a)] 
 
Most of the C pneumoniae sero-epidemiological studies have used the technique of 
microimmunofluorescence (MIF). A few have used enzyme-linked immunosorbent 
assay (ELISA) tests to investigate the relationship between C pneumoniae 
seropositivity and stroke. [Kawashima and Kawada, 2000] [Tanne et al, 2003] 
[Johnsen et al, 2005] [Piechowski-Jozwiak et al, 2007] [Ngeh et al, 2004(a)] However, 
data on the reproducibility of ELISA used in C pneumoniae serology is limited. This 
study aimed to investigate the reproducibility of SeroCP commercial ELISA kits used 
in the detection of C pneumoniae-specific antibodies. [Ngeh et al, 2004(a)] 
 
3.2. Patients and Methods 
 
The sera used in this study were obtained from a consecutive series of 187 elderly 
acute stroke / TIA patients and control medical patients (median age= 80 years) 
recruited prospectively in the C-PEPS study as described in previous chapter. [Ngeh 
et al, 2003] Patient’s sera were stored at -20 oC before analysis.  
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SeroCP commercial ELISA kits, manufactured by Israeli company Savyon 
Diagnostics Limited, in accordance with GMP standards and ISO-9002 certification 
for the production and sale of diagnostics, were used for serological analysis. The 
antigens in these ELISA kits originated from purified C pneumoniae elementary 
bodies (TW 183), and enabled specific and sensitive detection of C pneumoniae 
immunoglobulin (Ig) A, IgG, and IgM. [Ngeh et al, 2004(a)] 
 
Sera for IgM testing were pre-treated with the manufacturer’s serum diluent which 
contained anti-IgG, to remove rheumatoid factor and reduce IgG interference. Each 
serum was diluted at a 1:105 dilution with the supplied serum diluent before analysis, 
as recommended by the manufacturer. The case or control status of the sera was 
blinded during analyses. These were performed by two experienced investigators 
following the manufacturer’s instructions. Due to a limited availability of the SeroCP 
ELISA kits, only the first 122 consecutive patients’ sera were examined for C 
pneumoniae IgA and IgG, and 138 for IgM. The serological tests were then repeated, 
and the results analysed to establish the reproducibility of these SeroCP ELISA kits. 
[Ngeh et al, 2004(a)] 
 
The determination and validation of the test results were in accordance with the 
manufacturer’s instructions. The absorbance or optical density (OD), proportional to 
the amount of specific antibodies bound to the coated antigens in each plate, was read 
at a wave-length of 450nm by a photometric machine (Organon Teknika Reader 530, 
Version 1.20). For a valid test, two criteria must be met: (1) the OD450 of the positive 
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control at 450nm should be >0.8; and (2) the mean OD450 of the negative control (NC) 
at 450nm should be >0.1 but <0.4. [Ngeh et al, 2004(a)] 
 
In order to normalise the results from different tests, a cut-off index (COI) was 
calculated according to the formula: COI= serum sample OD450 ÷ cut-off value 
(COV); and where the COV was calculated using the formula: COV= twice the mean 
of two negative control OD450 readings. As defined by the manufacturer, a COI of < 
1.0 means negative (n) result (i.e. no detectable antibodies), a COI of 1 to 1.1 means 
borderline (b) result (i.e. low level of antibodies), and a COI of > 1.1 means positive 
(p) result (i.e. relevant level of antibodies). [Ngeh et al, 2004(a)] 
 
The manufacturer suggested that if borderline results were obtained from two 
specimens taken from the same patient 2 to 4 weeks apart, the specimens should be 
considered negative. However, in this study, second serum samples were not collected 
from patients giving borderline results. Therefore, a single borderline result was 
defined as negative, as the low level of antibodies detected was not sufficient to be 
considered positive. [Ngeh et al, 2004(a)] 
 
3.3. Results 
 
The COI of positive samples ranged from 1.15 to 6.16 for C pneumoniae IgA, from 
1.12 to 4.91 for IgG, and from 1.12 to 5 for IgM. In the repeat tests or second run, the 
COI of positive samples ranged from 1.14 to 5.23 for IgA, 1.101 to 3.45 for IgG, and 
from 1.20 to 3.49 for IgM. [Ngeh et al, 2004(a)] 
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Table 1 on the following page shows the COI values of samples with borderline 
results in one run and their corresponding COI in another run. [Ngeh et al, 2004(a)] 
The mean Cut-Off Index of all borderline samples in the first and second runs versus 
their mean COI in the corresponding second and first runs were similar for IgA and 
IgM: 1.06 versus 1.01 for IgA (9 samples in each run), 1.04 versus 0.89 for IgM (12 
samples). They were 1.08 versus 1.89 for IgG, but the comparison was made on only 
3 samples that gave borderline COI.   
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Table 1a. Cut-off index (COI) of samples with borderline results in the first run 
and their corresponding COI in the second run 
  
 
Sample   IgA                          Sample   IgG                         Sample   IgM 
                1st run   2nd run                     1st run   2nd run                     1st run   2nd run               
 
37            1.05(b)   0.46(n)      107          1.08(b)   2.12(p)     17            1.00(b)   0.99(n) 
39            1.09(b)   0.83(n)      115          1.08(b)   1.70(p)     25            1.10(b)   0.45(n) 
56            1.04(b)   0.69(n)                                                     30            1.08(b)   0.53(n) 
74            1.09(b)   1.17(p)                                                     45            1.09(b)   0.63(n) 
99            1.10(b)   0.50(n)                                                     54            1.04(b)   0.92(n) 
104          1.05(b)   1.17(p)                                                     60            1.04(b)   0.97(n)      
                                                                                               83            1.06(b)   1.04(b) 
                                                                                               114          1.03(b)   1.23(p) 
                                                                                               119          1.00(b)   1.57(p) 
 
Mean       1.07       0.80                           1.08        1.91                         1.05       0.93 
       
 
Table 1b. Cut-Off Index (COI) of samples with borderline results in the second 
run and their corresponding COI in the first run 
 
Sample   IgA                          Sample   IgG                         Sample   IgM 
                2nd run   1st run                      2nd run   1st run                     2nd run   1st run               
 
10            1.02(b)   1.85(p)      80            1.07(b)   1.85(p)     83            1.04(b)   1.06(b) 
78            1.08(b)   1.27(p)                                                     136          1.02(b)   0.71(n)   
110          1.03(b)   1.17(p)                                                     138          1.01(b)   0.54(n) 
 
Mean       1.04       1.43                                                                          1.02       0.77 
 
 
Table 1c. Mean Cut-Off Index (COI) of samples with borderline results in either 
the first or second runs and mean of their corresponding COI 
 
                 Mean of all borderline COI          Mean of all corresponding COI 
 
IgA           1.06                                                  1.01 
 
IgG           1.08                                                  1.89 
 
IgM          1.04                                                  0.89                                       
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The COI of those samples with discrepant results are given in Table 2. [Ngeh et al, 
2004(a)] The mean COI of the discrepant samples were 1.39 versus 0.97 for IgA (15 
samples in each run), 1.43 versus 1.21 for IgG (20 samples), 1.32 versus 0.80 for IgM 
(14 samples). The differences in the mean COI of these discrepant samples were small: 
0.42 for IgA, 0.22 for IgG, 0.52 for IgM. [Ngeh et al, 2004(a)]   
 
 
Table 2. Cut-Off Index of samples giving discrepant results in the first and 
second runs  
 
Sample   IgA                          Sample   IgG                         Sample   IgM 
                1st run   2nd run                     1st run   2nd run                     1st run   2nd run               
 
10            1.85(p)   1.02(b)       5            0.93(n)   1.29(p)      2              1.22(p)   0.46(n)   
17            1.37(p)   0.71(n)      17           1.47(p)   0.79(n)      3              1.21(p)   0.55(n) 
28            1.51(p)   0.75(n)      21           1.44(p)   0.90(n)      6              1.58(p)   0.60(n) 
44            1.15(p)   0.40(n)      47           2.04(p)   0.68(n)      8              1.23(p)   0.64(n) 
74            1.09(b)   1.17(p)      48           0.83(n)   1.28(p)      24            1.12(p)   0.78(n) 
78            1.27(p)   1.08(b)      50           3.56(p)   0.80(n)      27            1.29(p)   0.61(n) 
80            1.67(p)   0.98(n)      56           0.80(n)   1.96(p)      29            2.52(p)   0.91(n) 
91            1.15(p)   0.66(n)      65           1.13(p)   0.59(n)      31            1.93(p)   0.70(n) 
95            1.40(p)   0.89(n)      66           4.13(p)   0.39(n)      37            1.25(p)   0.65(n) 
96            2.64(p)   0.95(n)      80           1.85(p)   1.07(b)      41            1.19(p)   0.66(n) 
98            1.63(p)   0.71(n)      90           2.71(p)   0.78(n)      42            1.25(p)   0.66(n) 
104          1.05(b)   1.17(p)      95           0.71(n)   1.43(p)      98            0.64(n)   1.20(p) 
110          1.17(p)   1.03(b)      97           0.60(n)   1.44(p)      114          1.03(b)   1.23(p) 
117          0.96(n)   1.16(p)      102         0.80(n)   1.17(p)      119          1.00(b)   1.57(p) 
122          0.89(n)   1.81(p)      106         0.76(n)   1.25(p) 
                                                107         1.08(b)   2.12(p) 
                                                113         0.96(n)   1.101(p) 
                                                115         1.08(b)   1.70(p) 
                                                117         0.92(n)   1.38(p) 
                                                122         0.89(n)   2.12(p) 
 
 
Mean       1.39        0.97                         1.43       1.21                             1.32      0.80 
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The results of SeroCP ELISA reproducibility are summarised in Table 3. [Ngeh et al, 
2004(a)] For the detection of C pneumoniae IgA, IgG, and IgM, the first and repeated 
runs of ELISA tests gave different results i.e. one negative / borderline, one positive, 
or vice versa, in 15/122, 20/122 and 14/138 samples, respectively. The percentage (%) 
sample disagreement and 95% confidence interval (CI) were 12% (CI= 6 to 18%), 
16% (CI= 9 to 23%), and 10% (CI= 5 to 15%) for C pneumoniae IgA, IgG and IgM, 
respectively. The reproducibility of ELISA used for the detection of C pneumoniae 
IgA, IgG, and IgM, expressed as Kappa values, were 0.73, 0.60, and 0.53, 
respectively (P < 0.001). [Ngeh et al, 2004(a)] 
 
 
Table 3.  SeroCP ELISA Reproducibility 
    
 
 
The first and second runs of ELISA    
Chlamydia        
pneumoniae  
Antibody 
Both  
tests 
negative 
Both  
tests 
positive 
One test 
negative or 
borderline, 
one positive 
% sample  
disagreement 
(95% CI) 
Kappa  
value 
(P value) 
 
      
      
Ig A 
(n= 122) 
36 71 15 12% (15/122) 
(6-18%) 
0.73 
(p < 0.001) 
      
Ig G 
(n= 122) 
25 77 20 16% (20/122) 
(9-23%) 
0.60 
(p < 0.001) 
      
Ig M 
(n= 138) 
114 10 14 10% (14/138) 
(5-15%) 
0.53 
(p < 0.001) 
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3.4. Discussion and conclusions 
 
The results in Table 3 show a good sample agreement of > 80%, which is similar to 
that reported for MIF tests [Peeling et al, 2000]. The Kappa value quantifies the 
agreement between the first and repeated ELISA tests, after allowing for random 
variation and the number of observations used [Siegel and Castellan, 1988]. A Kappa 
value of 0 indicates no agreement, whereas a value of 1.0 indicates perfect agreement. 
If 0.61 < Kappa < 0.80, good concordance is indicated, while 0.41 < kappa < 0.60 
indicates a moderate concordance. The kappa values for SeroCP ELISA’s 
reproducibility were 0.73 for C pneumoniae IgA, 0.60 for IgG, and 0.53 for IgM, and 
these were statistically significant with P < 0.001. [Ngeh et al, 2004(a)]   
 
Serological testing is considered the most useful means of determining the prevalence 
of C pneumoniae infection in epidemiological studies [Dowell et al, 2001]. The MIF 
is currently the reference standard in C pneumoniae serology, but it is subjective and 
requires an expert microscopist to interpret the results [Dowell et al, 2001] 
[Ossewaarde et al, 2000]. The interlaboratory variation or reproducibility of MIF tests 
among 14 research laboratories has been assessed by testing 22 identical sera, and the 
overall percentage agreement with the reference laboratory is around 60% to 80%. 
[Peeling et al, 2000] [Ngeh et al, 2004(a)] [Ieven and Hoymans, 2005] In addition to 
the subjective issue, other factors such as the type, purity, and concentration of the 
antigen used and the assay procedure might contribute to the disagreement between 
the MIF tests. [Ieven and Hoymans, 2005] 
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The antigens in the SeroCP ELISA kits originated from purified C pneumoniae 
elementary bodies (TW 183), and enabled specific and sensitive detection of C 
pneumoniae immunoglobulin (Ig) A, IgG, and IgM. [Ngeh et al, 2004(a)] In contrast, 
earlier ELISA that used Chlamydia genus-specific lipopolysaccharides (LPS) as the 
antigen can cross-react non-specifically with other Chlamydia species. [Ossewaarde et 
al, 2000] Indeed, cross-reactivity between C pneumoniae and other Chlamydia species 
has been demonstrated with the MIF test. [Ieven and Hoymans, 2005] [Apfalter, 2006] 
 
In comparison, ELISA is a more objective test than MIF [Dowell et al, 2001] [Ieven 
and Hoymans, 2005]. The SeroCP ELISA result is qualitative, and is reported on the 
basis of a single 1:105 dilution of a serum sample, and not as an endpoint titre. It can 
be automated by a photometric machine, with the advantages of high throughput and 
electronic records. ELISA is therefore easier to standardise and is the preferred 
diagnostic method in routine laboratories [Ossewaarde et al, 2000]. Because ELISAs 
can afford a relatively high throughput and objectivity, they are increasingly used in 
seroepidemiological studies. [Ngeh and Gupta, 2004] [Ngeh et al, 2004(a)]   
 
In the clinical setting, a single ELISA test result should not be used for a final 
diagnosis. Serum samples obtained early during primary infection may not contain 
detectable antibodies. If C pneumoniae infection is suspected, a second sample should 
be obtained 2 to 4 weeks later and tested in parallel with the original sample. However, 
all clinical and laboratory data should be considered when making a diagnosis. [Ngeh 
et al, 2004(a)] Traditionally, the interpretation of serological results should be based 
on a combination of C pneumoniae IgA, IgG and IgM profiles. [Ngeh et al, 2004(a)] 
A combination of positive IgM, negative or positive IgG, and negative or positive IgA 
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results indicate current C pneumoniae infection. A positive IgG and a combination of 
negative IgM and IgA results indicate past or current infection. A positive IgA, with 
positive or negative IgG and negative IgM would refer to current or chronic infection. 
Although unvalidated, others have commented that IgA antibodies, which are 
produced for only 3 to 5 days after exposure, are a marker of persistent, chronic 
infection; whereas IgG antibodies, which remain elevated for several years after 
infection, are a marker of remote, completed infection. [Elkind et al, 2006] [Dowell et 
al, 2001] As the seroprevalences of C pneumoniae in the general population are high, 
whether seropositivity for C pneumoniae results either from a chronic, active infection 
or from a past infection, remains an unresolved issue. [Ieven and Hoymans, 2005] 
 
According to the SeroCP ELISA  kit manufacturer, when sera obtained from 55 
suspected patients attending a respiratory disease clinic and 33 healthy individuals 
were tested using in-house MIF and SeroCP ELISA, the overall agreement between 
the two tests were 98% for IgA, 95% for IgG, 89% for IgM. Others have also reported 
a moderately good correlation between MIF results and ELISA (Labsystems, Helsinki, 
Finland) tests (r= 0.8, P= 0.001) [Ossewaarde et al, 2000] [Messmer et al, 2001]. 
Similarly, as reported in other studies [Persson and Boman, 2000] [Numazaki et al, 
1996], the sensitivity and specificity for ELISA when compared to MIF were reported 
as around 90% by the manufacturer. Subsequent study using ELISA test (Vircell, 
Spain) to detect C pneumoniae IgG has demonstrated 100% sensitivity and 85% 
specificity, and good concordance with the MIF test. [Gutierrez et al, 2002] 
 
A previous study has reported good reproducibility for Labsystems ELISA kit for the 
detection of C pneumoniae IgG. The mean and median coefficients of variation were 
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reported as 10.2% and 8.6% respectively [Messmer et al, 2001]. As recommended, 
the accuracy of new diagnostic kit such as SeroCP ELISA’s reproducibility needs 
proper evaluation, and this was the focus of the current study. [Ngeh et al, 2004(a)] 
The present study was the first to evaluate and report the reproducibility of SeroCP 
ELISA kits used to detect C pneumoniae specific IgA, IgG and IgM antibodies 
simultaneously, in the C-PEPS study that involved over a hundred elderly acute stroke 
and general medical patients. [Ngeh et al, 2004(a)] Subsequent study confirmed a 
good agreement between SeroCP ELISA and Labsystems MIF tests for the detection 
of C pneumoniae IgG (r= 0.93; P= 0.0008) and IgA (r= 0.72; P= 0.00072), in patients 
with coronary heart disease. [Ciervo et al, 2004]   
 
Several studies have demonstrated that the link between C pneumoniae and coronary 
artery disease depends on the serologic method chosen to measure the C pneumoniae 
antibodies. [Apfalter, 2006] [Schumacher A et al, 2001] [Hoymans et al, 2003] 
[Maraha et al, 2004] Because C pneumoniae is an intracellular pathogen, there is a 
poor correlation between direct detection e.g. by culture / polymerase chain reaction, 
and serology. For example, in two multicentre pneumonia treatment studies, it was 
shown that only 1% to 3% of the culture positive patients met the serologic criteria 
and around 70% with positive cultures for C pneumoniae were seronegative. 
[Hammerschlag 2000] [Apfalter, 2006] Whether the results obtained by SeroCP 
ELISA might correlate with endovascular chronic infection remains controversial. 
[Ngeh et al, 2004(a)]   
 
Nevertheless, preliminary data have suggested that ELISA has a good sensitivity, 
specificity, and reproducibility when compared to MIF. [Ngeh and Gupta, 2004] 
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[Ngeh et al, 2004(a)] ELISA may become a preferred, objective test used in the sero-
epidemiological study of C pneumoniae infection and its link with atherosclerotic 
vascular disease. However, further efforts to standardise new commercially available 
ELISA kits against MIF tests, and to express their results in international units will be 
required [Dowell et al, 2001] [Tuuminen et al, 2000(a)].  
 
This study concluded that SeroCP ELISA had a good reproducibility for IgA, and a 
moderately good reproducibility for IgG and IgM. Although SeroCP ELISA was 
comparable to MIF, its level of reproducibility was not perfect and this fact should be 
considered when using such a kit for further epidemiological or diagnostic study. 
[Ngeh et al, 2004(a)] Indeed, the use of ELISA in seroepidemiological studies of 
atypical respiratory or other pathogens in the setting of stroke / TIA should be 
considered in similar context relating to the various methodological issues concerning 
C pneumoniae serology and atherosclerosis.  
 
The next chapter will present the ‘Mycoplasma pneumoniae in elderly patients with 
stroke’ or M-PEPS study which was based on the same cohort of patients as in the C-
PEPS study.  
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Chapter 4 
 
Mycoplasma pneumoniae in elderly patients with stroke: a 
case-control study on the seroprevalence of Mycoplasma 
pneumoniae in elderly patients with acute stroke / transient 
ischaemic attack. The M-PEPS study 
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4.1. Introduction 
 
As discussed in previous chapters, infections are recognised as risk factors for stroke 
[Elkind and Cole, 2006] [Palm and grau, 2007]. Specifically, Chlamydia pneumoniae 
is an atypical respiratory pathogen that has been linked to atherosclerotic vascular 
diseases [Kalayoglu et al, 2002] [Ngeh et al, 2002]. Mycoplasma pneumoniae, another 
atypical respiratory micro-organism, has similar epidemiological behaviour and 
ability to cause extra-pulmonary manifestations and chronic sequelae following 
respiratory tract infection [Taylor-Robinson, 1996] [Taylor-Robinson and Thomas, 
1998]. In fact, a link between M pneumoniae and ischaemic heart disease (IHD) has 
been investigated in several seroepidemiological [Pönkä et al, 1981] [Gurfinkel et al, 
1997] [Horne et al, 2000] [Reunanen et al, 2002] [Momiyama et al, 2004] [Goyal et al, 
2007] and pathological [Maraha et al, 2000] [Higuchi et al, 2000] [Maraha et al, 2001] 
[Higuchi and Ramires, 2002] [Higuchi et al, 2003] [Gois et al, 2006] studies. The 
results of these investigations were largely supportive of a relationship between M 
pneumoniae infection and IHD or atherosclerosis.  
 
Specifically, a positive association between M pneumoniae infection and 
cerebrovascular disease has also been reported [Ode and Gronberg, 1976] [Arthur and 
Margolis et al, 1977] [Parker et al, 1981] [Nakahata et al, 1983] [Mulder et al, 1987] 
[Dowd et al, 1987] [Mulder and Spierings et al, 1987] [Visudhiphan et al, 1992] [Fu 
et al, 1998] [Benito-Leon et al, 1998] [Ganesan et al, 1999] [Padovan et al, 2001] 
[Ovetchkine et al, 2002] [Antachopoulos et al, 2002] [Leonardi et al, 2005] [Greco et 
al, 2006] [Tanir et al, 2006]. [Sotgiu et al, 2003] [Tsiodras et al, 2005]  These reports 
are limited to a number of clinical case studies involving mainly paediatric and 
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younger patients. As age is one of the most important risk factors for cerebrovascular 
disease [Wolf, 1998], the aim of the present study was to establish for the first time 
whether serological markers of M pneumoniae infection were associated with acute 
stroke / transient ischaemic attack (TIA) versus control medical patients aged 65 years 
or older. [Ngeh et al, 2004(b)] 
 
4.2. Subjects and Methods 
 
The findings of the C-PEPS (Chlamydia pneumoniae in elderly patients with stroke) 
case-control study were presented in Chapter 2 [Ngeh et al, 2003]. The present 
‘Mycoplasma pneumoniae in elderly patients with stroke’ or M-PEPS study was a 
case-control study nested within the C-PEPS study. The M-PEPS study had 10 fewer 
patients than the C-PEPS. [Ngeh et al, 2004(b)] 
 
The investigation took place at Whipps Cross University Hospital in north-east 
London, during the period 20 December 1999 to 31 March 2000. The inclusion and 
exclusion criteria of the patients in the M-PEPS study were similar to that in the C-
PEPS study as described previously. [Ngeh et al, 2003] [Ngeh et al, 2004(b)] 
 
Ninety-five consecutive patients admitted with a primary diagnosis of acute stroke / 
TIA and 82 control patients admitted with acute non-cardiopulmanary, non-infective 
medical conditions were included in the present study. Patients’ demographic history 
and profile of vascular risk factors such as history of hypertension, smoking, diabetes 
mellitus, hypercholesterolaemia, IHD, stroke or TIA were obtained. Investigations 
such as computed tomography (CT) brain scan, electrocardiography (ECG), and 
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routine blood tests, were performed under the requests made by clinicians not directly 
involved in the recruitment of patients. [Ngeh et al, 2004(b)] 
 
4.2.1. Serological Analysis 
 
Up to 2 ml of each patient’s serum obtained on admission was stored at -200C for 
subsequent analysis at the end of the study period. Three separate commercial 
enzyme-linked immunosorbent assay (ELISA) kits: SeroMP-IgA, SeroMP-IgG, Sero-
MP-IgM, manufactured by Savyon Diagnostics Limited, Israel, were used for 
serological analysis. [Ngeh et al, 2004(b)] The microtitre plates of the SeroMP kits 
were coated with a purified fraction of M pneumoniae P1-enriched membrane 
antigens to ensure specific detection of M pneumoniae specific IgA, IgG and IgM 
antibodies. Serum samples intended for M pneumoniae IgM testing were pre-treated 
to remove rheumatoid factor and reduce IgG interference. Two experienced 
investigators blinded to patients’ case or control status were involved in serological 
analysis in accordance to standard manufacturer’s instruction. [Ngeh et al, 2004(b)] 
 
The SeroMP ELISA result was determined on the basis of a single 1:105 dilution of a 
serum sample and absorbance value i.e. optical density (OD) measured by an ELISA 
reader (Organon Teknika Reader 530, Version 1.21) at a wavelength of 450/620 nm. 
The absorbance value (OD) was proportional to the level of specific M pneumoniae 
antibody tested. Using a graph paper, a linear curve was plotted with 3 validated OD 
values (generated from 3 calibrators) on the Y-axis against their corresponding 
concentrations of 10, 50, 100 BU/ml (binding units per ml of serum) on the X-axis. 
By using this standard curve, the level of specific antibody expressed as BU/ml in the 
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tested sample was interpolated from each absorbance or OD measured. According to 
the manufacturer’s instruction, values of < 10 BU/ml were considered negative or no 
detectable antibody, > 10 BU/ml were considered positive or relevant level of 
antibody, and > 50 BU/ml were considered high positive or high level of antibody. 
[Ngeh et al, 2004(b)] 
 
4.2.2. Statistical methods 
 
The sample size calculation generating a size of 89 cases and 89 controls in the 
original C-PEPS study has been described in chapter 2. [Ngeh et al, 2003]. Using the 
SAS statistical package, a logistic regression model controlling for history of 
hypertension, smoking, diabetes mellitus, age and sex, history of IHD and ischaemic 
ECG was constructed to determine the association of M pneumioniae antibody 
prevalence and stroke / TIA. The odds ratios (ORs) expressing the associations of 
stroke or TIA with M pneumoniae IgA, IgG and IgM, and the corresponding 95% 
confidence intervals (CIs), and P values, were derived. [Ngeh et al, 2004(b)] 
 
4.2.3. Ethics committee approval 
 
This study was approved by the Local Research Ethics Committee, Redbridge and 
Waltham Forest Health Authority, London. Informed consent was obtained from 
every patient or his / her next of kin. 
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4.3. Results 
 
The median age was 80 years in both groups (range= 65 to 98 in cases, 66 to 95 in 
controls). Fifty-six stroke / TIA patients (59%) and 57 control medical patients (70%) 
were females. Among the cases (85 stroke and 10 TIA cases), 62 subjects were 
admitted with their first ever acute stroke or TIA. Thirty-two subjects had history of 
stroke or TIA in the past. In 1 case, past history of stroke or TIA was not available. 
[Ngeh et al, 2004(b)] 
 
The acute medical conditions of the control patients on admission were grouped as: (1) 
gastrointestinal (38 subjects), (2) musculoskeletal pain / immobility / falls (20 
subjects), (3) haematological (12 subjects), (4) neurological / psychiatric (8 subjects), 
(5) renal / metabolic disturbances (4 subjects). [Ngeh et al, 2004(b)] 
 
CT head scan results were available for 76 of the 95 cases. Of the 76 stroke / TIA 
patients who had had CT head scan, 48 were found to have an infarct, 6 had a 
haemorrhage, 2 a haemorrhagic infarct, 1 a haemorrhage with old infarct, and in 19 no 
lesion was demonstrated. These data were not entirely new as they have been 
published [Ngeh et al, 2003] and discussed in chapter 2 of this thesis. [Ngeh et al, 
2004(b)] 
 
Table 1 shows the distribution of vascular risk factors in 95 stroke / TIA patients and 
82 control medical patients. This was similar to that in C-PEPS study as the sample 
sizes in both studies were almost identical.  
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Table 1.  Distribution of risk factors in 95 stroke / TIA cases and 82 controls 
Confounder / vascular risk factor Cases (%) Controls (%)  
    
History of         No 
hypertension    Yes 
   n 
47 (50) 
47 (50) 
94 
   
50 (61) 
32 (39) 
82 
 
 
   
 
  
Smoking habits Never 
   Former 
   Current 
   n   
35 (38) 
40 (43) 
18 (19) 
93 
  
26 (32) 
45 (55) 
11 (13) 
82 
  
  
  
History of diabetes No 
mellitus             Yes 
   n 
 86 (91) 
   9 (9) 
  95 
73 (89) 
  9 (11) 
82 
 
History of raised No 
cholesterol  Yes 
   n 
   Missing 
 6 (50) 
 6 (50) 
12 
83 
 8 (67) 
 4 (33) 
12 
70 
 
History of ischaemic No 
heart disease            Yes 
                                     n 
79 (83) 
16 (17) 
 95 
60 (73) 
22 (27) 
82 
 
ECG ischaemia No  
                                    Yes 
                                    n 
 41 (45) 
 50 (55) 
 91  
38 (58) 
28 (42) 
66  
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As shown in table 2, the seroprevalence of M pneumoniae antibodies IgA, IgG and 
IgM in the stroke / TIA group was similar to the control group.  
 
Table 2.  Seroprevalence of M pneumoniae antibody in cases and controls 
 
    
M  pneumoniae Cases (%) Controls (%) P  
antibody    
    
Ig A Negative 
  
 Positive 
 
 Total 
20 (21) 
  
75 (79) 
 
 95  
13 (16) 
  
69 (84) 
 
82 
0.44 
Ig G Negative 
  
 Positive 
 
 Total 
37 (39) 
 
58 (61) 
 
95  
41 (50) 
 
41 (50) 
 
 82  
0.17 
Ig M Negative 
  
 Positive 
 
 Total 
89 (94) 
  
  6 (6) 
 
95  
73 (89) 
 
  9 (11) 
 
 82  
0.29 
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The ORs of having a stroke / TIA compared to not having a stroke / TIA in relation to 
M pneumoniae seropositivity are presented in table 3 and are not statistically 
significant. 
 
Table 3. Odds ratios for stroke / TIA in relation to serological markers of M 
pneumoniae infection 
 
    
M pneumoniae 
antibody 
Odds ratio 95% confidence 
interval 
P 
    
    
 Unadjusted for confounders 
IgA 0.71 0.30-1.63 0.44 
IgG 1.57 0.83-2.98 0.17 
IgM 0.55 0.15-1.82 0.29 
    
 Adjusted for history of high blood pressure, smoking, 
diabetes, age, sex, history of IHD and ischaemic ECG 
IgA 0.63 0.26-1.52 0.31 
IgG 1.32 0.66-2.64 0.43 
IgM 0.52 0.14-1.92 0.32 
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In order to examine for any potential influence of IHD on the seroprevalence of M 
pneumoniae, a subgroup of 42 (27 females) acute stroke / TIA patients (median age= 
80) and 43 (30 females) control medical patients (median age= 80), who had no 
known history of IHD or ischaemic ECG (defined as the presence of abnormal Q-
wave patterns, ST segment depression or elevation, T-wave inversion or flattening, 
left bundle branch block) or both, were identified in the study retrospectively. The 
seroprevalence of M pneumoniae IgA, IgG and IgM were 83%, 52% and 2% 
respectively in cases, and 84%, 47% and 12% respectively in controls. The ORs were 
0.82 for IgA (95% CI 0.24 to 2.78; P= 0.75), 1.16 for IgG (95% CI 0.47 to 2.85; P= 
0.75), 0.18 for IgM (95% CI 0.02 to 1.73; P= 0.14), after adjusting for history of 
hypertension, smoking, diabetes mellitus, age and sex. 
 
4.4. Discussion 
 
In the context of ischaemic heart disease (IHD), M pneumoniae antibodies have been 
found more frequently in cases of unstable angina than in controls [Gurfinkel et al, 
1997]. M pneumoniae antibodies IgA [Horne et al, 2000] and IgG [Reunanen et al, 
2002] were shown to predict the diagnosis of IHD and incidence of coronary events 
respectively. A Japanese study also reported that M pneumoniae seropositivity was 
associated with coronary artery disease (CAD), but only in patients with C 
pneumoniae seropositivity (odds ratio= 5.1; 95% CI= 1.8 to 14.9) [Momiyama et al, 
2004] Recently, a study has found that combined seropositivity to C pneumoniae and 
M pneumoniae was significantly higher (P < 0.05) in CAD patients with myocardial 
infarction (MI) than in those without MI. [Goyal et al, 2007] Indeed, M pneumoniae 
has also been detected in atherosclerotic specimens, along with C pneumoniae. 
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[Maraha et al, 2000] [Higuchi et al, 2000] [Maraha et al, 2001] [Higuchi and Ramires, 
2002] [Higuchi et al, 2003] [Gois et al, 2006] [Higuchi et al, 2006] The Mycoplasmas 
were initially found mainly in the lipid core of the ruptured thrombosed plaque, since 
vulnerable atheromas were rich in cholesterol which the micro-organisms dependend 
for growth and survival. [Higuchi et al, 2000]  
 
It has been suggested that co-infection by M pneumoniae and C pneumoniae may 
represent an important co-factor for plaque instability and rupture, leading to coronary 
plaque thrombosis and acute myocardial infarction; since larger amount of these 
bacteria was strongly correlated with histological signs of more plaque vulnerability, 
thrombosis, rupture, and inflammation. [Higuchi et al, 2000] [Higuchi and Ramires, 
2002] [Higuchi et al, 2003] [Gois et al, 2006] However, M pneumoniae and C 
pneumoniae antigens were also found to be present in early atheromas, and a higher 
M pneumoniae to C pneumoniae ratio was correlated with increased growth factors, 
lower inflammation and plaque stability. [Higuchi et al, 2006] In contrast, a 
predominace of C pneumoniae in relation to M pneumoniae was found to favour 
progression of the plaque, which was associated with increased B-cell proliferation. 
[Gois et al, 2006] 
 
Although M pneumoniae was known to cause central nervous system diseases 
[Taylor-Robinson et al, 1996] [Sotgiu et al, 2003] [Greenlee et al, 2000] [Tsiodras et 
al, 2005], specific association between M pneumoniae and acute cerebrovascular 
disease was limited to case reports involving mainly younger patients [Arthur and 
Margolis et al, 1977] [Ode and Gronberg, 1976] [Parker et al, 1981] [Nakahata et al, 
1983] [Mulder et al, 1987] [Dowd et al, 1987] [Mulder and Spierings et al, 1987] 
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[Visudhiphan et al, 1992] [Fu et al, 1998] [Benito-Leon et al, 1998] [Padovan et al, 
2001] [Ovetchkine et al, 2002] [Antachopoulos et al, 2002] [Leonardi et al, 2005] 
[Greco et al, 2006] [Tanir et al, 2006]. [Sotgiu et al, 2003] [Tsiodras et al, 2005]   
 
This M-PEPS case-control study was the first to recruit elderly hospital patients 
prospectively to examine for the seroprevalence of M pneumoniae, and its relationship 
with acute stroke or TIA. [Ngeh et al, 2004(b)] The study utilised SeroMP commercial 
ELISA kits. According to the manufacturer, these kits had been validated and used in 
the serodiagnosis of M pneumoniae infection, and were found to have good sensitivity 
(92% for IgA, 89% for IgG, 80% for IgM) and specificity (74% for IgA, 90% for IgG, 
82% for IgM); as reported in the literature. [Watkins-Riedel et al, 2001] [Lieberman 
et al, 2002] [Beersma et al, 2005]. The SeroMP ELISA results were semi-quantitative 
and not based on specific cut-off antibody titres. [Ngeh et al, 2004(b)] 
 
The interpretation of serological results should be based on a combination of IgA, IgG 
and IgM antibodies’ profile. The presence of M pneumoniae IgA, IgG or IgM in the 
serum generally reflects current / recurrent, past / current or current infection, 
respectively. [Ngeh et al, 2004(b)] The serological markers of M pneumoniae 
infection in the M-PEPS study were found to be much more prevalent than in other 
studies [Rastawicki et al, 1998] [Hauksdottir et al, 1998] [Tuuminen et al, 2000(b)] 
[Daxboeck et al, 2002], and reached a seroprevalence of 79% of cases and 84% of 
controls for IgA, 61% of cases and 50% of controls for IgG, and 6% of cases and 11% 
of controls for IgM antibodies. [Ngeh et al, 2004(b)]  
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Previous studies in the UK have reported that during the outbreaks of M pneumoniae 
infection, infection confirmed by laboratory tests was least common in adults over 65 
years of age. [Rastawicki et al, 1998] [Noah, 1976] [Noah and Urquhart, 1980] 
[Ghosh and Clements, 1992] Other studies have reported that older patients (over 50 
years of age) have significantly lower M pneumoniae seropositivity rate or antibody 
titres than younger patients. [Hauksdottir et al, 1998] [Daxboeck et al, 2002] However,  
in a healthy Finnish population study using quantitative enzyme immunoassays, the 
seroprevalence of M pneumoniae was found to level off at about 40% to 50% in 
adulthood, and the prevalence did not exceed 60% for IgG or 35% for IgA in subjects 
aged over 65 years. [Tuuminen et al, 2000(b)] 
 
Despite a high M pneumoniae seroprevalence in this M-PEPS study, it is interesting to 
note that there was no clinical evidence of acute or serious M pneumoniae respiratory 
tract infection especially in the control patients recruited in this study. This may be 
explained by subclinical or asymptomatic infections in up to 15% of cases [Daxboeck 
et al, 2002]; or related to a problem with test specificity. [Ngeh et al, 2004(b)] 
 
The seroprevalence of M pneumoniae in stroke / TIA patients did not differ 
significantly from controls (Table 2). The unadjusted ORs for having an acute stroke / 
TIA in relation to IgA, IgG and IgM seropositivity were 0.71, 1.57 and 0.55, 
respectively (Table 3). Using a logistic regression statistical model, the ORs were 
adjusted for history of hypertension, smoking, diabetes, age and sex, history of IHD 
and ischaemic ECG. The adjusted ORs for having an acute stroke or TIA were 0.63, 
1.32 and 0.52 for IgA, IgG, IgM seropositivity, respectively, and the corresponding P 
values were not significant. These results suggested that serological markers of M 
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pneumoniae infection were not significantly associated with acute stroke / TIA. The 
ORs were not adjusted for history of hypercholesterolaemia as the data for cholesterol 
history were not available in most patients (Table 1). [Ngeh et al, 2004(b)] 
 
The inclusion of haemorrhagic stroke or thromboembolic stroke arising from valvular 
heart disease in the study might weaken any association between M pneumoniae 
infection and ischaemic stroke, since atherosclerosis could be an important 
aetiological link. [Ngeh et al, 2004(b)] However, only 6 out of the 95 cases had a 
radiological confirmation of a haemorrhagic stroke without any new or old infarct. 
For these 6 cases, the M pneumoniae seropositivity was 83.3% (positive in 5/6 cases), 
66.7% (4/6 cases) and 16.7% (1/6 cases) for IgA, IgG and IgM, respectively, and 
these seroprevalences were in fact higher than those in ischaemic stroke cases. Hence, 
the inclusion of these 6 cases would not have lessened the ability of the study to detect 
any specific association between M pneumoniae seropositivity and atherothrombotic 
stroke. Interestingly, seropositivity of C pneumoniae infection had been reported to 
associate with haemorrhagic stroke [Cook et al, 1998]. Data on the prevalence of 
valvular heart disease in the cases and controls were not available. However, using 
echocardiography to exclude specific thromboembolic stroke arising from valvular 
heart disease in the cases (i.e. non-atherosclerotic stroke) may be helpful in future 
studies. [Ngeh et al, 2004(b)] 
 
As discussed, IHD has been associated with M pneumoniae infection. To examine for 
any possible influence of IHD on the seroprevalence of M pneumoniae, 42 acute 
stroke / TIA patients (median age= 80) and 43 control medical patients (median age= 
80) without any history of IHD or ischaemic ECG were identified in the M-PEPS 
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study retrospectively. After adjustment for history of hypertension, smoking, diabetes, 
age and sex, the ORs did not suggest any association between M pneumoniae 
serological markers and acute stroke / TIA. This is in contrast to the C-PEPS study 
whereby a trend towards increased ORs for acute stroke or TIA was observed, which 
suggested that C pneumoniae serological markers may be weakly associated with 
acute cerebrovascular disease in this subgroup of patients without any known history 
of IHD or ischaemic ECG. [Ngeh et al, 2003] [Ngeh et al, 2004(b)] 
 
This M-PEPS study had several limitations. Only the first 177 of 187 consecutive 
series of cases and controls recruited concurrently in the C-PEPS study were included 
in this M-PEPS study, due to limited availability of ELISA kits. Like the C-PEPS 
study, this M-PEPS study was powered to detect an OR of > 3.0 [Ngeh et al, 2003]. 
Therefore, while this study might rule out M pneumoniae seropositivity as a major 
risk factor for stroke in this elderly population, a smaller effect could not be excluded 
or detected due to the small sample size. A much larger study would be required to 
effectively rule out Mycoplasma infection as a risk factor for stroke. Silent or 
subclinical cerebrovascular disease in the control patients could not be excluded, 
although CT brain scan would have been helpful to detect asymptomatic stroke in this 
group. Subclinical M pneumoniae infection or even recent winter epidemic during the 
study period (December 1999 to March 2000) might temporarily induce a high 
antibody response in the control subjects, thereby obscuring any genuine serological 
association between M pneumoniae infection and stroke or TIA. [Ngeh et al, 2004(b)] 
 
However, it is likely that a high M pneumoniae seroprevalence in the elderly 
population simply reflect life-long recurrent or chronic infection without any 
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significant relationship with atherosclerosis. [Ngeh et al, 2004(b)] It is interesting to 
note that most published cases [Tsiodras et al, 2005] reporting strokes associated with 
acute M pneumoniae infection occurred mainly in paediatric or younger age groups of 
patients- a population with much less atherosclerotic burden. Indeed, the mechanisms 
postulated to link M pneumoniae infection and stroke in these younger patients 
included focal vasculitis, direct invasion of vessel wall, post-infectious autoimmune 
process (molecular mimicry), and intravascular hypercoagulable state, leading to 
cerebrovascular thromboembolic phenomena. [Ngeh et al, 2004(b)] [Greenlee and 
Rose, 2000] [Sotgiu et al, 2003] [Tsiodras et al, 2005] In fatal cases, cerebral 
pathology frequently combines capillary thromboses and microangiopathy, 
perivenular lymphocytic infiltrations and demyelination in perivascular location 
[Sotgiu et al, 2003]. [Ngeh et al, 2004(b)] 
 
4.5. Conclusions 
 
The M-PEPS study revealed a high seroprevalence of M pneumoniae in older stroke / 
TIA and medical patients in hospital using ELISA. Although the study ruled out M 
pneumoniae seropositivity as a major risk factor for stroke in this elderly population, a 
smaller effect could not be excluded due to the small sample size. Future adequately 
powered studies may be required to clarify and define the precise role of M 
pneumoniae infection as a potential factor in the pathogenesis of different subtypes of 
ischaemic stroke, in all age groups, and in different ethnic populations. [Ngeh et al, 
2004(b)] 
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In the next chapter, results of the ‘Legionella pneumophila in elderly patients with 
stroke’ or L-PEPS study will be presented. The L-PEPS study was also based on the 
same cohort of patients as in the C-PEPS study. A case-control analysis on the 
aggregate number of chronic infectious burden of atypical respiratory pathogens in 
elderly patients will also be presented and discussed. 
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Chapter 5 
 
Chlamydia pneumoniae, Mycoplasma pneumoniae and 
Legionella pneumophila in elderly patients with stroke (C-
PEPS, M-PEPS, L-PEPS): a case-control study on the 
infectious burden of atypical respiratory pathogens in 
elderly patients with acute stroke / transient ischaemic 
attack 
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5.1. Introduction 
 
Multiple studies have suggested acute and chronic respiratory infections as potential 
risk factors for stroke. [Lavallee et al, 2002] [Paganini-Hill et al, 2003] [Linsberg et al, 
2003] As discussed in previous chapters, the link between atypical respiratory 
pathogens such as Chlamydia pneumoniae and Mycoplasma pneumoniae and 
cerebrovascular disease has been investigated in seroepidemiological, pathological 
and clinical case studies. [Ngeh et al, 2003] [Ngeh et al, 2004(b)] Recent studies have 
reported an association between exposure to a number of infectious pathogens, i.e. 
infectious burden, and the occurrences and prognoses of atherosclerotic vascular 
diseases. [Zhu et al, 2000] [Rupprecht et al, 2001] [Zhu et al, 2001] [Auer et al, 2002] 
[Bloemenkamp et al, 2002] [Espinola-Klein et al, 2002(a)] [Espinola-Klein et al, 
2002(b)] [Horne et al, 2002] [Prasad et al, 2002] [Pugh et al, 2002] [Basinkevich et al, 
2003] [Cotter et al, 2003]  [Smieja et al, 2003] [Lobzin et al, 2005] [Corrado et al, 
2006] These studies mainly focussed on ischaemic heart disease (IHD) and were 
performed mainly in younger patients. [Ngeh and Goodbourn, 2005(a)] However, 
negative results have also emerged. [Ridker et al, 1999] [Choussat et al, 2000] 
[Schiele et al, 2001] [Haider et al, 2002] [Khairy et al, 2003] [Rothenbacher et al, 
2003] [Niu et al, 2005] [Hagiwara et al, 2007] 
 
Legionella pneumophila, like C pneumoniae and M pneumoniae, is an atypical 
respiratory pathogen. [Poshni and Millian, 1985] [File et al, 1998] The aim of the 
present study was to investigate whether serological markers or immunoglobulins (Igs) 
of L pneumophila infection and the aggregate number (infectious burden) of C 
pneumoniae, M pneumoniae and L pneumophila seropositivity were associated with 
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acute stroke / transient ischaemic attack (TIA) in subjects aged 65 years or older. 
[Ngeh and Goodbourn, 2005(a)] 
 
5.2. Subjects and Methods 
 
The C-PEPS (Chlamydia pneumoniae in elderly patients with stroke) and M-PEPS 
(Mycoplasma pneumoniae in elderly patients with stroke) case-control studies were 
reported in previous chapters. [Ngeh et al, 2003] [Ngeh et al, 2004(b)] The C-PEPS 
had 100 cases and 87 controls, whereas the M-PEPS had 95 cases and 82 controls. 
The subjects of the current ‘Legionella pneumophila in elderly patients with stroke’ or 
L-PEPS case-control study originated from the C-PEPS study. The L-PEPS study had 
excluded 7 cases of haemorrhagic stroke without acute infarction as detected on 
computed tomography (CT) head scan. Additionally, the L-PEPS study had excluded 
2 cases and 1 control because of a shortage of enzyme-linked immunosorbent assay 
(ELISA) kits. Thus, the L-PEPS study consisted of the remaining 91 cases and 86 
controls. The seroprevalence of L pneumophila IgG was measured for all of them, but 
that of L pneumophila IgM was measured for only 81 cases and 72 controls because 
of a shortage of IgM ELISA kits. Of the 91 cases and 86 controls of the L-PEPS study, 
the seroprevalences of C pneumoniae, M pneumoniae, and L pneumophila were 
measured for only 88 cases and 82 controls for IgG and for 81 cases and 72 controls 
for IgM because of a limited supply of ELISA kits. All studies were approved by the 
hospital’s local research ethics and research and development committees. [Ngeh and 
Goodbourn, 2005(a)] 
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The study population was recruited at a 750-bed acute district general hospital in 
north-east London from 20 December 1999 to 31 March 2000. [Ngeh et al, 2003] All 
patients’ demographics and history of vascular risk factors such as hypertension, 
smoking, diabetes mellitus, hypercholesterolaemia, IHD, stroke / TIA were obtained. 
Investigations such as CT brain scan, electrocardiography (ECG), and routine blood 
tests were ordered / performed by clinicians not directly involved in the recruitment of 
patients. The inclusion and exclusion criteria of the patients were similar to that in the 
C-PEPS study. [Ngeh et al, 2003] [Ngeh and Goodbourn, 2005(a)] 
 
5.2.1. Serological analysis 
 
Up to 2 millilitres of each patient’s serum obtained on admission was stored at -20°C 
for subsequent analysis at the end of the study period. A commercial ELISA kit 
(Vircell SL, Granada, Spain) was used for the analysis of L pneumophila serogroup 1- 
specific IgG and IgM antibodies in serum. The antigens used are derived from 
inactivated LPS antigens of L pneumophila serogroup 1. Sera intended for L 
pneumophila IgM testing were pre-treated with manufacturer's anti-IgG sorbent to 
remove rheumatoid factor and reduce IgG interference. The results of the ELISA were 
interpreted as negative, equivocal, or positive on the basis of a single dilution of a 
serum sample and optical density measured by a spectrophotometer at a wavelength 
of 450/620 nm. Sera were analysed independently by two investigators blinded to the 
case or control status of the patients, in accordance with the manufacturer’s protocol. 
[Ngeh and Goodbourn, 2005(a)] 
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5.2.2. Statistical methods 
 
The sample size calculation was based on the C-PEPS study, which had 90% power to 
detect an odds ratio (OR) of ≥ 3.0. [Ngeh et al, 2003] Raw data were initially 
computed with the use of the Microsoft Excel programme. With the use of the SAS 
statistical package, a logistic regression model adjusting for confounders such as age, 
sex, hypertension, smoking, diabetes mellitus, hypercholesterolaemia, IHD and 
ischaemic ECG was constructed to analyse the association of L pneumophila 
serogroup 1 antibody and stroke / TIA. Cases and controls that were tested IgG or 
IgM seropositive for either 0, 1, 2, or all 3 pathogens were identified. Fisher’s exact 
tests were used for crude analysis, and logistic regression was used to adjust for 
confounders. The ORs for stroke / TIA in relation to infectious burden were 
determined. Specific combinations of C pneumoniae-M pneumoniae, M pneumoniae-
L pneumophila, or L pneumophila-C pneumoniae IgG seropositivity and the risk of 
stroke / TIA were also investigated. [Ngeh and Goodbourn, 2005(a)] 
 
5.3. Results 
 
In this L-PEPS study, the median age was 80 years (range= 65 to 98 years) in the 91 
cases and 82 years (range= 65 to 95 years) in the 86 controls. Fifty-three cases (58%) 
and 59 controls (69%) were females. CT head scan results were available for 71 of the 
91 cases: 49 had an infarct, 2 had a haemorrhagic infarct, and in 20 no lesion was 
demonstrated. [Ngeh and Goodbourn, 2005(a)] 
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Table 1 shows the distribution of vascular risk factors in 91 stroke / TIA cases and 86 
controls. [Ngeh and Goodbourn, 2005(a)] 
 
Table 1. Distribution of risk factors in 91 stroke / TIA cases and 86 controls* 
 
 
    
Vascular risk factor Cases (%) Controls (%)  
      
    
Hypertension    
 No 47 (52) 51 (59)  
 Yes 43 (48) 35 (41)  
 N 90  86   
    
Smoking     
 Never 34 (38) 28 (32)  
 Former 41 (45) 47 (55)  
 Current 15 (17) 11 (13)  
 N 90  86   
    
Diabetes mellitus    
 No 83 (91) 76 (88)  
 Yes   8 (9) 10 (12)  
 N 91  86   
    
Hypercholesterolaemia    
 No   5 (50)   8 (67)  
 Yes   5 (50)   4 (33)  
 N 10  12   
 Missing 81 74  
    
Ischaemic heart disease    
 No 74 (81) 62 (72)  
 Yes 17 (19) 24 (28)  
 N 91  86   
    
ECG ischaemia    
 No 38 (44) 38 (54)  
 Yes 49 (56) 32 (46)  
 N 87  70   
    
*Because of missing values, the numbers of cases and controls do not always add to 
91 and 86, respectively 
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The seroprevalences of L pneumophila IgG and IgM in the stroke / TIA group were 
29% and 12% respectively, and were similar to those in the control group (22% and 
10%) (Table 2). [Ngeh and Goodbourn, 2005(a)] 
 
Table 2.  Seroprevalence of L pneumophila antibody in cases and controls 
 
    
L pneumophila Cases Controls P* 
Antibody n (%) n (%)  
    
Ig G    
 Negative 52 (57) 57 (66) 0.50 
 Equivocal 13 (14) 10 (12)  
 Positive 26 (29) 19 (22)  
 Total 91   86   
    
Ig M    
 Negative 67 (83) 62 (86) 0.84 
 Equivocal   4 (5)   3 (4)  
 Positive 10 (12)   7 (10)  
 Total 81   72   
    
 
* From Fisher’s exact test 
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The ORs for stroke / TIA in relation to L pneumophila seropositivity were 1.52 (95% 
CI, 0.70 to 3.28; P= 0.29) for IgG and 1.49 (95% CI, 0.45 to 4.90; P= 0.51) for IgM, 
after statistical adjustment for potential confounders (Table 3). [Ngeh and Goodbourn, 
2005(a)] 
 
Table 3. Odds ratios for stroke / TIA in relation to serological markers of L 
pneumophila infection 
 
    
L pneumophila 
antibody 
Odds ratio* 95% confidence 
interval 
P 
    
    
 Unadjusted for confounders 
    
Ig G 1.41 0.71-2.79 0.32 
Ig M 1.31 0.47-3.64 0.61 
    
 Adjusted for hypertension, smoking, diabetes, ischaemic heart 
disease, age, sex, and ischaemic ECG 
    
Ig G 1.52 0.70-3.28 0.29 
Ig M 1.49 0.45-4.90 0.51 
    
 
*Odds ratio of being antibody positive compared with antibody negative / equivocal 
by logistic regression analysis 
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The ORs for stroke / TIA in relation to the number of pathogens tested seropositive 
for IgG or IgM are presented in Table 4. The ORs in relation to IgG seropositivity for 
1, 2, or 3 atypical respiratory pathogens after adjustment were 3.89 (95% CI, 1.13 to 
13.33), 2.00 (95% CI, 0.64 to 6.21), and 6.67 (95% CI, 1.22 to 37.04), respectively 
(P= 0.06). [Ngeh and Goodbourn, 2005(a)] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 147
Table 4. Odds ratios for stroke / TIA in relation to IgG or IgM seropositivity for 
0, 1, 2 or 3 of C pneumoniae, M pneumoniae, and L pneumophila 
 
Number 
of 
pathogens 
Number 
of cases          
 
Number 
of   controls 
Odds ratio  
(crude)  
Odds ratio  
(adjusted)*  
IgG 
 
    
0  8 16 1 1 
1 30 21 2.86 (1.03-7.89)† 3.89 (1.13-13.33)† 
2 39 42 1.86 (0.72-4.82)† 2.00 (0.64-6.21)† 
3 11  3 7.33 (1.58-33.97)† 6.67 (1.22-37.04)† 
     
All 88 82 P= 0.04‡ P= 0.06‡   
The P-value for a test of trend across the odds ratios was 0.10 (crude) and 0.23 
(adjusted)  
 
IgM 
 
    
0 60 55 1 1 
1 17 10 1.56 (0.66-3.69)† 1.44 (0.53-3.91)† 
2  4  6 0.61 (0.16-2.28)† 0.77 (0.17-3.50)† 
3  0  1 Not estimable Not estimable 
     
All 81 72 P= 0.87‡ P= 0.91‡ 
 
 
Number 
of 
pathogens 
Number 
of first-ever 
cases           
Number 
of   controls 
Odds ratio  
(crude)  
Odds ratio  
(adjusted)*  
IgG 
 
    
0  5 16 1 1 
1 19 21 2.90 (0.89-9.43)† 3.80 (0.89-16.39)† 
2 26 42 1.98 (0.65-6.05)† 2.25 (0.59-8.55)† 
3  7   3 7.47 (1.39-40.25)† 7.09 (1.05-47.62)† 
     
All 57 82 P= 0.09‡ P= 0.15‡   
 
The P-value for a test of trend across the odds ratios was 0.12 (crude) and 0.20 
(adjusted)  
 
* Adjusted for age, sex, hypertension, diabetes mellitus, smoking, ischaemic heart 
disease and ischaemic ECG 
† Numbers in parentheses are 95% confidence intervals 
‡ From logistic regression analysis (test of association between number of pathogens 
and risk of stroke / TIA)  
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Table 5 shows the ORs for stroke / TIA in relation to specific combinations of C 
pneumoniae-M pneumoniae, M pneumoniae-L pneumophila, and L pneumophila-C 
pneumoniae IgG seropositivity. [Ngeh and Goodbourn, 2005(a)] 
 
Table 5.  Odds ratios for stroke / TIA in relation to specific combinations of C 
pneumoniae-M pneumoniae, M pneumoniae-L pneumophila, and L pneumophila-
C pneumoniae IgG seropositivity 
 
Combination of pathogens       Seropositivity           Odds ratio*                  P†    
(IgG) 
Cp-Mp                                        No pathogens‡           1.00                               0.20  
                                                    Either Cp or Mp         2.84 (0.90-8.93)                
                                                    Both Cp and Mp        2.50 (0.79-7.87) 
 
Mp-Lp                                         No pathogens‡           1.00                              0.47 
                                                     Either Mp or Lp         1.29 (0.56-2.95) 
                                                     Both Mp and Lp        2.09 (0.65-6.71) 
 
Lp-Cp                                          No pathogens‡            1.00                             0.18 
                                                     Either Lp or Cp           2.38 (0.80-7.09) 
                                                     Both Lp and Cp          3.22 (0.91-11.36) 
 
 
Cp indicates C pneumoniae; Mp, M pneumoniae; and Lp, L pneumophila 
Numbers in parentheses are 95% confidence intervals 
* Adjusted for age, sex, hypertension, diabetes mellitus, smoking, ischaemic heart 
disease and ischaemic ECG 
† From logistic regression analysis 
‡ Not positive for any of Cp, Mp, or Lp 
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As described previously, the acute medical conditions of the 87 controls in the C-
PEPS study were grouped as follows: (1) gastrointestinal (40 subjects); (2) 
musculoskeletal pain / immobility / falls (20 subjects); (3) haematological (12 
subjects); (4) neurological / psychiatric (11 subjects); and (5) renal / metabolic 
disturbances (4 subjects). [Ngeh et al, 2003]  
 
The seroprevalences of C pneumoniae, M pneumoniae, and L pneumophila were 
similar among the medical condition groups of the controls (except M pneumoniae 
and L pneumophila IgM; see Table 6). [Ngeh and Goodbourn, 2005(a)] 
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Table 6. Seroprevalences of C pneumoniae, M pneumoniae, and L pneumophila in the 
control medical condition groups 
 
                                                Number of Controls                                P, Fisher’s exact test                                   
 
                                                Positive / Total (%) 
 
C pneumoniae IgG 
GI                                                     27 / 40 (68)                                       0.86 
MIF                                                  12 / 20 (60) 
H                                                        9 / 12 (75)                                    
NP                                                      7 / 11 (64)  
RM                                                     2 /   4 (50) 
All                                                    57 / 87 (66) 
M pneumoniae IgG 
GI                                                     19 / 38 (50)                                        0.39 
MIF                                                    7 / 20 (35) 
H                                                        7 / 12 (58)                                   
NP                                                      6 /   8 (75) 
RM                                                     2 /   4 (50) 
All                                                    41 / 82 (50) 
L pneumophila IgG 
GI                                                       8 / 40 (20)                                         0.97  
MIF                                                    5 / 20 (25) 
H                                                        3 / 12 (25)                                    
NP                                                      2 / 10 (20) 
RM                                                     1 /   4 (25) 
All                                                    19 / 86 (22) 
C pneumoniae IgM 
GI                                                       7 / 40 (18)                                         0.99 
MIF                                                    4 / 20 (20) 
H                                                        2 / 12 (17)                                  
NP                                                      2 / 11 (18)  
RM                                                     0 /   4 (0) 
All                                                     15 / 87 (17)  
M pneumoniae IgM 
GI                                                        1 / 38 (3)                                           0.02 
MIF                                                     2 / 20 (10) 
H                                                         4 / 12 (33)                                  
NP                                                       2 /   8 (25)                  
RM                                                      0 /   4 (0) 
All                                                       9 / 82 (11) 
L pneumophila IgM 
GI                                                        1 / 32 (3)                                            0.06 
MIF                                                     1 / 17 (6) 
H                                                         3 / 11 (27)                                    
NP                                                       2 /   8 (25) 
RM                                                      0 /   4 (0) 
All                                                       7 / 72 (10) 
 
GI indicates gastrointestinal; MIF, musculoskeletal pain / immobility / falls; H, 
haematological; NP, neurological / psychiatric; and RM, renal / metabolic disturbances 
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Among the 81 stroke and 10 TIA cases in the L-PEPS study, 58 subjects were 
admitted with first-ever stroke / TIA. Thirty-two subjects had one or more episodes of 
stroke / TIA in the past. Table 7 compared the IgG and IgM seroprevalences of C 
pneumoniae, M pneumoniae, and L pneumophila, as well as their aggregate number in 
first-ever (including 1 case without data for previous stroke / TIA) and recurrent 
stroke / TIA cases, showing no significant differences in IgG and IgM status between 
the first-ever and recurrent cases. [Ngeh and Goodbourn, 2005(a)] 
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Table 7. Seroprevalences of C pneumoniae, M pneumoniae, and L pneumophila 
IgG and IgM and aggregate number of pathogens in first-ever and recurrent 
stroke / TIA cases 
                                                               Number of stroke / TIA cases (%) 
Pathogens               Seropositivity*         First ever               Recurrent               P† 
Cp IgG         Negative or equivocal         17 (28)                    12 (36)                    0.49 
                              Positive                        43 (72)                    21 (64) 
                                 All                             60                            33 
 
Mp IgG        Negative or equivocal          23 (40)                    11 (35)                    0.82 
                              Positive                        34 (60)                    20 (65) 
                                 All                             57                            31 
 
Lp IgG          Negative or equivocal         42 (71)                    23 (72)                    1.00 
                               Positive                       17 (29)                      9 (28) 
                                  All                            59                            32 
 
Aggregate of IgG    No. of pathogens  
                                  0                                 5 (9)                         3 (10)                   0.98 
                                  1                                19 (33)                     11 (35) 
                                  2                                26 (46)                     13 (42) 
                                  3                                  7 (12)                       4 (13) 
                                  All                             57                             31  
 
Cp IgM          Negative or equivocal         49 (82)                     31 (94)                  0.13 
                                Positive                       11 (18)                       2 (6) 
                                 All                              60                             33 
 
Mp IgM         Negative or equivocal         54 (95)                     29 (94)                  1.00 
                                Positive                         3 (5)                         2 (6)                    
                                 All                              57                             31 
 
Lp IgM           Negative or equivocal         46 (85)                     25 (93)                 0.48 
                                Positive                          8 (15)                       2 (7) 
                                 All                               54                             27 
 
Aggregate of IgM   No. of pathogens 
                                  0                                 38 (70)                     22 (81)                 0.62 
                                  1                                 13 (24)                       4 (15) 
                                  2                                   3 (6)                         1 (4) 
                                  All                               54                            27   
 
Cp indicates C pneumoniae; Mp, M pneumoniae; and Lp, L pneumophila 
† From Fisher’s exact test    
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5.4. Discussion 
 
In the L-PEPS study, the seroprevalences of L pneumophila serogroup 1 were 12% to 
29% for the elderly stroke / TIA patients and 10 to 22% for the elderly control 
patients, both within the range of 0.4% to 32% reported worldwide. [Poshni and 
Millian, 1985] Two Singaporean studies have reported L pneumophila seroprevalence 
of between 10% - 22% in the healthy population or blood bank donors, using indirect 
immunofluorescence test. [Nadarajah et al, 1987] [Heng et al, 1997] Using indirect 
immunofluorescence technique, the seroprevalence of L pneumophila infections 
(serogroups 1 to 6) among 562 healthy people in Naples, Italy was 23%. [Romano et 
al, 1989] In this group, there were no significant differences associated with sex and 
age, even though an apparent increase with age was observed. [Romano et al, 1989] 
In Chile, a study using similar method among 100 healthy blood donors reported that 
the seroprevalence of L pneumophila (serogroups 1 to 6) was 5%. [Lobos et al, 1993] 
Using indirect immunofluorescence assay and microagglutination test, another Italian 
study reported that the prevalence of L pneumophila serogroup 1 antibodies in 777 
blood donors was only 0.3%. [Franzin and Scramuzza, 1995] Most worldwide 
seroepidemiological studies showed no age or sex related L pneumophila 
seroprevalence differences, although others reported both a decreasing prevalence in 
the over 50 years age group in both sexes [Yonke et al, 1982] and a 2.7 times higher 
prevalence rate in men over 40 years of age compared to women of comparable ages 
[Helms et al, 1980]. [Poshni and Millian, 1985] 
  
In the L-PEPS study, the seroprevalence of L pneumophila in stroke / TIA patients did 
not differ significantly from that of controls (Table 2). With the use of logistic 
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regression to adjust for hypertension, smoking, diabetes, IHD, age, sex and ischaemic 
ECG, the ORs for stroke / TIA in relation to IgG and IgM seropositivity were 1.52 
(P= 0.29) and 1.49 (P= 0.51) respectively (Table 3). These results suggested that 
serological markers of L pneumophila infection were not significantly associated with 
acute stroke / TIA. [Ngeh and Goodbourn, 2005] 
 
Recent studies have suggested that an increasing number of micro-organisms, i.e. 
infectious burden, as evidenced by serological markers of chronic infection such as 
IgG, was associated with an incremental risk of cardiovascular and cerebrovascular 
diseases. [Zhu et al, 2000] [Kiechl et al, 2001]  [Rupprecht et al, 2001] [Zhu et al, 
2001] [Auer et al, 2002] [Espinola-Klein et al, 2002(a)] [Espinola-Klein et al, 2002(b)] 
[Horne et al, 2002] [Prasad et al, 2002] [Pugh et al, 2002] [Basinkevich et al, 2003] 
[Cotter et al, 2003] [Smieja et al, 2003] [Lobzin et al, 2005] [Corrado et al, 2006] A 
prospective study has reported that chronic bacterial infections e.g. respiratory, 
urinary tract, dental and others may amplify the risk of atherosclerosis development in 
the carotid arteries. [Kiechl et al, 2001]   The age and sex adjusted odds ratio for any 
chronic infection versus none was 4.08 (95% CI= 2.42 to 6.85; P< 0.0001) [Kiechl et 
al, 2001] Further studies have concluded that the number of infectious pathogens 
(pathogens’ IgG or IgA antibodies)  or infectious burden e.g. herpes simplex virus 1 
and 2, cytomegalovirus, Epstein-Barr virus, Hemophilus influenzae, Chlamydia 
pneumoniae, Mycoplasma pneumoniae, Helicobacter pylori and Hepatitis A virus, to 
which an individual has been exposed was not only an independent factor involved in 
the development and progression of carotid atherosclerosis [Espinola-Klein et al, 
2002(a)] [Espinola-Klein et al, 2002(b)] but also a predictor of an increased hazard of 
stroke, myocardial infarction or cardiovascular death [Smieja et al, 2003]. Indeed, a 
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recent prospective follow-up study found that the total burden of infections or IgG 
seropositivity for H pylori, Cytomegalovirus and C pneumoniae was highly predictive 
of cerebrovascular or cardiovascular events (P< 0.0001). [Corrado et al, 2006]   
 
However, negative reports have emerged. Other studies have reported that IgG and 
IgA seropositivity or previous infection to more than one micro-organisms such as C 
pneumoniae, H pylori, herpes simplex virus and cytomegalovirus was not associated 
with an increased risk for stroke, myocardial infarction or cardiovascular death. 
[Ridker et al, 1999] [Haider et al, 2002] A recent Japanese study reported a low 
detection rate for C pneumoniae, cytomegalovirus, herpes simplex virus, and H pylori 
in 50 carotid atherosclerotic plaque specimens using polymerase chain reaction and 
immunocytochemistry techniques. [Hagiwara et al, 2007] The investigators reported 
that the results of the plaque examination, serum antibodies and the number of 
seropositive antibodies to these micro-organisms did not correlate with the severely 
stenotic, ulcerative, or symptomatic plaques. [Hagiwara et al, 2007] 
 
The completion of the L-PEPS study provided a unique opportunity to investigate for 
the first time, in a case-control fashion, the infectious burden of the 3 most common 
atypical respiratory pathogens in elderly stroke / TIA patients. Although the data were 
suggestive of an association between stroke / TIA and chronic infectious burden of 
atypical respiratory pathogens as evidenced by IgG, but not IgM, seropositivity, a 
small sample size was suggested by the wide confidence intervals (Table 4).  The 
association was statistically significant (P= 0.04) before adjustment for confounders 
and close to significance after adjustment (P= 0.06). When recurrent stroke / TIA 
cases were excluded from analysis, the overall association became statistically less 
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significant, with P= 0.09 before adjustment, and P= 0.15 after adjustment. With only 
3 estimates of ORs, the probability value for a test of trend across the ORs was not 
significant. However, the OR for stroke / TIA and infectious burden after adjustment 
appeared strongest in subjects infected with at least 3 pathogens: OR= 6.67, 95% CI 
1.22 to 37.04, with OR= 7.09, 95% CI 1.05 to 47.62 for first-ever cases of stroke / 
TIA. Table 5 showed that specific combinations of C pneumoniae-M pneumoniae, M 
pneumoniae-L pneumophila, or L pneumophila-C pneumoniae did not increase the 
risk of stroke / TIA significantly. [Ngeh and Goodbourn, 2005] 
 
A number of bacteria and viruses may contribute to atherogenesis and 
atherothrombosis through inflammatory / immunological mechanisms. [Linsberg and 
Grau, 2003] Respiratory infections like influenza virus, [Lavallee et al, 2002] C 
pneumoniae [Linsberg and Grau, 2003] and M pneumoniae [Ngeh et al, 2004(b)] have 
been associated with cerebrovascular disease. C pneumoniae is the micro-organism 
most investigated in the ‘infectious hypotheses’ of atherosclerosis. L pneumophila, 
like C pneumoniae, is a gram-negative, intracellular bacterium that may exert a 
chronic immunological response. [Linsberg and Grau, 2003] [Espinola-Klein et al, 
2002(a)] [File et al, 1998] [Hindiyeh and Carroll, 2000] [Stout and Yu, 1997] [Fields 
et al, 2002] Together, L pneumophila, C pneumoniae and M pneumoniae share similar 
microbiological and clinical features, including neurological manifestations. [File et al, 
1998] [Hindiyeh and Carroll, 2000] [Johnson et al, 1984] [Easterbrook and Smyth, 
1992] [Yucesan and Sriram et al, 2001] They are important atypical respiratory 
pathogens that cause 8% to 50% of cases of community-acquired pneumonia. [File et 
al, 1998] [Ngeh and Goodbourn, 2005] 
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Serological methods such as indirect fluorescence antibody (IFA) and ELISA have 
test sensitivity of 40 to 80% and specificity of 95 to 99%. [File et al, 1998] [Hindiyeh 
and Carroll, 2000] [Murdoch, 2003] They have been recommended for 
epidemiological studies of Legionella infection. [File et al, 1998] [Hindiyeh and 
Carroll, 2000] [Murdoch, 2003]  The ELISA test is less subjective than the IFA 
standard reference test. [Murdoch, 2003] [Barka et al, 1986] According to the 
manufacturer, Vircell ELISA IgM used in the L-PEPS study had sensitivity of 83% 
and specificity of 97% compared with an immunofluorescence test. The sensitivity 
and specificity for Vircell ELISA IgG was reported as 95% and 97%, respectively. 
[Ngeh and Goodbourn, 2005] More recently, the clinical sensitivity and specificity for 
Vircell ELISA were determined and reported as 92.3% and 100% for the IgM ELISA, 
and 43.3% and 96.6% for the IgG ELISA. [Diederen et al, 2006] Compared to a 
validated Serion classic ELISA, the agreement, sensitivity, and specificity were 
89.5%, 82.0%, and 97.6% for Vircell IgM ELISA, and 81.9%, 88.9%, and 78.0% for 
the Vircell IgG ELISA. [Diederen et al, 2006] As the Vircell ELISA kits used in the 
L-PEPS study were far from perfect, the results in the study have to be read in that 
context. 
 
The C-PEPS, M-PEPS, and L-PEPS studies had several limitations. The number of 
controls was small and less than that of cases. The controls were selected from 
admitted patients and could be biased. The seroprevalences of C pneumoniae, M 
pneumoniae, and L pneumophila among the medical condition groups of the controls 
had been analysed. (Table 6). There was no association between atypical respiratory 
infection and medical conditions in the controls. Although the result was statistically 
significant for M pneumoniae IgM (P= 0.02), the number of positive controls was so 
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small (n= 9) that this could be due to chance. Silent or subclinical cerebrovascular 
disease in the controls could not be excluded, although CT would have been helpful to 
detect asymptomatic stroke in this group. Subclinical atypical respiratory infection or 
even epidemic during the study period might induce an antibody response in the 
controls, thereby obscuring any genuine serological association between infection and 
stroke / TIA.  
 
Patients with stroke could be more susceptible to respiratory tract infection. It could 
be argued that infection may not be a cause of the present stroke event but a result of 
past / recurrent stroke. However, the results in Table 7 showed that the 
seroprevalences of the pathogens did not differ between cases with first-ever or 
recurrent stroke / TIA. 
 
5.5. Conclusions 
 
Although a significant association between individual serological markers of C 
pneumoniae, [Ngeh et al, 2003] M pneumoniae, [Ngeh et al, 2004(b)] L pneumophila, 
and acute cerebrovascular events was not apparent, this preliminary case-control 
study nevertheless suggested that a collective burden of chronic atypical respiratory 
infection (IgG seropositivity) may be associated with an increased risk of acute stroke 
/ TIA. Whether seroprevalences of atypical respiratory pathogens in elderly patients 
could reflect a life-long recurrent infection or an infective burden related to an 
aetiological link with atherosclerosis will need to be confirmed in larger, prospective 
outcome studies.  
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The next chapter will present the results of a pilot study on the seroprevalence of 
Coxiella burnetii, another atypical respiratory pathogen, in the same cohort of patients 
as in the C-PEPS study.  
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Chapter 6 
 
Coxiella burnetii in elderly patient with stroke (C-BEPS): a 
case-control study on the seroprevalence of Coxiella burnetii 
in elderly patients with acute stroke / transient ischaemic 
attack 
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6.1. Introduction 
 
Historically, Rickettsiae were the microorganisms used in 1889 to successfully induce 
fatty sclerotic changes after inflicting slight mechanical injury to the arterial wall of 
the aorta of a rabbit. [Gilbert and Lion, 1889] [Lovey et al, 1999] As a member of the 
Rickettsiaceae family, Coxiella burnetii causes Q fever, a zoonosis with a worldwide 
distribution with the exception of New Zealand. [Maurin and Raoult, 1999]  It is well 
known that chronic C burnetii infection commonly causes endocarditis and less 
commonly causes vascular infections of aneurysms and vascular grafts. [Maurin and 
Raoult, 1999] [Lovey et al, 1999] Coxiella burnetii is also a well recognised atypical 
respiratory pathogen. [Maurin and Raoult, 1999] [Ngeh and Goodbourn 2005(b)] In 
Nova Scotia, Canada, Coxiella burnetii was the third most frequently recognised 
bacterial aetiological agent of atypical pneumoniae, after Mycoplasma pneumoniae 
and Chlamydia pneumoniae; and it was more frequently diagnosed than psittacosis 
and legionellosis. [Marrie et al, 1996] [Maurin and Raoult, 1999] 
 
The seroprevalences of three common atypical respiratory pathogens: Chlamydia 
pneumoniae, Mycoplasma pneumoniae and Legionella pneumohila, in case-control 
studies involving an elderly cohort of stroke / transient ischaemic attack (TIA) and 
medical patients were published and reported in previous chapters of this thesis. It 
was concluded that the risk of stroke / TIA appeared to associate with the aggregate 
number of chronic infectious burden of these atypical respiratory pathogens. [Ngeh 
and Goodbourn, 2005(a)] Conceivably, other respiratory pathogens may also 
contribute to this association. The aim of this ‘Coxiella burnetii in elderly patients 
with stroke’ or ‘C-BEPS’ study was to determine the seroprevalence 
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(immunoglobulins, IgG and IgM) of Coxiella burnetii in the same cohort of patients 
as in the original ‘Chlamydia pneumoniae in elderly patients with stroke’ or ‘C-PEPS’ 
study. [Ngeh and Goodbourn, 2005(b)] 
 
6.2. Subjects and Methods 
 
The details of the C-PEPS study, from which the present C-BEPS study was based, 
were described in chapter 2 of this thesis. In keeping with the ‘Legionella 
pneumophila in elderly patients with stroke’ or L-PEPS study discussed in the 
previous chapter, the C-BEPS study also excluded the 7 cases of haemorrhagic stroke 
without acute infarction as detected on computed tomography (CT) head scan. Using 
commercial enzyme-linked immunosorbent assay (ELISA) kits (PANBIO Limited, 
Australia), the seroprevalence of C burnetii in 85 ischaemic stroke / TIA patients and 
84 medical control patients was determined by laboratory technicians blinded to the 
case or control status of patients’ serum samples. The C-BEPS study had fewer 
patients than the C-PEPS study as it had excluded another 8 cases and 3 controls 
because of a shortage of ELISA kits. [Ngeh and Goodbourn, 2005(b)] 
 
6.3. Results 
 
The seropositivity of C burnetii IgG was found in 2 (2.4%) out of the 85 ischaemic 
stroke / TIA patients, and none in the 84 control medical patients. None of the 85 
stroke / TIA patients and 3 (3.6%) of the 84 control medical patients were 
seropositive for C burnetii IgM. [Ngeh and Goodbourn, 2005(b)] The 2 stroke 
patients tested seropositive for C burnetii IgG were both females aged 70 years and 93 
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years. Whereas the 3 control medical patients tested seropositive for C burnetii IgM 
were also all females aged 75 years, 78 years and 91 years. 
 
6.4. Discussion 
 
Previous studies in the United Kingdom using immunofluorescence test reported a C 
burnetii IgG seroprevalence of 15% to 27% in farm workers, and 4% to 11% in 
people working in non-farming sectors. [Maurin and Raoult, 1999] [Thomas et al, 
1995] [Davies et al, 1997] Worldwide, C burnetii seroprevalences in different human 
populations, not during the outbreaks, have been reported to range from less than 
1.5% [Kim et al, 2006] to over 50% in hyperendemic areas [Ruiz-Beltran et al, 1990] 
[Pascual-Velasco et al, 1998]. [Maurin and Raoult, 1999] The C burnetii 
seropositivity of 2.4% for IgG and 3.6% for IgM in the C-BEPS study is within the 
range of C burnetii seroprevalences published internationally. 
 
Some studies reported no association between C burnetii seropositivity and age 
[Thomas et al, 1995] or sex, [Davies et al, 1997] [Tissot Dupont et al, 1992] and in 
subjects older than 64 years [Suarez-Estrada et al, 1996]. However, several Spanish 
studies have reported C burnetii seroprevalence to be significantly higher in males 
than females, [Sanzo et al, 1993] and to increase significantly with age [Ruiz-Beltran 
et al, 1990] [Sanzo et al, 1993] [Marrie and Pollak, 1995] to over 70% in those over 
the age of 65 years. [Pascual-Velasco et al, 1998] In Taiwan, the seroprevalence of C 
burnetii was 4.2% in 616 subjects without any signs compatible with acute Q fever; 
and the antibody prevalence rate was higher in males than in females, and peaked in 
persons aged 61 to 70 years. [Ko et al, 2000] In a recent Spanish study, C burnetii 
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seroprevalence in 216 subjects was estimated to range from 9% to 15%; and the 
seropositive cases were significantly higher in patients over 44 years of age. 
[Cardenosa et al, 2006] However, the data in this Spanish study showed a sex ratio of 
1:1, [Cardenosa et al, 2006] which was similar to that reported in another study in 
Nova Scotia [Marrie and Pollak, 1995].  
 
The median age of the elderly patients in the C-BEPS study was 80 years. The 
relatively low C burnetii seropositivity of 2.4% to 3.6% found in the C-BEPS study 
would suggest that C burnetii exposure was rare and that seroprevalence did not 
increase with age in this cohort of elderly patients living in the urban areas of north-
east London, England. This would be in keeping with the other two British studies 
that showed no association between C burnetii seropositivity and age. [Thomas et al, 
1995] [Davies et al, 1997] Interestingly, all the 5 elderly patients tested seropositive in 
the C-BEPS study were females. Although this could be due to chance, the finding 
was in contrast to most studies which showed that C burnetii seropositivity was either 
increased in the males or not associated with sex. 
 
A limitation of this C-BEPS study was that a more detailed occupational / farming 
history of the patients was not possible to obtain retrospectively. However, in one 
study, 90% of C burnetii seropositive blood donors reported no contact with farm 
animals, and pet ownership was reported to have no impact on the seroprevalence. 
[Bartolome et al, 2007] Moreover, as C burnetii can be transported by the wind, a 
substantial number of infected patients have also reported no direct contact with 
animals. [Tissot-Dupont et al, 1999] It was noted that there was no clinical evidence 
of acute or serious C burnetii infection especially in the control medical patients 
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recruited in the C-BEPS study. This could be explained by subclinical or 
asymptomatic infection which could occur in almost 60% of Q fever cases, [Maurin 
and Raoult, 1999] [Marrie and Raoult, 2002] or related to a problem with ELISA test 
specificity [Ngeh and Goodbourn, 2005(b)].  
 
Detectable levels of specific IgG or IgM antibodies are considered evidence of past or 
recent C burnetii infection, respectively. (Cat No. E-QFB01G and E-QFB01M, 
PANBIO Limited, Australia) According to the manufacturer’s data, C burnetii ELISA 
(PANBIO Limited, Australia) had a sensitivity, specificity and agreement of 72.2%, 
100%, and 79.6%, respectively, for IgG, and 97.1%, 84.4%, and 89.8%, respectively, 
for IgM, when tested against the immunofluoresence reference method. Others 
reported that ELISA for the diagnosis of acute Q fever had sensitivity of 80% and 
sensitivity of > 99% for C burnetii anti-phase II IgG (> 1:1,024), and sensitivity of 
84% for C burnetii anti-phase II IgM (> 1:512). [Waag et al, 1995] [Fournier et al, 
1998] These results were not perfect. However, others have demonstrated that ELISA 
technique was even more sensitive than the immunofluorescence assay and could thus 
be used for the serodiagnosis of Q fever. [Peter et al, 1988] [Cowley et al, 1992] 
[Fournier et al, 1998] Indeed, ELISA had been proposed and recognised as a useful 
tool for seroepidemiological studies, [Peter et al, 1987] [Maurin and Raoult, 1999] 
[Kovacova and Kazar, 2002] and for the diagnosis of both acute and chronic Q fever 
[Kovacova and Kazar, 2002]. 
 
As discussed in previous chapters, various micro-organisms may contribute to 
atherogenesis and atherothrombosis through inflammatory / immunological 
mechanisms. Among these micro-organisms, C pneumoniae is the one most 
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investigated and implicated in the infectious hypothesis of atherosclerosis- an 
acknowledged inflammatory disease. [Ngeh and Gupta, 2004] Like C pneumoniae, C 
burnetii is a gram-negative, intracellular bacterium that may result in chronic 
infection and exert a chronic immunological or inflammatory response. [Maurin and 
Raoult, 1999] [Lovey et al, 1999] [Marrie and Raoult, 2002] [Bernit et al, 2002] 
[Ngeh and Gupta, 2004] [Ngeh and Godbourn, 2005(a)] Furthermore, C burnetii, C 
pneumoniae, M pneumoniae, and L pneumophila are all atypical respiratory pathogens 
that share similar microbiological and clinical features, including vascular invasion 
and neurological manifestations. [Ngeh and Godbourn, 2005(a)] [Maurin and Raoult, 
1999] [Marrie and Raoult, 2002] [Bernit et al, 2002]  
 
Indeed, C burnetii infection was reported to associate with cerebrovascular and 
ischaemic heart diseases. [Lovey et al, 1999] [Ngeh and Goodbourn, 2005(b)] In a 
cohort study in Switzerland, people affected by the largest reported outbreak of Q 
fever in 1983 were followed up 12 years later to evaluate the long term complications 
of C burnetii infection. [Lovey et al, 1999] The investigators reported that the 12-year 
risk of arterial disease was significantly higher among those patients who had been 
acutely infected (7%) as compared with those who had never been infected (4%) 
[Relative Risk (RR)= 2.2; 95% Confidence Interval (CI)= 1.4 to 3.6]. Specifically, 
there was an increased risk of developing a cerebrovascular event (RR= 3.7; CI= 1.6 
to 8.4) and cardiac ischaemia (RR= 1.9; CI= 1.04 to 3.4). The 12 year mortality was 
significantly higher among the 411 people who had been acutely infected in 1983 
(9.7%) (age adjusted RR= 1.8; CI= 1.2 to 2.6) when compared with the 1247 
participants who had remained serologically negative in 1983 (7.0%). [Lovey et al, 
1999] 
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In the present C-BEPS study, because of such sparse data and zero counts (i.e. 0/84 
and 0/85), it was not possible to estimate any meaningful relative risk, and therefore, 
impossible to make any conclusion about any association between C burnetii 
infection and stroke / TIA. [Ngeh and Goodbourn, 2005(b)] Nevertheless, the C-BEPS 
study served as a pilot seroepidemiological survey of C burnetii infection in a cohort 
of hospitalised elderly stroke, TIA and medical patients living in the urban areas of 
north-east London. The low C burnetii seroprevalence found in the C-BEPS study 
would suggest that C burnetii infection was relatively uncommon in the elderly 
population of north-east London in England. 
 
The next chapter will discuss the prevalence of electrocardiographic rhythms and 
ischaemic changes in the same cohort of acute stroke / TIA and medical patients as 
recruited in the C-PEPS study. 
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Chapter 7 
 
A case-control study on the prevalence of 
electrocardiographic rhythms and ischaemic changes in 
elderly patients with acute stroke / transient ischaemic 
attack 
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7.1. Introduction 
 
Electrocardiographic (ECG) abnormalities such as arrhythmias and ischaemic changes 
are known to occur in acute cerebrovascular disease. [Khechinashvili and Asplund, 
2002] [Oppenheimer, 2002] These abnormalities may represent pre-existing coronary 
heart disease or direct consequences of acute cerebral insults from subarachnoid 
haemorrhage, ischaemic stroke, or intra-cerebral haemorrhage. [Khechinashvili and 
Asplund, 2002] [Oppenheimer, 2002] Although cerebrovascular and ischaemic heart 
diseases (IHD) are associated with ageing, data on the prevalence of ECG changes in 
elderly patients with acute stroke are limited. [Khechinashvili and Asplund, 2002] 
This case-control study investigated the prevalence of ECG rhythms and ischaemic 
changes in elderly patients admitted with acute stroke or transient ischaemic attack 
(TIA) to a district general hospital in London, United Kingdom. [Ngeh, 2004] 
 
7.2. Methods 
 
The data used in this study originated from the ‘Chlamydia pneumoniae in elderly 
patients with stroke’ or ‘C-PEPS’ study as discussed in chapter 2 of this thesis. 
Ninety-seven consecutive stroke / TIA and 70 medical control patients who had a 12-
lead ECG tracing recorded within 48 hours of their acute admissions in the C-PEPS 
study were included in this study. [Ngeh, 2004] The control patients who had never 
had a stroke and who were admitted with acute non-cardiopulmonary disorders were 
recruited concurrently with the stroke / TIA patients. [Ngeh, 2004]  
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The patients’ ECG recordings were examined for rhythms, and ischaemic changes 
defined [De Bacquer et al, 2000] as the presence of abnormal Q-wave patterns, ST 
segment depression or elevation, T-wave inversion or flattening, and left bundle 
branch block. The prevalence of ischaemic ECG changes in the stroke / TIA patients 
were compared with that in the control patients using χ2 test. Using a logistic 
regression statistical model to adjust for possible confounding effect of background 
history of IHD, the odds ratio (OR) of having ischaemic ECG changes in acute stroke 
/ TIA patients was determined. [Ngeh, 2004] 
 
7.3. Results 
 
The median age of all patients was 80 years (range= 65 to 98 years in stroke / TIA 
patients, 65 to 95 years in control medical patients). Fifty-seven stroke / TIA patients 
(59%) and 47 control medical patients (67%) were females. Forty-eight stroke / TIA 
patients (49.5%) and 28 control medical patients (40%) had a history of hypertension, 
58 stroke / TIA patients (60%) and 48 control medical patients (69%) had a history of 
smoking, and 8 stroke / TIA patients (8%) and 7 control medical patients (10%) had a 
history of diabetes mellitus. [Ngeh, 2004] 
 
Among the 97 acute stroke / TIA patients (87 acute stroke, 10 TIA), 62 were admitted 
with their first-ever presentation of an acute stroke or TIA. Thirty-four patients had a 
history of one or more episodes of stroke or TIA. No data for previous stroke or TIA 
were available for one patient. [Ngeh, 2004] 
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Electrocardiographic sinus rhythm was observed in 67 stroke / TIA patients (69%) 
and 47 control medical patients (67%). These included 2 stroke patients in sinus 
bradycardia and 2 control medical patients in sinus tachycardia. The ECG recordings 
of 26 stroke / TIA patients (27%) and 17 control medical patients (24%) were in atrial 
fibrillation. Other rhythms observed were first-degree heart block (in two stroke / TIA 
patients and two control medical patients), junctional rhythm (one stroke patient and 
two control medical patients), paced rhythm (one stroke patient), bigeminy (one 
control medical patient), and first-degree heart block with bigeminy (one control 
medical patient). [Ngeh, 2004] [Ngeh, 2000] 
 
Ischaemic ECG changes were observed in 54 stroke / TIA patients (56%) and 32 
control patients (46%) [Odds ratio (OR)= 1.52; 95% confidence interval (CI)= 0.82 to 
2.83; P= 0.18). In contrast, only 17 stroke / TIA patients (18%) versus 19 control 
patients (27%) had a history of IHD.  Using a logistic regression statistical model to 
adjust for history of IHD, the OR of having an ischaemic ECG in relation to a stroke / 
TIA was 1.80 (95% CI= 0.93 to 3.45; P= 0.079). [Ngeh, 2004] 
 
Computerised tomography (CT) head scan results were available for 77 of the 97 
stroke / TIA patients. Of the 77 stroke / TIA patients with a CT head scan, 47 were 
found to have an infarct, 6 had a haemorrhage, 2 had a haemorrhagic infarct, 2 had a 
haemorrhage with old infarct, and no stroke lesion was demonstrated in 20 patients. 
The results of these CT head scans have been reported in the C-PEPS study and in 
chapter 2 of this thesis. [Ngeh et al, 2003] [Ngeh, 2004] 
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For the 6 stroke patients with only a haemorrhage on CT head scan, 2 of 6 patients 
(33%) showed atrial fibrillation and ischaemic changes on the ECG. Both ECG 
recordings of the 2 patients with haemorrhagic infarct showed sinus rhythm, one of 
which showed ischaemic changes. For the 2 patients whose CT revealed haemorrhage 
with old infarct, both ECG tracings showed sinus rhythm and ischaemic changes. 
Thus, for all the 10 stroke patients with haemorrhage on CT head scan, the ECG 
recordings showed that 2 out of 10 patients (20%) were in atrial fibrillation with the 
rest in sinus rhythm; and five out of the 10 (50%) showed ischaemic changes. [Ngeh, 
2004] 
 
7.4. Discussion 
 
The vast majority of previous studies on ECG changes in stroke were uncontrolled 
observational studies on younger patients that focused on ECG changes in the context 
of subarachnoid haemorrhage. [Khechinashvili and Asplund, 2002] [Davis et al, 1993] 
This case-control study was the first that investigated the prevalence of ECG rhythms 
and ischaemic changes prospectively in elderly patients admitted with acute stroke or 
TIA. As the requests for 12-lead ECG recordings were made by admitting doctors not 
involved in the study, only 96 out of 100 of the stroke / TIA patients and 70 out of 87 
of the control patints in the C-PEPS study had ECG recordings available. [Ngeh, 2004] 
 
In keeping with a clinical review of electrocardiographic changes associated with 
acute cerebrovascular disease, [Davis et al, 1993] atrial fibrillation was the most 
common cardiac arrhythmia found on ECG recordings in acute stroke / TIA patients 
(27%) and control medical patients (24%) in the present study. Atrial fibrillation 
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occurred in about a quarter of this very elderly hospital population (median age= 80 
years), [Ngeh, 2004] and this was much higher than the previously reported range of 
1% to 23% in the clinical review [Davis et al, 1993]. In two previous case-control 
studies with patients with a mean age of 68 years and 66.4 years, the prevalence of 
atrial fibrillation in the stroke cases versus controls was 21% versus 2% [Dimant and 
Grob, 1977] and 14% versus 4% [Goldstein, 1979], respectively. In a general 
population study, the prevalence of atrial fibrillation for the 65 years to 74 years age 
group was 2.70% for men and 1.53% for women, and was strongly related to age. [De 
Bacquer et al, 2000] Others have reported that atrial fibrillation was found in 2% of 
subjects under the age of 75 years, in 5% of all subjects over 75 years, in 14% over 85 
years, and in 27% of patients hospitalised or institutionalized aged over 90 years. 
[Molaschi et al, 1995] In a study involving 340 patients over the age of 80 years, 
hospitalised for diseases other than cardiovascular, atrial fibrillation was found in 
27.9% of the subjects. [Molaschi et al, 1995] This is similar to that of 27% and 24% 
found in the elderly (median age= 80 years) stroke / TIA patients and control medical 
patients, respectively, in the present study.  
 
The prevalence of ischaemic ECG findings, defined as abnormal Q-wave patterns, ST 
segment depression or elevation, T wave inversion or flattening, and left bundle 
branch block, in a general population aged 65 years to 74 years was 26.7% for men 
and 31.3% for women. [De Bacquer et al, 2000] Using the same definition for this 
present study, ischaemic ECG changes were more commonly observed in the stroke / 
TIA cases (56%) than in the controls (46%) (OR= 1.52; 95% CI= 0.82 to 2.83; P= 
0.18). In comparison, a Finnish cross-sectional epidemiological survey on 488 men 
and 708 women aged 64 to 97 years reported ischaemic ECG findings in 32.9% (95% 
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CI= 28.7 to 37.1) of men and 39.3% (95% CI= 35.7 to 43.0) of women; whereas only 
a minority of them reported typical angina pectoris. [Ahto et al, 1998] However, the 
high frequency of ischaemic ECG changes found in the stroke / TIA patients was not 
significantly different from that in the group of age-matched controls in the present 
study (56% vs 46%; OR= 1.52; 95% CI= 0.82 to 2.83; P= 0.18). This in itself 
suggested that ischaemic ECG changes were not specifically caused by acute stroke or 
TIA. [Khechinashvili and Asplund, 2002] [Ngeh, 2004] Indeed, others have 
concluded that ischaemic-like and repolarisation ECG changes were common in 
patients with acute ischaemic stroke, and that these changes were more likely to be 
due to pre-existing heart disease rather than the stroke event. [Familoni et al, 2006] 
 
As ischaemic ECG changes could reflect underlying IHD, the prevalence of IHD was 
determined from patients’ medical history and hospital records. The prevalence of 
past history of IHD was found to be lower in the stroke / TIA cases (18%) than in the 
control patients (27%). This unexpected finding suggesting the elderly stroke / TIA 
population had a lower prevalence of coronary heart disease than age-matched 
controls remains difficult to explain. It is possible that a history of IHD represents a 
soft marker of underlying coronary heart disease and is not inclusive of silent cardiac 
ischaemia. A selective bias in taking the history of IHD could be another possibility, 
but this is unlikely because the data originally came from the C-PEPS case-control 
study and histories were collected by the author only. [Ngeh, 2004] 
 
Because the prevalence of IHD was much lower than that of ischaemic ECG changes 
in both acute stroke / TIA patients (18% vs 56%) and control medical patients (27% 
vs 46%), ischaemic ECG changes could represent non-specific [Khechinashvili and 
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Asplund, 2002] findings or silent cardiac ischaemia in both groups. However, 
compared with the medical controls, ischaemic ECG changes occurred more 
frequently in acute stroke / TIA patients despite having a lower prevalence of IHD. 
Using a logistic regression statistical model to adjust for the possible confounding 
effect of IHD, there emerged a trend of borderline significance towards increased 
odds ratio for ischaemic ECG changes in acute stroke or TIA (OR= 1.80; 95% CI= 
0.93 to 3.45; P= 0.079). [Ngeh, 2004] 
 
The prevalence of atrial fibrillation and ischaemic changes appeared similar in both 
ischaemic and haemorrhagic strokes, although there were much fewer cases of 
haemorrhagic stroke in this study. In elderly patients with acute stroke or TIA, ECG 
changes may well reflect underlying, pre-existing coronary heart disease. This is not 
surprising because cerebrovascular and ischaemic heart diseases share many risk 
factors and commonly co-exist in the older population. Indeed, more than a third of 
stroke patients have asymptomatic coronary heart disease. [Sen and Oppenheimer, 
1998] However, a non-specific effect of an acute medical illness on ECG rhythm and 
ischaemic changes is also a possibility. [Ngeh, 2004]  
 
A direct consequence of a neurological insult from acute cerebrovascular disease on 
ischaemic ECG changes is well recognized. [Khechinashvili and Asplund, 2002] 
[Oppenheimer, 2002] [Davis et al, 1993] [Sen and Oppenheimer, 1998] 
[Oppenheimer and Hachinski, 1992] The proposed mechanisms include an increased 
sympathetic outflow, catecholamine-mediated cardiac injury and neural-mediated 
myocytolysis during the acute phase of a stroke. [Khechinashvili and Asplund, 2002] 
[Oppenheimer, 2002] [Davis et al, 1993] [Sen and Oppenheimer, 1998] 
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[Oppenheimer and Hachinski, 1992] In addition, involvement of the insular cortex 
after stroke may be associated with cardiac autonomic deregulation and arrhythmias. 
[Oppenheimer, 2002] [Sen and Oppenheimer, 1998] [Oppenheimer and Hachinski, 
1992] Studies have shown the lateralisation of cardiac autonomic regulation in many 
species including man, with cardiac sympathetic tone predominantly regulated by 
right insular regions, and parasympathetic cardiac mechanisms regulated by the left 
insula. [Oppenheimer, 2002] [Oppenheimer et al, 1992] [Zhang et al, 1998] However, 
coincidental myocardial infarction in acute stroke has been reported to be as high as 
15%. [Davis et al, 1993] Furthermore, the most common cause of death and new 
morbidity after stroke is from cardiac disease and may be unrelated to the severity of 
the acute stroke event. [Oppenheimer, 2002] [Wong et al, 2003] In summary, ECG 
abnormalities associated with stroke may be viewed as due to 3 interacting processes: 
(a) pre-existing atherosclerosis or hypertensive cardiovascular disease producing left 
ventricular ischaemic changes, Q waves, arrhythmias, bundle branch blocks, and left 
ventricular hypertrophy prior to the stroke; (b) ischaemic, arrhythmic, and 
repolarisation changes due to increased sympathetic outflow during the stroke; and (c) 
myocardial necrosis or myocytolysis precipitated by (a) or (b) or both. [Goldstein, 
1979] [Myers et al, 1982] [Oppenheimer, 2002] 
 
This study had several limitations. Like the C-PEPS study, this study was designed to 
have a 90% power to detect an OR of > 3.0. While the study might rule out ischaemic 
ECG changes as a major, specific consequence of an acute cerebrovascular event in 
this elderly population, a smaller effect that may be significant could not be excluded 
due to the small sample size. A much larger study would be required to effectively 
rule out or confirm the significance of ischaemic ECG changes in acute stroke or TIA 
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in the older population. However, the possibility of beta error in the study should be 
acknowledged. [Ngeh, 2004]   
 
Prior ECG recordings were not available for comparison with that taken after acute 
admission of the cases and controls. The true incidence of new ECG changes such as 
arrhythmia and ischaemic changes after acute stroke or TIA and medical illness could 
not be determined in this study. However, a previous study has reported that 
arrhythmias of any type occurred in 41/150 (27%) patients with acute stroke, and new 
arrhythmias occurred in 13/53 (25%) patients who had prior available ECG tracings 
for comparison. [Goldstein, 1979] Of 13 patients with cerebral embolic stroke who 
had prior available ECG tracings, 8 (62%) showed atrial fibrillation on the current 
ECG, and in 4 of these 8 patients (50%), atrial fibrillation was a new finding. 
[Goldstein, 1979] Another study has reported ECG findings that revealed a new 
diagnosis of atrial fibrillation in 28 out of the 1200 (2.3%) patients with TIA who has 
no prior history of atrial fibrillation. [Elkins et al, 2002] 
 
Electrocardiographic ST depression or T wave inversion has been reported to occur in 
59/150 (39%) of patients with acute stroke, and new ischaemic changes in 11/53 (21%) 
of patients who had prior available ECG tracings. [Goldstein, 1979] Another study 
has reported that patients with acute ischaemic stroke or TIA had a 29% prevalence of 
ST segment depression within the first five days after their event, as detected by 
continuous ECG monitoring. [McDermott et al, 1994] In logistic regression analysis, 
increasing age (P< 0.02) and a left-sided neurological event (P< 0.01) were significant 
predictors of ST segment depression; whereas atherosclerotic risk factors, history of 
cardiac disease, and mean arterial pressure were not. [McDermott et al, 1994] In 
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another study involving stroke patients (mean age= 73 + 9.3) without primary heart 
disease, new ST-T ECG changes of a small magnitude were seen in about half of the 
cases (13/27 patients) with daily ECG recordings, during the first 10 days after the 
acute stroke event. [Lindgren et al, 1994] 
 
Compared with continuous ECG monitoring and serial follow-up ECG recordings, 
single 12-lead ECG recordings in the present study were likely to underestimate the 
true incidence of ECG abnormalities after acute stroke and medical admissions. A 
study involving 271 stroke patients has reported that the incidence of detected 
arrhythmia was 61% with ECG monitoring and 41% in the unmonitored group. 
[Reinstein et al, 1972] [Davis et al, 1993] Although ECG monitoring resulted in 
increased arrhythmia detection, this was reported to have little or no effect on 30-day 
mortality. [Reinstein et al, 1972] [Davis et al, 1993] However, others reported that 
ECG dysrhythmia e.g. atrial fibrillation, is one of the most important indicators of 30-
day mortality in patients with first-time ischaemic stroke (OR=5.2; 95% CI= 2.37 to 
13.77). [Szczudlik et al, 2000] Furthermore, 3-month mortality in 692 patients with 
ischaemic stroke was predicted by atrial fibrillation (OR= 2.0; 95% CI= 1.3 to 3.1), 
and ischaemic changes such as ST elevation (OR= 2.8; 95% CI= 1.3 to 6.3), ST 
depression (OR= 2.5; 95% CI= 1.5 to 4.3), and inverted T wave (OR= 2.7; 95% CI= 
1.6 to 4.6); independent of stroke severity, pre-stroke disability and age. [Christensen 
et al, 2005] However, none of the ECG changes reached significance in 223 patients 
with TIA. [Christensen et al, 2005] A recent study has reported that Holter 24-hour 
ECG recording detected atrial fibrillation in 5% of acute ischaemic stroke or TIA 
patients with a normal standard ECG (7/139 patients), whereas an event loop recorder 
i.e. a 7-day ambulatory ECG monitoring detected atrial fibrillation in 5.7% of patients 
 179
with a normal standard ECG and Holter (5/88 patients). [Jabaudon et al, 2004] The 
investigators concluded that an event loop recorder should be considered in every 
acute ischaemic stroke or TIA patient in whom a cardioembolic mechanism was 
suspected. [Jabaudon et al, 2004] Indeed, previous studies showed that atrial 
fibrillation in stroke patients predicted poor outcome at 1 month and 1 year in 
comparison with subjects in sinus rhythm, [Feinberg et al, 1999] [Lin et al, 1996] with 
mortality rates of 50% at 1 year. [Carter et al, 2007] In keeping with previous studies, 
[Vernino et al, 2003] [Marini et al, 2005] atrial fibrillation was recently reported to be 
a significant and independent predictor of mortality in ischaemic stroke patients 
followed up for a median of 7.4 years. [Carter et al, 2007] 
 
In addition to conventional risk factors such as older age, male sex, history of angina 
and diabetes, investigators have reported that ECG evidence of anterior infarction, 
inverted T wave and left ventricular hypertrophy were all independent predictors for 
cardiac events in patients with TIA or minor ischaemic stroke. [Pop et al, 1994] 
Another study has reported that the 90-day risk for a cardiac event was greater in 
those TIA patients who had any abnormal ECG findings (4.2% vs 0.6%; P< 0.001), 
even after adjustment for medical history and examination findings (OR= 6.9; 95% 
CI= 1.6 to 29.5; P= 0.009). [Elkins et al, 2002] However, the ECG abnormalities were 
not found to associate with risk for stroke or death. [Elkins et al, 2002]  In another 
study, the 6-month mortality rate in the acute ischaemic stroke patients was 
significantly higher in patients with abnormal ECG changes when compared to those 
patients with normal ECG changes (38.9% versus 15.2%; P= 0.018). [Bozluolcay et al, 
2003] Specific ECG abnormality such as long QTc interval (e.g. in lead V6) or 
increased QT dispersion which may predict future cardiac death in stroke survivors 
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[Wong et al, 2003] or worse functional outcome [Lazar et al, 2003] [Fure et al, 2006] 
was not investigated in the present study. Indeed, insular involvement has been 
reported to independently predict QT prolongation in small infarcts. [Tatschl et al, 
2006] However, the main purpose of this present case-control study was to focus on 
the prevalence of ECG rhythms and ischemic changes in an elderly population within 
48 hours of their acute hospital admission. [Ngeh, 2004]  
 
Indeed, many studies have suggested a correlation between abnormal ECG findings 
and adverse stroke outcomes. [Davis et al, 1993] [Pop et al, 1994] [Dimant and Grob, 
1977] [Goldstein, 1979] [Szczudlik et al, 2000] [Elkins et al, 2002] [Wong et al, 2003] 
Future adequately powered prospective studies may be designed to investigate the 
relationships between new ECG abnormalities or ischaemic changes and clinical 
outcomes, in conjunction with specific evaluations of myocardial damage, such as 
troponin level measurements and echocardiography, in elderly patients presenting 
acutely with different subtypes of stroke. [Khechinashvili and Asplund, 2002] 
[Oppenheimer, 2002] [Davis et al, 1993] [Ngeh, 2004] Indeed, a recent study reported 
that ECG ST depression and Q waves prevalent in acute ischaemic stroke patients 
were significantly associated with a rise in troponin T, which in turn was significantly 
associated with a poor short-term neurological outcome (modified Rankin scale > 3) 
(P= 0.006). [Fure et al, 2006] Others have reported that infarctions in specific brain 
regions including the right insula were found to associate with elevated serum 
troponin T level indicative of myocardial injury. [Ay et al, 2006] Recently, a study 
has reported that raised troponin I was associated with elevation of epinephrine in 
acute ischaemic stroke, thereby suggesting that activation of the sympathoadrenal 
system may be an important contributor to myocardial damage. [Barber et al, 2007] 
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However, the same investigators concluded that an increased troponin I was not 
associated with insular damage and was not an independent predictor of death or 
dependency (Rankin > 2). [Barber et al, 2007] For those stroke or TIA patients who 
have atrial fibrillation, echocardiography may also be used to detect cardiac thrombus, 
which may be the source of the acute cerebrovascular event. [Ngeh, 2004] Meantime, 
it seems worthwhile to add ECG information to the conventional risk profile 
assessment in order to improve the identification, investigation or treatment of 
subjects at an increased risk for the development of future disease. [De Bacquer and 
De Backer, 2002] 
 
7.5. Conclusions 
 
This study showed that atrial fibrillation was the most common arrhythmia and 
accounted for about a quarter of all ECG rhythms in elderly stroke / TIA and medical 
patients. The high frequency of ischaemic ECG changes found in the stroke / TIA 
patients (56%) was not significantly different from that in the control patients (46%). 
Although ischaemic ECG changes could reflect underlying coronary heart disease, 
they could also be due to non-specific effects of an acute cerebrovascular event or 
medical illness. After statistical adjustment for a possible confounding effect of IHD, 
there was a trend of borderline significance to suggest that ischaemic ECG changes 
were more strongly associated with elderly acute stroke or TIA patients than control 
medical patients. Larger outcome study will be required to establish and follow-up the 
significance of ECG abnormalities and ischaemic changes, and also to determine if 
these changes could represent direct consequences following acute cerebrovascular 
events in older patients. [Ngeh, 2004] 
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The next chapter will explore the relationship between socioeconomic deprivation, 
atypical respiratory infections and survival outcome in the same cohort of patients as 
in the C-PEPS study. 
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Chapter 8 
 
The relationship between socioeconomic deprivation, 
atypical respiratory infections and survival outcome in 
elderly stroke and medical patients 
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8.1. Introduction 
 
Stroke is primarily a disease affecting older people. Worlwide, stroke remains a 
significant economic and health burden to an increasingly ageing population. 
Established risk factors such as hypertension, smoking, diabetes and hyperlipidaemia 
do not fully account for the clinical and epidemiological occurrences of stroke. Other 
factors such as socioeconomic deprivation (SED) [Kurth and Berger, 2007] [Cox et al, 
2006] [Wong et al, 2006] [Weir et al, 2005] [Arrich et al, 2005] [Aslanyan et al, 2003] 
[Gillum and Mussolino, 2003] [Kapral et al, 2002] [Jakovljevic et al, 2001] [Peltonen 
et al, 2000] and infections [Elkind and Cole, 2006] [Grau et al, 2006] have emerged as 
potentially important modifiable stroke risk factors. However, published data on the 
relationship between SED, atypical respiratory infections and survival outcome in the 
context of elderly stroke and control medical patients is very limited. [Ngeh et al, 
2007] 
 
The aims of the current study were to investigate in a cohort of elderly stroke / 
transient ischaemic attack (TIA) and control medical patients simultaneously for: (1) 
the SED scores of the two groups; (2) the mean SED scores of stroke / TIA and 
medical control patients who were seropositive or seronegative for atypical 
respiratory infections; (3) the relationship between SED scores and seropositivity 
(immunoglobulins IgG and IgM) of individual and aggregate number of atypical 
respiratory pathogens; (4) the effect of SED on the association between chronic (IgG) 
atypical respiratory infectious burden and stroke / TIA; and (5) the effect of SED on 
the survival of stroke / TIA patients and control medical patients. [Ngeh et al, 2007] 
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8.2. Subjects and Methods 
 
The seroprevalences (IgG and IgM antibodies) of atypical respiratory pathogens such 
as Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila and 
their association with stroke / TIA versus control medical patients were published and 
reported in previous chapters of this thesis. The methods of the C-PEPS (Chlamydia 
pneumoniae in Elderly Patients with Stroke), M-PEPS (Mycoplasma Pneumoniae in 
Elderly Patients with Stroke) and L-PEPS (Legionella Pneumophila in Elderly 
Patients with Stroke) case-control studies were also detailed previously in this thesis. 
[Ngeh et al, 2003] [Ngeh et al, 2004(b)] [Ngeh and Goodbourn, 2005(a)]  The original 
C-PEPS, M-PEPS and L-PEPS studies were approved by the hospital’s local research 
ethics and research and development committees. Informed consent / assent were 
obtained from patients / carers to access patients’ health records as described in the 
original C-PEPS study. [Ngeh et al, 2003] 
 
The SED and mortality outcome data of the current study were based on the same 
cohort of patients as in the original C-PEPS study. To ensure homogeneity, 8 acute 
haemorrhagic stroke cases were excluded. This study focussed on the remaining 92 
ischaemic stroke / TIA patients and 87 control medical patients. [Ngeh et al, 2007] 
 
8.2.1. Socioeconomic status  
 
Area based measures of socioeconomic status [Cox et al, 2006] such as the English 
Index of Multiple Deprivation 2004 (IMD 2004) and Income Deprivation Affecting 
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Older People Index (IDAOPI) were used as indices of SED in the present study. The 
IMD 2004 and IDAOPI were validated and published in 2004 by the then Office of 
the Deputy Prime Minister of the United Kingdom (UK) government in collaboration 
with the Social Disadvantage Research Centre at the Department of Social Policy and 
Social Research, University of Oxford. [The English Indices of Deprivation, 2004] 
[Ngeh et al, 2007]  
 
The IMD 2004 and IDAOPI were available to measure SED for the whole of England 
at a small area level, i.e. a specific, census-based geographical unit known as Super 
Output Area (SOA), in a consistent manner. [The English Indices of Deprivation, 
2004] Each of the 32,482 SOA in England was assigned a deprivation score and rank 
for the IMD 2004 and IDAOPI which were published officially. [The English Indices 
of Deprivation, 2004]  
 
All the patients’ socioeconomic status in the present study was determined 
ecologically from their postcode areas of residence as recorded on their recruitment in 
the original C-PEPS study. These postcodes were also verified by the hospital’s 
computerised administrative record. Each postcode was then entered into the 
computer to allow for a specific administrative area search for a specific SOA using 
Gigateway, an official web service provided by the Association for Geographic 
Information, UK. [Gigateway, UK] After obtaining all the patients’ resident SOAs, 
their individual, relative levels of SED were then assigned by the corresponding IMD 
and IDAOPI numerical scores with rankings. [The English Indices of Deprivation, 
2004] [Ngeh et al, 2007] For example, a higher numerical scoring would correspond 
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to a higher degree of deprivation and a lower ranking number whereby 1 would be the 
ranking for the most deprived. 
 
8.2.2. Survival outcome 
 
The duration of patients’ survival was determined from the date of their hospital 
admission at the time of recruitment until the date of their death, or if they were still 
alive, until the end of a 6-year follow-up period ending on the 31 March 2006. The 
primary end point in the study was all-cause mortality, which was described as an 
objective, unbiased and clinically relevant outcome. [Shishehbor et al, 2006] In the 
UK, there is a statutory requirement for an official registration within 5 days of the 
occurrence of a death. In this study, individual patient’s administrative record was 
cross-checked with the hospital computerised National Health Service (NHS) 
Strategic Tracing Service [NHS Strategic Tracing Service, 2005] for any record of 
individual patient’s date of death, in May 2006. The NHS Strategic Tracing Service is 
a database of people, places and NHS organisations in England and Wales, UK. The 
NHS Strategic Tracing Service receives weekly death data from the UK Office of 
National Statistics. If there was no statutory public record of a date of death found for 
a particular patient in this study, it was assumed that the patient was still alive by the 
31 March 2006. [Ngeh et al, 2007] 
 
8.2.3. Statistical analyses 
 
The IMD and IDAOPI scores were normally distributed and compared between the 
groups using the t-test. Survival curves were obtained using Kaplan-Meier plots and 
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compared using the logrank test. Multiple logistic regressions were used to obtain 
odds ratios (ORs), with and without adjustment for possible confounding factors. 
[Ngeh et al, 2007]  
 
8.3. Results 
 
The mean IMD scores of the 92 ischaemic stroke / TIA patients and 87 control 
medical patients were 23.3 and 25.0, respectively. The difference was calculated as 
23.3 - 25.0= -1.7; 95% confidence interval (CI)= -4.9 to 1.5; P= 0.29. The mean 
IDAOPI score of the stroke / TIA patients and control medical patients were 0.19 and 
0.21, respectively. The difference was -0.02; 95% CI= -0.05 to 0.01; P= 0.22. [Ngeh 
et al, 2007] The minus signs indicated that the IMD and IDAOPI scores were lower in 
the cases than controls. 
 
Table 1 shows the difference in the mean IMD and IDAOPI scores between those 
who were seropositive and seronegative or equivocal in the cohort. Among the control 
medical patients, there was a statistical difference in the mean IMD and IDAOPI 
scores (P= 0.02 and 0.005, respectively) between those who were seropositive and 
seronegative or equivocal for IgM. [Ngeh et al, 2007]  
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Table 1.  The difference in the mean IMD or IDAOPI deprivation scores between IgG 
/ IgM seropositive and IgG / IgM seronegative or equivocal patients in stroke / TIA 
cases and medical control 
 
 
 Deprivation 
score 
Difference in the mean 
scores (seropositive minus 
seronegative or equivocal) 
and 95% CI  
P-value from t-test 
    
  IgG   
Cases IMD -1.50 (-6.44 to 3.43) 0.55 
 IDAOPI 0.002 (-0.046 to 0.051) 0.92 
    
Controls IMD -0.22 (-5.10 to 4.66) 0.93 
 IDAOPI -0.014 (-0.062 to 0.034) 0.55 
    
   
IgM  
 
Cases IMD 1.15 (-5.36 to 7.65) 0.73 
 IDAOPI 0.033 (-0.031 to 0.096) 0.31 
    
Controls IMD 7.16 (1.14 to 13.19) 0.02 
 IDAOPI 0.084 (0.026 to 0.142) 0.005 
    
 
IMD indicates Index of Multiple Deprivation 
IDAOPI indicates Income Deprivation Affecting Older People Index 
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The relationship between patients’ mean IMD and IDAOPI scores and their IgG and 
IgM aggregate number of atypical respiratory pathogens is shown in Table 2. There 
was no clear trend of an association between the number of pathogens and deprivation 
scores except that for IgM seropositivity, there was a statistically significant 
association between the number of atypical respiratory pathogens and IDAOPI scores 
(P= 0.004), even after allowing for case-control status. [Ngeh et al, 2007] 
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Table 2.  The relationship between patients’ mean IMD and IDAOPI deprivation 
scores and their seropositivity (IgG and IgM) for 0, 1, 2 or 3 of C pneumoniae, M 
pneumoniae, and L pneumophila  
 
    
Number of pathogens, IgG Number of 
patients 
Mean IMD 
score 
Mean IDAOPI 
score 
0   24 25.7 0.21 
1   51 21.7 0.18 
2   81 24.6 0.21 
3   14 23.9 0.18 
All 170*   
P-value  0.37 0.50 
P-value after allowing for case-
control status 
 0.44 0.60 
    
Number of pathogens, IgM Number of 
patients 
Mean IMD 
score 
Mean IDAOPI 
score 
0 115 22.8 0.18 
1   27 26.4 0.24 
2   10 24.4 0.20 
3     1 44.3 0.49 
All 153*   
P-value  0.12 0.003 
P-value after allowing for case-
control status 
 0.13 0.004 
 
IMD indicates Index of Multiple Deprivation 
IDAOPI indicates Income Deprivation Affecting Older People Index 
*Because 170 was the maximum number of ischaemic stroke / TIA and medical 
patients tested for M pneumoniae IgG and 153 for L pneumophila IgM, the numbers 
do not add up to the total of 179 patients (92 cases and 87 controls) 
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The unadjusted and adjusted odds ratios (ORs) for stroke / TIA in relation to IgG 
seropositivity for 0, 1, 2 or 3 of C pneumoniae, M pneumoniae and L pneumophila 
were published [Ngeh and Goodbourn, 2005(a)] and discussed in chapter 5 of this 
thesis. To investigate if SED could influence the association between chronic (IgG) 
atypical respiratory infectious burden and stroke / TIA, the ORs were adjusted for 
IMD 2004 and IDAOPI scores. As shown in Table 3, the association was significant 
(P= 0.04) before adjustment, and close to significance after adjusting for IMD (P= 
0.052) and IDAOPI (P= 0.054). The association became less significant after 
adjusting for IMD or IDAOPI, age, sex, hypertension, diabetes mellitus, smoking, 
ischaemic heart disease and ischaemic ECG (P= 0.09 for IMD, 0.08 for IDAOPI). 
[Ngeh et al, 2007] 
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Table 3. The effect of IMD and IDAOPI deprivation scores on the odds ratios (ORs) 
for sroke / TIA in relation to IgG seropositivity for 0, 1, 2 or 3 of C pneumoniae, M 
pneumoniae, and L pneumophila 
 
Number of  
pathogens, 
IgG 
No. of 
cases 
No. of 
controls 
Unadjusted Adjusted  
for IMD 
Adjusted 
for 
IDAOPI 
0   8 16 1 1 1 
1 30 21 2.86 (1.03-7.89) 2.74 (0.98-7.63) 2.78 (1.00-7.69) 
2 39 42 1.86 (0.72-4.82) 1.84 (0.71-4.78) 1.86 (0.72-4.85) 
3 11   3 7.33 (1.58-33.97) 7.25 (1.56-33.3) 7.14 (1.53-33.3) 
All 88 82 P= 0.04 P= 0.052 P= 0.054 
      
Number of 
pathogens, 
IgG 
No. of 
cases 
No. of 
Controls 
Unadjusted Adjusted  
for IMD, age, 
sex, 
hypertension, 
diabetes mellitus, 
smoking, 
ischaemic heart 
disease and 
ischaemic ECG 
Adjusted for 
IDAOPI, age, sex, 
hypertension, 
diabetes mellitus, 
smoking, 
ischaemic heart 
disease and 
ischaemic ECG 
0   8 16 1 1 1 
1 30 21 2.86 (1.03-7.89) 3.48 (1.00-12.05) 3.68 (1.07-12.66) 
2 39 42 1.86 (0.72-4.82) 1.89 (0.60-5.92) 1.98 (0.64-6.13) 
3 11   3 7.33 (1.58-33.97) 6.49 (1.17-35.7) 6.45 (1.17-35.7) 
All 88 82 P= 0.04 P= 0.09 P= 0.08 
P-value for 
trend 
across ORs 
  P= 0.10 P= 0.23 P= 0.22 
IMD indicates Index of Multiple Deprivation 
IDAOPI indicates Income Deprivation Affecting Older People Index 
 
 194
The median age of the stroke / TIA patients and control medical patients were 80 
years (range= 65 to 98 years) and 82 years (range= 65 to 95 years), respectively, on 
recruitment. By the end of the 6-year follow-up period, 69 out of 92 stroke / TIA 
patients (75%) died with a median survival of 22.4 months; 95% CI= 8.7 to 43.8. 
During the same period, 68 out of 87 control medical patients (78%) also died with a 
median survival of 36.5 months; 95% CI= 15.4 to 51.7. 14 of the 69 TIA / stroke 
patients and 6 of the control medical patients in fact died < 1 month of their acute 
hospital admission.  
 
For the cases, the mean IMD for those who died < 1 month, died > 1 month, and those 
who were alive after 6 years were 22.4, 24.6, and 20.4, respectively; and the P-value 
for the difference between the means was 0.26. The mean IDAOPI for cases who died 
< 1 month, died > 1 month, and those who were alive after 6 years were 0.16, 0.21, 
and 0.17, respectively; and the P-value for the difference between the means was 0.16. 
For the controls, the mean IMD for those who died < 1 month, died > 1 month, and 
those who were alive after 6 years were 20.9, 25.2, and 25.6, respectively; and the P-
value for the difference between the means was 0.64. The mean IDAOPI for the 
controls who died < 1 month, died > 1 month, and those who were alive after 6 years 
were 0.14, 0.22, and 0.21, respectively; and the P-value for the difference between the 
means was 0.24. 
 
Table 4 shows the median survival (in months) of the stroke / TIA patients and 
control medical patients  as divided into tertiles of low, medium and high IMD or 
IDAOPI scores.  
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Table 4. The median survival (in months) of the stroke / TIA cases and medical 
controls as divided into 3 tertile groups of low, medium and high IMD or IDAOPI 
scores 
 
 IMD group (tertile) Median survival in months, 
95% CI 
 
Cases Low (≤18.29) 32.8 (7.6 to 61.4) 
 Medium (18.30 to 31.62)  16.5 (5.5 to 50.2) 
 High (>31.62) 13.6 (6.7 to 43.8) 
   
Controls Low (≤18.29) 41.6 (10.7 to 61.6) 
 Medium (18.30 to 31.62)  16.9 (7.3 to 53.0) 
 High (>31.62) 29.8 (15.0 to 62.9) 
   
 IDAOPI group (tertile) Median survival in months, 
95% CI 
 
Cases Low (≤0.14) 33.8 (7.6 to 66.9) 
 Medium (0.15 to 0.25)  14.1 (5.5 to 24.5) 
 High (>0.25) 30.1 (6.7 to 52.4) 
   
Controls Low (≤0.14) 33.4 (7.3 to 61.6) 
 Medium (0.15 to 0.25)  41.2 (11.3 to 67.2) 
 High (>0.25) 22.9 (5.6 to 56.1) 
 
IMD indicates Index of Multiple Deprivation 
IDAOPI indicates Income Deprivation Affecting Older People Index 
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The logrank test for a difference between the Kaplan-Meier survival curves for the 
stroke / TIA cases and medical controls was not statistically significant; P= 0.83. 
(Figure 1a) The hazard ratio of the cases compared to the controls was 1.04; 95% CI= 
0.74 to 1.45.  
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Figure 1a. Kaplan-Meier plot for stroke / TIA cases and medical controls 
 
Logrank test, P= 0.83 (no evidence of a difference between the survival curves) 
 
 
 
 
 
 
 
 197
Figures 1b and 1c show the Kaplan-Meier survival curves in stroke / TIA patients and 
control medical patients using the IMD score. Whereas Figures 1d and 1e show the 
Kaplan-Meier survival curves in stroke / TIA patients and control medical patients 
using the IDAOPI score. 
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Figure 1b. Kaplan-Meier plot for stroke / TIA cases  
 
IMD scores divided into tertiles (based on controls): Low (≤18.29), Medium (18.30 to 
31.62), High (>31.62) 
Logrank test, P= 0.53 (no evidence of a difference between the survival curves) 
Logrank test for trend, P= 0.31 (no evidence of a trend between the curves) 
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Figure 1c. Kaplan-Meier plot for medical controls  
 
IMD scores divided into tertiles (based on controls): Low (≤18.29), Medium (18.30 to 
31.62), High (>31.62) 
Logrank test, P= 0.61 (no evidence of a difference between the survival curves) 
Logrank test for trend, P= 0.96 (no evidence of a trend between the curves) 
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Figure 1d. Kaplan-Meier plot for stroke / TIA cases  
 
IDAOPI scores divided into tertiles (based on controls): Low (≤0.14), Medium (0.15 
to 0.25), High (>0.25) 
Logrank test, P= 0.37 (no evidence of a difference between the survival curves) 
Logrank test for trend, P= 0.43 (no evidence of a trend between the curves) 
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Figure 1e. Kaplan-Meier plot for medical controls  
 
IDAOPI score divided into tertiles (based on controls): Low (≤0.14), Medium (0.15 to 
0.25), High (>0.25) 
Logrank test, P= 0.78 (no evidence of a difference between the survival curves) 
Logrank test for trend, P= 0.65 (no evidence of a trend between the curves) 
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Figures 1f and 1g show the Kaplan-Meier survival curves according to the number of 
0, 1, and 2 or 3 of atypical repiratory pathogens in cases and controls, for IgG and 
IgM seropositivity, respectively  
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Figure 1f. Kaplan-Meier survival curves according to the number of atypical 
respiratory pathogens for IgG seropositivity 
 
Cases: Logrank test P= 0.002 (Logrank trend test, P= 0.34) 
Controls: Logrank test P= 0.59 
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Figure 1g. Kaplan-Meier survival curves according to the number of atypical 
respiratory pathogens for IgM seropositivity 
 
 
Cases: Logrank test P= 0.36 
Controls: Logrank test P= 0.84 
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8.4. Discussion 
 
The term ‘socioeconomic status’ is a framework of concepts and resources ordered in 
at least 3 levels: material, behavioral and psychosocial. [Kurth and Berger, 2007] For 
the first time, the English Indices of Deprivation IMD 2004 and IDAOPI were used as 
an area based measure of socioeconomic status or deprivation  in the context of 
atypical respiratory infections and survival outcome in elderly stroke / TIA and 
medical patients. The IMD 2004 contained 7 specific domains of deprivation that 
were weighted in percentage (%) and related to: (1) income (22.5%); (2) employment 
(22.5%); (3) health and disability (13.5%); (4) education, skills and training (13.5%); 
(5) housing and services (9.3%); (6) crime (9.3%); and (7) living environment (9.3%). 
[The English Indices of Deprivation, 2004] The supplementary index, IDAOPI, was 
specifically created for older people aged over 65 years. [The English Indices of 
Deprivation, 2004] The denominators of the IMD and IDAOPI were based on the 
2001 Census and 2001 Mid-Year Population Estimates. [The English Indices of 
Deprivation, 2004] Recently, these official English indices of deprivation 2004 were 
academically peer-reviewed and endorsed. [Alcock, 2007] 
 
Generally, area based measures of socioeconomic status in the UK are consisted of a 
composite of multiple variables to characterize a geographical area. [Cox et al, 2006] 
The variables used can vary and are usually taken from census data. [Cox et al, 2006] 
For example, the Townsend index of deprivation uses unemployment, non-car 
ownership, non-home ownership, and overcrowding as the variables. [Cox et al, 2006] 
[Townsend et al, 1987] For the Carstairs deprivation index, the variables used are 
unemployment, households with no car, overcrowding, and head of household social 
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class. [Cox et al, 2006] [Carstairs and Morris, 1991]  Whereas unemployment, 
overcrowding, lone pensioners, single parents, ethnic minorities, children under the 
age of 5 years, head of household social class and 1 year migrants are the variables 
used in the Jarman deprivation score. [Cox et al, 2006] [Jarman, 1983] [Jarman, 1984] 
In comparison with these UK indices of SED such as the Townsend, Carstairs and 
Jarman, the IMD 2004 and IDAOPI were more up-to-date and statistically robust. 
[The English Indices of Deprivation, 2004]   
 
In this elderly cohort of 92 ischaemic stroke / TIA patients and 87 control medical 
patients, their socioeconomic status as determined by the difference in their mean 
IMD (P= 0.29) and IDAOPI (P= 0.22) scores was not significantly different. [Ngeh et 
al, 2007]  
 
In the stroke / TIA patients, there was no statistical difference in the mean IMD and 
IDAOPI scores between those who were seropositive and seronegative / equivocal, 
for both IgG and IgM of the atypical respiratory pathogens. An association between 
SED and atypical respiratory infection was not found in the elderly stroke / TIA 
patients. However, in the medical controls, there was a statistical difference in the 
mean IMD (P= 0.02) and IDAOPI (P= 0.005) scores between patients seropositive 
and seronegative for IgM, but not for IgG. This suggested that an acute atypical 
respiratory infection could be associated with SED in the elderly medical patients. 
[Ngeh et al, 2007] 
 
In the present study, an association between the number of atypical respiratory 
pathogens and deprivation scores was not found in the cohort except that for IgM 
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seropositivity, there was a statistically significant association between the number of 
pathogens and IDAOPI scores (P= 0.004). This suggested that acute infection of 
multiple atypical respiratory pathogens or infectious burden was significantly and 
specifically associated with income deprivation in the elderly, even allowing for case-
control status in this study. [Ngeh et al, 2007] In comparison, a recent study reported 
that although infectious burden by summing of the seropositivity for C pneumoniae, 
cytomegalovirus, and herpes simplex virus 1 was associated with a lower 
socioeconomic status i.e. employment grade; it did not appear to mediate 
socioeconomic status differences in cardiovascular disease risk. [Steptoe et al, 2007] 
However, suggested mechanisms by which socioeconomic status influences 
cardiovascular disease and stroke risk include differences in major stroke risk factors, 
in lifestyles and behaviour patterns, in psychosocial factors, in access to health care, 
and effects of chronic stress mediated by the brain. [Pickering, 1999] [Cox et al, 2006] 
[Kurth and Berger, 2007] 
 
SED had been positively linked with hospital admission for acute respiratory tract 
infections and pneumonia (P< 0.0001) in all age groups, particularly in children. 
[Hawker et al, 2003] However, the risk of mortality from respiratory infections was 
also found to increase with increasing age and deprivation quintile using Townsend 
deprivation scores. [Jordan et al, 2006] Indeed, highly deprived areas are associated 
with poverty, and poverty is a predictor of respiratory infections in all age groups. 
[Rojas, 2007] The mechanisms mediating SED and respiratory infections at individual 
levels and examination of other areas would merit further studies to identify target 
groups for effective intervention; although it has been reported that smoking-related 
causes were found to have the strongest positive relationships with deprivation. 
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[Romeri et al, 2006] Indeed, behavioural factors such as smoking, drinking, obesity 
were found to explain a substantial part of the inverse association between 
socioeconomic status and inflammatory markers e.g. interleukin-6, C-reactive protein, 
and tumour necrosis factor-α, [Koster et al, 2006] which themselves are biological 
markers linked to cardiovascular disease. [Pickering, 1999] 
 
As published and discussed in chapter 5 of this thesis, the association between stroke / 
TIA and IgG seropositivity for 0, 1, 2 or 3 of C pneumoniae, M pneumoniae, and L 
pneumophila infections was statistically significant before statistical adjustment (P=  
0.04). [Ngeh and Goodbourn, 2005(a)] After adjustment for IMD and IDAOPI in this 
study, the association remained close to significance with P= 0.052 and 0.054, 
respectively. This suggested that SED on its own had only a modest effect on the 
association between chronic atypical respiratory infections and elderly stroke / TIA 
patients. [Ngeh et al, 2007] 
 
The overall association between stroke / TIA and chronic infectious burden of 
atypical respiratory infection became statistically less significant after adjustment for 
confounding factors  such as age, sex, hypertension, diabetes mellitus, smoking, 
ischaemic heart disease and ischaemic ECG (P= 0.06). [Ngeh and Goodbourn, 
2005(a)] The overall association became even less significant after further adjustment 
with IMD (P= 0.09) and IDAOPI (P= 0.08) in this study. However, the OR for stroke 
/ TIA in relation to atypical respiratory infectious burden after this further adjustment 
remained strongest in subjects infected with at least 3 pathogens: OR= 6.5 (CI= 1.17 
to 35.7). [Ngeh et al, 2007] Although adjusting SED together with other confounding 
factors appeared to have weaken the association (P= 0.08 and 0.09) between stroke / 
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TIA and atypical respiratory infectious burden, it had been criticised as statistical over 
adjustment in this context. [West, 2000]     
 
In the present study, three quarters of the stroke / TIA patients and control medical 
patients, respectively, had died by the end of the 6-year follow-up period. Whilst the 
median age of cases and controls on recruitment in the original C-PEPS study were 80 
years, respectively, the median age of death of the stroke / TIA patients and control 
medical patients were 82 years and 85 years, respectively. There was no statistical 
difference between the means of IMD and IDAOPI scores for patients who died 
within one month or after 1 month of their acute admission, or those who remained 
alive after 6 years of follow-up, in both the cases and controls. Although the median 
survival of stroke / TIA patients appeared shorter than the control medical patients 
(22.4 versus 36.5 months), the 95% CI overlapped greatly, indicating that the 
difference could have been due to chance. There was no survival difference between 
the groups as divided into tertiles of IMD and IDAOPI deprivation scores, in either 
the cases or controls. [Ngeh et al, 2007]  
 
Indeed, the relationship between SED and survival outcome after stroke were 
investigated in several studies with conflicting results. [Cox et al, 2006] [Zhou et al, 
2006] [Wong et al, 2006] [Weir et al, 2005] [Arrich et al, 2005] [Aslanyan et al, 2003] 
[Gillum and Mussolino, 2003] [Kapral et al, 2002] [Jakovljevic et al, 2001] [Peltonen 
et al, 2000] Some of these studies showed an inverse relationship between higher 
level of SED and worse survival outcome after a stroke, [Zhou et al, 2006] [Arrich et 
al, 2005] [Gillum and Mussolino, 2003] [Kapral et al, 2002] [Jakovljevic et al, 2001] 
whilst others did not demonstrate such a relationship. [Wong et al, 2006] [Weir et al, 
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2005] [Aslanyan et al, 2003] [Peltonen et al, 2000] For the first time, this 6-year 
follow-up study suggested that hospitalised elderly patients’ duration of survival after 
an acute stroke / TIA event was not significantly affected by their background SED 
status on their hospital admission; and that their duration of survival was not 
statistically different from other hospitalised control medical patients. [Ngeh et al, 
2007] In comparison, a study has  reported that white, elderly participants (aged 65 
years and older) living in the most disadvantaged neighbourhood was associated with 
higher rates of cardiovascular deaths, even after adjustment for income, education, 
and occupation (Hazard ratios= 1.5; 95% CI= 1.2 to 1.9). [Diez Roux et al, 2004] 
However, no neighbourhood differences were observed for non-cardiovascular deaths 
in this elderly cohort. [Diez Roux et al, 2004] Others have also found no association 
between poverty area of residence and mortality in older adults. [Diez Roux et al, 
2004] [Haan et al, 1987] [Waitzman and Smith, 1998] 
 
Although there were debates about the most appropriate way to detect SED in an 
elderly population whereby small area-based census variables would generally reflect 
characteristics of a younger part of the population, it was nevertheless suggested that a 
combination of SED measures was a very appropriate way to capture and predict the 
socioeconomic position in an elderly population. [Breeze et al, 2005] [Bowling, 2004] 
[Grundy and Holt, 2001] Amongst the more conventional SED indicators of education, 
occupation, income and wealth, it was found that SED of income and wealth were as 
strongly associated with mortality as, if not more strongly associated with mortality 
than, education and occupation, even for elderly people aged over 65 years. [Duncan 
et al, 2002] These suggestions were supportive of the application of IMD and 
specifically IDAOPI in the current study. [Ngeh et al, 2007] Indeed, income 
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deprivation has been found to be independently associated with adverse short and 
long-term mortality among elderly patients following acute myocardial infarction. 
[Rao et al, 2004] 
  
Apart from area based measures, other specific measures of socioeconomic status 
such as education, occupation, income, and material ownership do have their own 
advantages and limitations as reported in a recent review. [Cox et al, 2006] The use of 
education as a socioeconomic status measure can determine an individual’s number of 
years in full-time education and age on leaving full-time education. An individual’s 
education can be reliably recalled, easily quantified, unaffected by poor health in 
adulthood, and be a marker of early life circumstances. However, education may be 
culturally specific, and less applicable to some subgroups or cohorts e.g. the link 
between education and income is weaker in older women. [Cox et al, 2006] 
 
Occupation as a measure of socioeconomic status is usually a categorical ordering of 
occupational social class e.g. Registrar General Great Britain social class I – V, 
[Office of Population Censuses and Surveys, 1991] United States standard 
occupational classification system, [US Department of Labor, 2000] ISCO-88 
international standard classification of occupations [International Labour Office, 
1990]. [Cox et al, 2006] It is an advantage that occupation can be an indicator of 
social status, power, income, and education. However, there are limitations such as 
subjectivity and inconsistency of ranking systems, limitations in capturing 
socioeconomic status for some subgroups e.g. women and some ethnic minorities, 
difficulties incorporating new occupations, people who don’t work and older adults, 
and it may be determined by poor health in adulthood. [Cox et al, 2006] 
 211
 
When income is used as a socioeconomic status measure, it can measure total cash 
income (month / year), disposable income, individual / household income, and non-
cash benefits. An individual’s income is a good measure of purchasing capacity e.g. 
of goods, education, and health care. However, it may be difficult to collect income 
data, with high non-response rate, and confidentiality concerns. An individual’s 
income may be determined by poor health in adulthood, and it may vary throughout 
one’s life course. Moreover, hosuehold members may have unequal access to 
household income. [Cox et al, 2006] 
 
Material ownership measures ownership of home, car, electrical or white goods e.g. 
washing machine. Although material ownership is highly correlated with income and 
education, and is an indicator of standard of living; it may also be an indicator of 
lifestyle differences. [Cox et al, 2006] 
 
8.4.1. Limitations 
 
Although the use of area based measures e.g. IMD 2004 and IDAOPI as a measure of 
socioeconomic status in this study was prone to the bias of ‘ecological fallacy’ i.e. 
assuming that all individuals living in an area had similar socioeconomic 
characteristics, it could nevertheless capture and measure important aspects of SED 
for a homogeneous elderly population in a small neighbourhood or area (i.e. SOA) 
that could not be measured individually. [Cox et al, 2006] [Grundy and Holt, 2001] 
[Kaplan and Keil, 1993] 
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The SED measures and patients’ risk factors in the present study were based on the 
demographics and clinical information recorded on recruitment. These elderly 
patients’ earlier, life-course, socioeconomic experience was not measured in this 
study. This could influence the SED measures and risk factors collected at baseline 
which in turn could change during the follow-up period. [Hart et al, 2000] However, 
certain vascular risk factors such as hypertension, antihypertensive drug use, 
prevalence of atrial fibrillation and left ventricular hypertrophy were not found to be 
associated with SED consistently in a large cohort of elderly Dutch women. [van 
Rossum et al, 1999] Nevertheless, it has been shown that stroke, stomach cancer and 
respiratory disease mortality all seem to be related to early life socioeconomic 
conditions in international ecological studies, [Ben-Shlomo and Davey-Smith, 1991] 
[Guallar-Castillon et al, 1999] [Leon and Davey-Smith, 2000] and in agreement with 
findings from prospective studies of individuals. [Davey-Smith et al, 1998] [Davey-
Smith et al, 2001] This correspondence in findings between ecological and individual 
level studies suggests that they reflect underlying causal processes that can be indexed 
through specific area-based measures with indices relating to social circumstances 
during early life or through collecting the relevant information on people. [Davey-
Smith et al, 2001] Examples of early-life socioeconomic position indicators used in 
cross-sectional and longitudinal studies included education level, income, occupation, 
living conditions, family structure and residential mobility. [Chittleborough et al, 
2006] 
 
In the present study, it was not possible to determine neither the length of residence 
nor residential mobility of the elderly patients. [Stjarne et al, 2004] This might lead to 
a misclassification bias, which could affect the relationship of SED on survival 
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outcome. [Stjarne et al, 2004] Indeed, it has been suggested that residential 
environments over the life course, rather than the place of residence in old age, is 
particularly relevant to longevity. [Diez Roux et al, 2004] Information on patients’ 
long term residence before enrolment in this study was unavailable. The extent to 
which features of residential environments in old age are correlated with features of 
places or socioeconomic status earlier in life in this cohort of elderly patients cannot 
be established. [Diez Roux et al, 2004] 
 
8.5. Summary 
 
In this study, the socioeconomic status of hospitalised acute elderly stroke / TIA 
patients was not significantly different from the control medical patients. Whilst an 
association between SED and atypical respiratory infections was not found in the 
stroke / TIA patients, an association between acute atypical respiratory infection and 
SED was found to be statistically significant in the control medical patients.  
 
Allowing for case-control status, acute atypical respiratory infectious burden was 
significantly and specifically associated with income deprivation in this cohort of 
elderly stroke / TIA and medical patients. However, SED on its own had only a 
modest effect on the association between chronic (IgG) atypical respiratory infectious 
burden and elderly stroke / TIA patients. 
 
After 6-years of follow-up, the present study suggested that hospitalised elderly 
patients’ duration of survival after an acute stroke / TIA or medical event was not 
significantly affected by their background SED status on hospital admission. The 
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duration of survival of elderly stroke / TIA patients (median= 22.4 months) was not 
statistically different from that of elderly medical controls (median= 36.5 months). 
Within either the cases or controls, there was no survival difference between the 
deprivation groups in tertiles of low, medium and high SED scores. 
 
Socioeconomic deprivation, in particular income deprivation, should be adjusted for 
in studies on the association between stroke and infections, [Lindsberg and Grau, 
2003] especially in the context of acute respiratory infections. Because SED, 
infections and stroke are potentially important modifiable risk factors, larger, 
prospective epidemiological and interventional studies to explore the mechanistic 
relationship between these factors in targeted populations are justified. 
 
The next chapter shall conclude and summarise the main findings of all the published 
works submitted for this thesis. Some directions for future research study are 
suggested. 
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Chapter 9 
 
General discussion of published works and conclusions 
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9.1. Introduction 
 
Stroke as a major clinical manifestation of atherosclerosis, is the leading cause of 
disability and death in the world. Classical vascular risk factors such as hypertension, 
smoking, diabetes mellitus and dyslipidaemia do not fully account for the clinicial 
occurrence and epidemiology of stroke. Other novel risk factors such as infection and 
socioeconomic deprivation have emerged as potential risk factors for stroke.  
 
9.2. Infections and stroke 
 
Infections, both acute and chronic, are recognised as potentially important and 
treatable risk factor for stroke. Many specific acute or recent infections can affect the 
individual either at a local organ level or systemically. Apart from acute infection of 
the central nervous system by specific micro-organism resulting in an acute 
cerebrovascular event, the association between acute systemic infection secondary to 
acute respiratory tract infection and stroke has also been established.  
 
Since atherosclerosis is recognised as a chronic inflammatory disease, chronic 
infections are hypothesised to contribute to atherogenesis and atherothrombosis 
through chronic inflammatory stimuli and immunological mechanisms. These 
processes could occur in susceptible individuals and synergistically with traditional 
vascular risk factors. In accordance to the infectious hypothesis of atherosclerosis, 
specific chronic infections could contribute to atherosclerosis, and thus ischaemic 
stroke events. Apart from Cytomegalovirus, Helicobacter pylori and dental pathogens, 
Chlamydia pneumoniae is the micro-organism most studied and implicated in this 
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context of infection and atherosclerotic vascular diseases such as stroke and coronary 
heart disease.  
 
9.3. Chlamydia pneumoniae and atherosclerosis 
 
Chlamydia pneumoniae, an atypical respiratory pathogen, is the micro-organism most 
investigated in the model of chronic infection and atherosclerotic vascular diseases. 
The investigations include (1) seroepidemiologoical observations which are cross-
sectional, case-control and prospective in design; (2) laboratory studies which include 
pathological specimen examinations, animal model experimentations and 
immunological / molecular studies; and (3) clinical investigations such as human 
antibiotic intervential trials. Overall, the evidence is compelling but remains 
inconclusive.  
 
Sero-epidemiological studies have provided weak, circumstantial evidence linking C 
pneumoniae infection and various atherosclerotic vascular diseases. The challenge in 
this area of study is to identify other (blood) surrogate markers that are accessible and 
reliable in reflecting underlying endovascular C pneumoniae infection, applicable in 
large scale population studies e.g. antimicrobial treatment studies in the context of 
stroke. The development of reliable laboratory techniques, and refinement of existing 
methods e.g. ELISA, to detect blood markers of C pneumoniae infection is a priority.  
 
Similarly, the various pathological methods used to detect C pneumoniae and its 
antigens in atherosclerotic specimens will need further improvement and 
standardisation. Pathological specimen examinations have detected genetic material 
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of, or even viable, C peneumoniae in atheromatous lesions. Although less likely, the 
possibility of C pneumoniae residing in the atheroma as an innocent bystander 
remains. In conjunction with studies from other areas, pathological specimen studies 
will help to clarify a possible atherogenic role of C pneumoniae infection.  
 
Most animal model studies have demonstrated that C pneumoniae could induce 
atherosclerotic lesions, synergistically or in conjuction with traditional vascular risk 
factors such as genetic predisposition to develop atherosclerosis, and dyslipidaemia. 
Animal models will continue to be useful in the investigation of infection induced 
atherogenic mechanisms, in conjunction with other atherosclerotic risk factors and 
antibiotic treatment studies.  
 
As a whole, immunological and molecular studies have strongly implicated the roles 
of C pneumoniae in atherogenesis and atherothrombosis. A mechanistic 
understanding of the interaction between C pneumoniae infection and the genesis and 
progression of atherosclerosis at the molecular or immunological levels will provide 
possible therapeutic opportunities and/or surrogates of treatment effects. Indeed, C 
pneumoniae has been shown to involve in key events of atherogenesis and 
athethrombosis in in-vitro studies.  
 
To date, large-scale clinical antibiotic interventional trials have failed to establish 
antibiotic treatment benefit in the context of C pneumoniae infection in patients with 
coronary heart disease. However, these studies could not prove or disprove a causal 
role of C pneumoniae in atherogenesis or atherosclerosis, since the process in its early 
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or stable stages may not always manifest itself clinically as adverse vascular events. 
Conversely, most of these trials focused on potential antibiotic treatment benefit on 
patients with pre-existing (advanced) atheromas, and secondary prevention of acute 
athero-thrombotic events. Future antibiotic treatment studies should incorporate 
specific surrogate parameters of atherosclerosis, apart from adverse clinical events, as 
outcome measures. Antibiotic treatment studies should be considered and conducted 
in the context of other atherosclerotic vascular diseases such as ischaemic stroke / 
transient ischaemic attack (TIA), in different populations exposed to C pneumoniae 
that may have different atherosclerotic burdens, in both primary and secondary 
prevention settings. In addition, different antibiotics active against C pneumoniae (and 
against other micro-organisms), and their treatment regimes will need to be developed 
and standardised in these studies. This is of particular relevance if and when a causal 
association between C pneumoniae and atherosclerosis is proven, since widespread 
antibiotic misuse and resistance may then become a serious problem. In fact, a 
minority (4%) of physicians (mostly cardiologists) in the United States have used 
antibiotics to treat cardiovascular diseases as if it were an infectious disease; although 
this practice is currently considered inappropriate and premature. [Gimenez-Sanchez 
et al, 2001] 
 
Chlamydia pnemoniae on its own is an important pathogen that causes a wide 
spectrum of respiratory tract infections and extra-pulmonary diseases worldwide. The 
recognition of an association between C pneumoniae infection and atherosclerotic 
vascular diseases has generated a great interest in this area of research over the last 
decade. Although antibiotics active against C pneumoniae have failed to show a 
treatment benefit in the context of coronary heart disease, the body of evidence as a 
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whole is supportive of C pneumoniae as a plausible and modifiable risk factor in 
atherosclerosis. With the recent discovery of C pneumoniae’s genome, the 
development of an effective vaccination programme in future is becoming a reality 
that will not only prevent C pneumoniae infection but may also clarify if C 
pneumoniae has a causal relationship with atherosclerosis.  
 
9.4. The C-PEPS study 
 
Seroepidemiological studies have shown a weak relationship between chronic C 
pneumoniae infection and coronary heart disease; although preliminary studies have 
suggested that the association was stronger for stroke in younger patients. As the 
occurrence of stroke / TIA increases with age, the relationship between serological 
markers of C pneumoniae infection and older stroke / TIA patients was investigated in 
the ‘Chlamydia pneumoniae in elderly patients with stroke’ or C-PEPS case-control 
study.  
 
The C-PEPS was a case-control study that investigated the seroprevalence of C 
pneumoniae in elderly stroke / TIA and medical patients. One-hundred white patients 
aged over 65 years admitted with acute stroke or TIA, and 87 control patients 
admitted with acute non-cardiopulmonary, non-infective disorders, were recruited 
prospectively. With the use of SeroCP commercial ELISA kits (Savyon, Israel), the 
presence of C pneumoniae immunoglobulins IgA, IgG, IgM in patients’ sera was 
determined. The seroprevalence of C pneumoniae specific IgA, IgG, IgM were 63%, 
71%, and 14% in the stroke / TIA group (median age= 80), and 62%, 65%, 17% in the 
control group (median age= 80), respectively. With the use of a logistic regression 
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statistical model, adjusting for age and sex, history of hypertension, smoking, diabetes, 
ischaemic heart disease (IHD), ischaemic electrocardiogram (ECG), the odds ratios 
(ORs) of having a stroke / TIA in relation to C pneumoniae specific IgA, IgG, IgM 
were 1.04, 1.24, 0.79; and the associated P-values were not significant.  
 
Further analysis of the C-PEPS study identified 43 acute stroke / TIA cases and 44 
controls without history of IHD or ischaemic ECG or both. After adjusting for history 
of hypertension, smoking, diabetes, age and sex, the ORs in this subgroup were 1.40 
for IgA (95% confidence interval= 0.53 to 3.65; P= 0.49), 2.41 for IgG (95% CI, 0.90 
to 6.46; P= 0.08), 1.55 for IgM (95% CI, 0.45 to 5.40; P= 0.49).  
 
The C-PEPS study concluded that a high seroprevalence of C pneumoniae in elderly 
patients was confirmed, although no significant association between serological 
markers of C pneumoniae infection and acute stroke / TIA events was found. There 
was, however, a weak trend towards increased ORs for acute stroke / TIA in a 
subgroup of C pneumoniae seropositive elderly patients without any history of IHD or 
ischaemic ECG. Adequately powered, prospective outcome study may be conducted 
to see if serological or other blood markers of C pneumoniae (endovascular) infection 
are associated with ischaemic stroke / TIA in younger versus older patients, without 
clinical evidence of ischaemic heart disease or other atherosclerotic vascular diseases 
at baseline. The results of such study may help with the targeting of patients for future 
antimicrobial treatment studies in the context of ischaemic stroke / TIA.    
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9.5. SeroCP ELISA reproducibility 
 
One of the limitations of seroepidemiological studies was the laboratory methods used 
in serological analyses. The issues included sensitivity, specificity, reproducibility, 
and operator objectivity of a particular laboratory method or technique. The 
serological method used in the C-PEPS study was a commercial enzyme-linked 
immunosorbent assay (ELISA) kit known as SeroCP, which was manufactured by 
Savyon Diagnostics Limited (Israel). As remarked, ELISA technique was more 
objective and correlated well with the operator dependent micro-immunofluorescence 
technique, the reference standard for C pneumoniae serological analyses. 
 
With the use of SeroCP ELISA kits, C pneumoniae immunoglobulins (Ig) or 
antibodies in a consecutive series of 122 patients’ sera for IgA and IgG respectively, 
and 138 for IgM, were detected. The ELISA tests on these sera were then repeated. 
The percentage (%) sample disagreement between the first and repeated ELISA tests 
were 12%, 16%, and 10% for C pneumoniae IgA, IgG, and IgM, respectively. The 
reproducibility of SeroCP ELISA expressed as Kappa values for IgA, IgG, IgM were 
0.73, 0.60, 0.53, respectively (P< 0.001). These results suggested that SeroCp ELISA 
had a good reproducibility for detecting C pneumoniae IgA, and moderately good 
reproducibility for detecting C pneumoniae IgG and IgM.  
 
This study has implication in the validity or reproducibility of test results in the C-
PEPS and similar seroepidemiological studies. As the results obtained by ELISA is 
not perfect, they shall have to be read in that context. With further refinement and 
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improvement, ELISA technique could potentially supercede the immunofluorescence 
assay and assume an increasingly important role in seroepidemiological studies.  
 
9.6. The M-PEPS study  
 
Mycoplasma pneumoniae, another well known atypical respiratory pathogen, has been 
linked to coronary heart disease and detected along with C pneumoniae in 
atherosclerotic specimens. Further to the C-PEPS study, there was an opportunity to 
investigate the serological association between Mycoplasma pneumoniae and stroke / 
TIA.  The ‘Mycoplasma pneumoniae in elderly patients with stroke’ or M-PEPS case-
control study was nested within the C-PEPS study. 95 patients admitted consecutively 
with acute stroke / TIA, and 82 control patients admitted concurrently with acute non-
cardiopulmonary, non-infective disorders, were included in the M-PEPS study.  
 
With the use of SeroMP commercial ELISA kits manufactured by Savyon 
Diagnostics Limited (Israel), the presence of M pneumoniae immunoglobulins IgA, 
IgG, and IgM in patients' sera was determined. The seroprevalence of M pneumoniae 
IgA, IgG, and IgM in the stroke / TIA patients (median age= 80 years) were 79%, 
61%, and 6%, respectively. In the control group (median age= 80 years), the 
seroprevalence of M pneumoniae IgA, IgG, and IgM were 84%, 50%, and 11%, 
respectively.  
 
With the use of a logistic regression statistical model, adjusting for history of 
hypertension, smoking, diabetes mellitus, age and sex, history of IHD, and ischaemic 
ECG, the ORs of having a stroke / TIA in relation to M pneumoniae IgA, IgG, and 
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IgM were 0.63 (95% CI= 0.26 to 1.52; P= 0.31), 1.32 (95% CI= 0.66 to 2.64; P= 
0.43), 0.52 (95% CI= 0.14 to 1.92; P= 0.32), respectively. The M-PEPS study showed 
a high seroprevalence of M pneumoniae in an elderly hospital population but ruled out 
M pneumoniae seropositivity as a major risk factor for stroke / TIA in this age group. 
Adequately powered, prospective outcome study may be warranted to see if 
serological or other blood markers of M pneumoniae infection are associated with 
ischaemic stroke / TIA or other atherosclerotic vascular diseases in younger versus 
older patients.   
 
9.7. The L-PEPS study 
 
Legionella pneumophila is another well known atypical respiratory pathogen. The 
‘Legionella pneumophila in elderly patients with stroke’ or L-PEPS was another case-
control study based on the same cohort of patients as in the C-PEPS study. Using 
commercial ELISA kits (VIRCELL SL, Spain), the seroprevalence of L pneumophila 
IgG and IgM antibodies in this cohort of patients were determined. The 
seroprevalence of L pneumophila IgG and IgM were respectively 29% (n= 91) and 
12% (n= 81) in the stroke / TIA group, and 22% (n= 86) and 10% (n= 72) in the 
controls.  
 
With the use of logistic regression to adjust for age, sex, hypertension, smoking, 
diabetes, IHD and ischaemic ECG, the ORs for stroke / TIA in relation to L 
pneumophila IgG and IgM were 1.52 (95% CI= 0.70 to 3.28; P= 0.29) and 1.49 (95% 
CI= 0.45 to 4.90; P= 0.51), respectively. The L–PEPS study established the 
seroprevalence of L pneumophila and showed that its seropositivity was not 
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significantly associated with stroke / TIA, in this cohort of hospitalised elderly 
patients. Whether serological or other blood markers of L pneumophila infection are 
associated with ischaemic stroke / TIA or other atherosclerotic vascular diseases in 
younger or susceptible populations may need to be clarified in future studies.    
 
9.8. Atypical respiratory infectious burden and stroke 
 
Previous studies showed that simultaneous or cumulative infections by certain 
bacteria and viruses, as evidenced by their seropositivities, were associated with 
cardiovascular events. It was hypothesised that intracellular micro-organisms, such as 
atypical respiratory pathogens, could exert chronic inflammatory or immunological 
stimuli contributing to atherosclerosis. Furthermore, atypical respiratory pathogens 
were known to share similar microbiological and clinical features that included 
neurological manifestations.  
 
Having established the seroprevalences of C pneumoniae, M pneumoniae and L 
pneumophila in the C-PEPS, M-PEPS and L-PEPS studies, a further opportunity 
existed to determine the ORs for stroke / TIA in relation to IgG seropositivity for any 
1, 2, or 3 of these chronic atypical respiratory infections. The ORs after statistical 
adjustment for age, sex, hypertension, diabetes, smoking, IHD, and ischaemic ECG 
were 3.89 (95% CI= 1.13 to 13.33), 2.00 (95% CI= 0.64 to 6.21), 6.67 (95% CI= 1.22 
to 37.04), respectively; P= 0.06.  
 
This further analysis concluded that the risk of stroke / TIA appeared to associate with 
the aggregate number of chronic infectious burden of atypical respiratory pathogens 
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such as C pneumoniae, M pneumoniae and L pneumophila. Indeed, the relationship 
between stroke / TIA and infectious burden appeared strongest in subjects infected 
with all three atypical respiratory pathogens.  
 
If the infectious hypothesis of atherosclerosis holds true, it is likely that a large but 
specific group of microorganisms (specific infectious burden), rather than a selected 
few, will be discovered to be involved in atherogenesis and atherothrombosis. [Ngeh 
and Goodbourn, 2005(b)] This concept has implication in the design of future anti-
microbial interventional clinical trials in stroke and other atherosclerotic vascular 
diseases, because subjects infected with a specific infectious burden may be identified 
and randomised to receive specific antimicrobial / therapeutic agents or even vaccines. 
[Ngeh and Goodbourn, 2005(b)] Atypical respiratory pathogens can cause up to 50% 
of cases of community-acquired pneumonia, [File et al, 1998] in addition to other 
systemic manifestations. The development of effective vaccination programme in 
future is becoming a pressing public health issue that will not only prevent atypical 
respiratory infection but also may clarify if the infectious burden has a causal 
relationship with stroke and other atherosclerotic vascular diseases. [Ngeh and 
Goodbourn, 2005(b) 
 
9.9. The C-BEPS study 
  
The ‘Coxiella burnetii in elderly patients with stroke’ or C-BEPS case-control study 
was based on the same cohort of patients as in the C-PEPS study. The C-BEPS study 
established the seroprevalence of Coxiella burnetii, another well-recognised atypical 
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respiratory pathogen, in 85 stroke / TIA and 84 control medical patients in hospital 
setting.  
 
With the use of commercial ELISA kits (PANBIO, Australia), the seropositivity of C 
burnetii IgG was found in 2 out of 85 ischaemic stroke patients (2.4%), and none in 
the 84 control patients. None of the 85 cases and 3 out of the 84 control patients 
(3.6%) were seropositive for C burnetii IgM. With such sparse data and zero counts 
(i.e. 0/84 and 0/85), the association between Coxiella burnetii infection and stroke / 
TIA was undetermined. However, the C-BEPS study served as a pilot 
seroepidemiological survey of C burnetii infection in a cohort of hospitalised, elderly 
stroke / TIA and medical patients from the urban areas of north-east London, and in a 
non-outbreak setting.  
 
9.10. ECG and stroke 
 
Electrocardiographic (ECG) abnormalities have been observed in acute 
cerebrovascular events. An opportunity existed for a case-control study on the 
prevalence of ECG rhythms and ischaemic changes of 97 elderly stroke / TIA patients 
and 70 control medical patients based on the same cohort of patients as in the C-PEPS 
study.  
 
Patients’ median age was 80 years. Atrial fibrillation occurred in 26 stroke / TIA 
patients (27%) and 17 control medical patients (24%). Ischaemic ECG changes 
occurred in 54 stroke / TIA patients (56%) and 32 control medical patients (46%) 
(OR= 1.52; 95% CI= 0.82 to 2.83; P= 0.18). 17 stroke / TIA patients (18%) versus 19 
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control medical patients (27%) had history of IHD.  After adjustment for IHD, the OR 
in relaion to stroke / TIA for ischaemic ECG changes was 1.80 (95% CI= 0.93 to 3.45; 
P= 0.079).  
 
This study found that atrial fibrillation accounted for a quarter of ECG rhythms in 
elderly, acute stroke / TIA and medical patients. The rate of atrial fibrillation in this 
study was amongst the highest in any published series. The high frequency of 
ischaemic ECG changes found in the stroke / TIA patients was not significantly 
different from that in the control medical patients. However, after adjustment for IHD, 
there emerged a statistical trend of borderline significance to suggest that ischaemic 
ECG changes were more strongly associated with elderly, acute stroke / TIA patients 
than control medical patients. The prognostic significance of various ECG 
abnormalities, sequential monitoring and possible intervention in the context of acute 
cerebrovascular events in elderly patients would merit further studies. 
 
9.11. Socioeconmic deprivation, atypical respiratory infections, survival outcome 
and stroke 
 
Previous studies have suggested a relationship between socioeconomic deprivation 
(SED), stroke and infections. An opportunistic study was conducted to investigate the 
relationship between SED, atypical respiratory infections and survival outcome in 
elderly stroke and medical patients that came from the same cohort of patients as in 
the C-PEPS study. The socioeconomic status of 92 ischaemic stroke / TIA patients 
and 87 control medical patients were determined using the English Index of Multiple 
Deprivation (IMD) and Income Deprivation Affecting Older People Index (IDAOPI) 
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deprivation scores which were updated and published by the UK government in 2004. 
Patients’ survival was determined from their health records after 6-years of follow-up.  
 
The mean IMD scores of stroke / TIA patients and control medical patients were 23.3 
and 25.0, respectively (difference= 1.7; P= 0.29). The mean IDAOPI scores of stroke 
/ TIA patients and control medical patients were 0.19 and 0.21, respectively 
(difference= 0.02; P= 0.22). The socioeconomic status of elderly stroke / TIA and 
medical patients was therefore similar i.e. no significant differences in their mean 
SED scores.  
 
In the control medical patients, but not the stroke / TIA patients, there was a statistical 
difference in the mean IMD (P= 0.02) and IDAOPI (P= 0.005) scores between 
patients seropositive and seronegative for IgM, but not for IgG. This suggested that 
acute atypical respiratory infection could be associated with SED in the control 
medical patients. There was also an association between number of pathogens (IgM 
but not IgG) and IDAOPI scores (P= 0.004), suggesting that acute atypical respiratory 
infectious burden was significantly and specifically associated with income 
deprivation in both the elderly stroke / TIA and control medical patients.  
 
The association between stroke / TIA and IgG seropositivity for atypical respiratory 
infectious burden was significant before adjustment (P= 0.04) and close to 
significance after adjusting for IMD (P= 0.052) and IDAOPI (P= 0.054). SED 
therefore has only a modest effect on the association between chronic atypical 
respiratory infectious burden and elderly stroke / TIA patients.  
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After 6-years of follow-up, 69 out of the 92 stroke / TIA patients (75%) (median 
survival= 22.4 months) and 68 out of the 87 control medical patients (78%) (median 
survival= 36.5 months) died. There was no significant difference between the Kaplan-
Meier survival curves for stroke / TIA patients and control medical patients, and as 
divided into tertiles of IMD and IDAOPI deprivation scores. Therefore, SED was not 
found to affect elderly patients’ survival in this study. 
 
9.12. Conclusions 
 
Acute infections due to specific micro-organisms causing stroke events are well 
recognised. Chronic infections caused by specific micro-organisms are also known to 
associate with stroke. It has been hypothesised that specific chronic infections could 
contribute to atherosclerosis through chronic inflammatory and immunological 
mechanisms. Chlamydia pneumonia, an atypical respiratory pathogen, is the micro-
organism most investigated in this model of infectious hypothesis of atherosclerosis. 
Although the evidence as a whole is compelling, definitive proof of a causal 
relationship between C pneumoniae and atherosclerosis or stroke remains elusive. 
   
In accordance with the infectious hypothesis of atherosclerosis, it is likely that chronic 
infections by a number of specific micro-organisms would contribute to atherogenesis 
and atherothrombosis. This thesis has established the seroprevalences of individual 
atypical respiratory pathogens i.e. C pneumoniae, M pneumoniae, L pneumophila and 
C burnetii, in a cohort of hospitalised, elderly acute stroke / TIA and control medical 
patients. This thesis has shown that rather than any individual micro-organism, an 
aggregate number (infectious burden) of specific chronic atypical respiratory 
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infections i.e. C pneumoniae, M pneumoniae, L pneumophila was more likely to 
associate with stroke / TIA. Anti-microbial intervention, ideally targeted to specific 
infectious burden in susceptible individuals, and immunisation studies, in the context 
of chronic atypical respiratory infections and stroke prevention, are possible areas for 
future research studies.  
 
This thesis has established the reproducibility of SeroCP ELISA kits used in the C-
PEPS study. The reproducibility was good in the detection of C Pneumoniae IgA, and 
it was moderately good in the detection of C pneumoniae IgG and IgM. The 
reproducibility study has highlighted an important issue of laboratory test limitation 
or reliability in seroepidemiological studies. Further standardisation, refinement and 
improvement in serological and laboratory techniques have been proposed.  
 
It has been documented that as frequently as one in four elderly patients has ECG 
evidence of atrial fibrillation on their acute hospital admission. This thesis has 
established that there was a statistical trend to suggest that ischaemic ECG changes in 
elderly stroke / TIA patients could be due to the underlying acute cerebrovascular 
events, independent of their background history of ischaemic heart disease. Future 
outcome study may be required to establish the significance of ischaemic ECG 
changes and other ECG abnormalities in the context of acute cerebrovascular events 
in older patients. 
 
Finally, this thesis has established that the socioeconomic status of elderly stroke / 
TIA and general medical patients was similar on their acute hospital admission; and 
that their 6-year survival outcome was similar. It has further established that acute 
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atypical respiratory infectious burden was associated with income deprivation in 
hospitalised elderly stroke / TIA and medical patients. Future study may be required 
to test the hypothesis that if measures to improve elderly patients’ socioeconomic 
status or income would reduce the rate of acute atypical respiratory infections in these 
patients. Although this thesis established that socioeconomic status has only a modest 
effect on the association between chronic atypical respiratory infections and stroke / 
TIA, it has recommended that socioeconomic deprivation (SED), particularly income 
deprivation, should be adjusted for in similar future studies. As SED, infections and 
stroke are potentially important modifiable risk factors in older patients, adequately 
powered interventional and outcome studies to explore the relationship between these 
factors are potential areas for future research. 
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Appendix A 
 
Principle and procedure of Enzyme-Linked Immunosorbent Assay (ELISA) test 
 
1. Microtitre plates or microwells are supplied coated with purified antigens i.e. C 
pneumoniae* TWTM-183 elementary bodies, M pneumoniae† P1-enriched 
membrane antigens, L pneumophila‡ serogroup-1 LPS antigens or C burnetii§ 
Phase-II antigens. 
 
2. The serum to be tested is diluted (e.g. 1/21‡, 1/100§ or 1/105*†). For IgM testing, 
the serum is pre-treated with the manufacturer’s serum diluent containing anti-IgG 
absorbent, to remove rheumatoid factor (i.e. to reduce false positive result), and to 
reduce excessive IgG interference (i.e. to reduce false negative result).  
 
3. 50*†, 100§, or 105‡ μL diluted serum is incubated in the microtitre plate for 30§, 
45‡ or 60*† minutes at 37±1°C. In this step, specific antibodies in the serum tested 
are bound to the immobilised antigens attached to the polystyrene surface of the 
microwells. 
 
4. Non-specific or unbounded antibodies in the residual serum are removed by 
washing with Wash Buffer 3*†, 5‡ or 6§ times. 
 
5. Anti-human IgA, IgG or IgM conjugated to Horseradish Peroxidase (HRP) is 
diluted e.g. 1/300*† with a conjugate diluent. Dispense 50*† or 100‡§ μL of diluted 
conjugate solution into each well. Cover and incubate for 30‡§ or 60*† minutes at 
37±1°C in a moisture chamber. In this step, the HRP-Ig-Conjugate is bound to the 
prebound antigen-antibody complex formed in step 2 above.  
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6. Unbound conjugate is removed by washing with Wash Buffer 3*†, 5‡ or 6§ times. 
 
7. Upon the addition of 100 μL colourless Tetramethylbenzidine*†‡/Hydrogen 
Peroxide-Substrate§ (TMB/H2O2-Substrate), the Substrate is hydrolysed by the 
peroxidase (HRP), yielding a blue solution of the reduced Substrate. Cover plates 
and incubate at room temperature (20-25oC) for 10§, 15*† or 20‡ minutes. 
 
8. Upon the addition of 50‡ or 100*†§ μL acid Stop Solution (contains 0.5‡ or 1*†§ M 
sulphuric*†‡ or phosphoric§ acid), the blue colour turns yellow and should be read 
by an ELISA reader at a wavelength of 450nm with a reference filter of 620nm, 
within 30*†§ or 60‡ minutes of stopping. 
 
9. The absorbance or optical density (OD) read is proportional to the amount of the 
specific antibodies that are bound to the coated antigens. 
 
10. Calculate and interpret results. See Appendix B. 
 
* refers to Chlamydia pneumoniae-SeroCP ELISA (Savyon, Israel) 
† refers to Mycoplasma pneumoniae-SeroMP ELISA (Savyon, Israel) 
‡ refers to Legionella pneumophila-ELISA (VIRCELL SL, Spain) 
§ refers to Coxiella burnetii-ELISA (PANBIO, Australia) 
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Appendix B 
 
ELISA test validation, calculation and interpretation of results 
 
Chlamydia pneumoniae-SeroCP ELISA (Savyon, Israel) 
 
1. For the test to be valid, two criteria must be met:  
a. the absorbance value or optical density OD450 of the positive control should be > 
0.8 at 450nm,  
b. the average OD450 of the two negative controls NC should be 0.1 < NC < 0.4.  
 
2. The Cut-Off Value (COV) is calculated using the formula:  
COV = (the average OD450 of the negative control run in duplicate) X2  
 
3. In order to normalise the results obtained in different tests, the Cut-Off Index (COI) 
is calculated according to the formula:  
COI = OD450 ÷ COV 
 
4. As defined by the manufacturer: 
COI < 1.0 = negative i.e. no detectable antibodies,  
COI = 1-1.1 = borderline i.e. low level of antibodies, second sample testing 
recommended, 
COI > 1.1 = positive i.e. relevant level of antibodies.  
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Mycoplasma pneumoniae-SeroMP ELISA (Savyon, Israel) 
 
1. The following criteria must be met for the test to be valid: 
a. ODP100  > 1.2 
The absorbance value or optical density OD at 450/620nm for the Calibrator P100 
containing 100 Ig BU/ml (immunoglobulin binding units per ml of serum) should be 
greater than 1.2. 
b.  Ratio: ODP10 / ODNC > 1.5 
The ratio of the OD450/620 for the Calibrator P10 containing 10 Ig BU/ml and the 
OD450/620 for the negative control NC should be greated than 1.5. 
c. Ratio: ODP50 / ODNC > 4 
ODP50 is the OD450/620 for the Calibrator P50 containing 50 Ig BU/ml. ODNC is the 
OD450/620 for the negative control. 
d. Ratio: ODP100 / ODNC > 7 
 
2. Using a squared graph paper, plot the OD450/620 of the 3 calibrators P10, P50 and 
P100 on Y-axis (OD450/620) versus their concentration i.e. 10, 50, 100 BU/ml, 
respectively, on X-axis. 
 
3. Draw the best fitted linear curve through the points. 
 
4. Using the standard curve, interpolate the concentration of the tested sample values 
in BU/ml (on X-axis) from each absorbance or OD (on Y-axis) measured. 
 
5. As defined by the manufacturer, concentration value of: 
< 10 BU/ml = negative i.e. no detectable antibodies,  
> 10 BU/ml = positive i.e. relevant level of antibodies,  
> 50 BU/ml = high positive i.e. high level of antibodies.  
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Legionella pneumophila-ELISA (VIRCELL SL, Spain) 
 
1. For the test to be valid, the following criteria must be met:  
a. the optical density OD450/620 of the positive control should be > 0.9,  
b. the OD450/620 of the negative control should be < 0.55, 
c. the OD450/620 of the cut-off control should be < 0.7 X (OD positive control) and 
> 1.5 X (OD negative control). 
 
2. Calculate the mean OD for the 2 cut-off serum controls. 
 
3. Antibody Index = (sample OD ÷ cut-off serum mean OD) X 10 
 
4. As defined by the manufacturer, Antibody Index of: 
< 9 = negative i.e. no detectable antibodies, 
9-11 = equivocal, retesting/new sample obtained for confirmation recommended, 
> 11 = positive i.e. antibodies detected 
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Coxiella burnetii-ELISA (PANBIO, Australia) 
 
1. Each kit contains cut-off calibrator, positive and negative control sera. 
 
2. Acceptable values for these sera are found on the accompanying specification sheet. 
 
3. The negative and positive controls are intended to monitor for substantial reagent 
failure. 
 
4. The test is invalid and should be repeated if the absorbance readings of either the 
controls or the calibrator do not meet the specifications. 
 
5. The cut-off value COV is the average absorbance of the triplicates of the cut-off 
calibrator. 
 
6. A sample’s Index Value = Sample Absorbance ÷ COV 
 
7. PANBIO Units = Index Value X 10 
 
8. As defined by the manufacturer, PANBIO Units of: 
< 9 = negative i.e. no detectable antibodies, 
9-11 = equivocal, retesting/new sample obtained for confirmation recommended, 
> 11 = positive i.e. antibodies detected. 
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Appendix C 
 
List of relevant oral and poster presentations, and peer-reviewed abstract 
publications 
 
1. Prevalence of electrocardiographic (ECG) abnormalities in acute stroke and 
medical patients- poster presentation at the British Geriatrics Society Spring Meeting, 
10-12 April 2003, in Aberdeen. 
 
1.1. Ngeh J. Prevalence of electrocardiographic (ECG) abnormalities in acute stroke 
and medical patients. Age and Ageing 2003;32-S2:19. 
 
2. Seroprevalence of Mycoplasma pneumoniae in elderly stroke and medical patients: 
a nested case-control study- oral, platform presentation at the British Geriatrics 
Society Autumn Meeting, 18-19 October 2001, in London. 
 
2.1. Ngeh J, Gupta S, Goodbourn C, McElligott G. Seroprevalence of Mycoplasma 
pneumoniae in elderly stroke and medical patients: a nested case-control study. Age 
and Ageing 2002;31-S1:45. 
 
3. Seroprevalence of Chlamydia pneumoniae in elderly stroke and medical patients: a 
case-control study- oral, platform presentation at the Regional British Geriatrics 
Society Meeting (Joint North-East and North-West Thames), 4 July 2001, RAF 
Museum, Graham Park Way, Colindale, London NW9 5LL. 
 
4. Seroprevalence of Chlamydia pneumoniae in elderly stroke and medical patients: a 
case-control study- poster presentation at the British Geriatrics Society Spring 
Meeting, 5-7 April 2001, in Cardiff. Awarded Ferguson Anderson Best Poster Prize, 
2001. 
 
4.1. Ngeh J, Gupta S, Goodbourn C, Panayiotou B, McElligott G. Seroprevalence of 
Chlamydia pneumoniae in elderly stroke and medical patients: a case-control study. 
Age and Ageing 2001;30-S2:60. 
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